Abstract Titles
Skip to Late-Breaking Abstracts »
All accepted abstracts will be available in the Journal for ImmunoTherapy of Cancer (JITC).
Abstract Titles
Onsite Posters
Onsite posters will be presented in the Poster Hall at the Walter E. Washington Convention Center in Washington, D.C. All odd numbered posters will be presented on Friday, Nov. 12, 2021. Even numbered posters will be presented Saturday, Nov. 13, 2021.
ePosters
ePosters will be on display on the SITC 2021 virtual meeting platform from 7 a.m. EST on Friday, Nov. 12, 2021 until the virtual meeting platform is closed on Jan. 9, 2022.
| # | Type | Title | Authors | Category | Keywords | |
|---|---|---|---|---|---|---|
| 3 | Poster Presentation | Development of an integrated method to quantify receptor occupancy for agonist immunotherapeutics that stimulate target cells to migrate from the peripheral blood | Louis E. Gonzalez, PhD; Bo Ma, PhD; Robert Hernandez, PhD; Hannah McKay; Fatima Rangwala, MD, PhD; Lini Pandite, MD; Taylor H. Schreiber, MD, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Immune contexture | |
| 8 | Poster Presentation | Multiparameter characterization of CAR T cells | Xueting Wang, M.Sc.; Christina Pitzka; Daniela Rheindorf; Nadine Mockel-Tenbrinck; Tatjana Holzer, PhD; Anne Richter, PhD; Toni Cathomen, PhD; Cesar Evaristo, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy;Biomarkers;CAR T cells;Costimulation;COVID and Immunotherapy;Immune monitoring;Immune tolerance;Leukemia/Lymphoma;Tumor evasion;Tumor microenvironment | |
| 10 | Poster Presentation | Tertiary lymphoid structure in pancreatic ductal adenocarcinoma; a potential target in an immunologically inert malignancy | Kasimu U. Adoke, MBBS, FMCPath; Sanusi M. Haruna | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy;Antibody;B cell;Biomarkers;Dendritic cell;Immune toxicity;T cell | |
| 11 | Poster Presentation | Molecular characterization of naturally occurring colorectal and breast cancer in non-human primates to model human immunotherapeutic agents | Simon Deycmar, PhD; Brendan Johnson, DVM; Declan Ryan; William S. Sills, DVM; David L. Caudell, PhD; Greg Dugan, PhD; Kiran K. Solingapuram Sai, PhD; Michael Hettich, PhD; Bruno Gomes, DVM PhD; Maurizio Ceppi; Mark Cline, DVM PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Bispecifics;Carcinogenesis;Checkpoint blockade;Immune monitoring;Neoantigens;Solid tumors | |
| 13 | Poster Presentation | DexterTM microfluidic platform coupling single-cell resolution of dynamic tumor-immune interaction with AI for elucidating mechanistic modulation in cancer immunotherapy | Pradip K. Majumder, Ph.D.; Biswanath Majumder; Ranjeet Singh; Abhay Sane; Rushil Manglik; Ravi R. Keshari; Mohanasundaram S. M; Ashwin Dr. Lal, Ph.D. | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;CAR T cells;Cytokine;Dendritic cell;Immune monitoring;Monocyte/Macrophage;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 15 | Poster Presentation | First-line platinum-based chemotherapy combined with PD-1/PD-L1 inhibitors (ICI) prevents hyperprogression in non-small cell lung cancer (NSCLC) patients by reducing circulating immature neutrophils | Roberto Ferrara, MD; Giuseppe Lo Russo; Elena Jachetti; Giuseppina Calareso; Claudia Proto; Arsela Prelaj; Giulia Galli; Diego Signorelli; Marta Brambilla; Alessandro De Toma; Mario Occhipinti; Sara Manglaviti; Giulia Apollonio; Laura Mazzeo; Monica Ganzinelli; Antonia Martinetti; Filippo De Braud; Marina Garassino; Mario Paolo Colombo; Sabina Sangaletti, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Chemotherapy;Granulocyte;Immune monitoring;Myeloid cells;Solid tumors | |
| 16 | Poster Presentation | Tumor growth inhibition mediated by a single dose of intratumoral TransCon™ TLR7/8 agonist was associated with activated circulating T and B cells and sustained low levels of systemic cytokines | Amer M. Mirza, PhD; Luis A. Zuniga, PhD; Karan Uppal, PhD; Kathy Bang; Enping Hong, PhD; Simran Sabharwal, PhD; Yuchi Lee, PhD; Salomon Martinez; David Rosen, PhD; Juha Punnonen, MD, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy;Biomarkers;Chemokine;Cytokine;Dendritic cell;Immune monitoring;Monocyte/Macrophage;Myeloid cells;T cell lineages;TLR | |
| 25 | Poster Presentation | Potential role of serum proteome in predicting immune-related adverse events from immunotherapy in non-small cell lung cancer | Leeseul Kim, MD; Young Kwang Chae, MD, MPH, MBA; Dong-Uk Lee | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Checkpoint blockade;Immune toxicity | |
| 36 | Poster Presentation | Digital Whole Slide Image (WSI) Scoring is Equivalent to Microscope Glass Slide Scoring for Evaluation of Programmed Death-Ligand 1 (PD-L1) Expression Across Multiple Tumor Indications | Micki Adams, BS; Deanna Moquin, BS; Joshua Littrell, BA; Jay Milo, M.A.S; Stephanie Hund, B.S.; Angeliki Apostolaki, Ph.D. | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody;Biomarkers;Checkpoint blockade;COVID and Immunotherapy;Solid tumors;Targeted therapy;Tumor evasion | |
| 42 | Poster Presentation | The role of tissue stiffness in predicting the immunotherapy response in hepatocellular carcinoma | Betul Gok Yavuz, MD-PhD; Elshad Hasanov; Lianchun Xiao; Yehia I. Mohamed; Sunyoung S. Lee; Asif Rashid, MD, PhD; Ahmed O. Kaseb, MD; Aliya Qayyum, MD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Checkpoint blockade | |
| 43 | Oral Presentation | Intravital multiphoton imaging of infiltrating CD8 T cell and tumor cell metabolism during immunotherapy in a murine melanoma model | Alexa R. Heaton, PhD; Anna Hoefges, MS; Peter R. Rehani, BS; Angelica F. Lopez; Nathaniel J. Burkard; Alexander L. Rakhmilevich, MD, PhD; Amy K. Erbe, PhD; Paul M. Sondel, MD, PhD; Melissa C. Skala, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody;Checkpoint blockade;Metabolism;Radiotherapy;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine | |
| 45 | Poster Presentation | AI-assisted whole-body assessment of immunotherapy response using [18F]F-AraG, a PET agent for activated T cells | Jelena Levi, PhD; Timothy Perk, PhD; Lyna Huynh; Juliet Packiasamy, PhD; Serena Cheng, PhD; John B. Sunwoo, MD; A. Dimitrios Colevas, MD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Checkpoint blockade;Immune monitoring;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 61 | Poster Presentation | Biomarkers of favorable prognosis guides the identification of tumor reactive CD4+ and CD8+ TILs in Endometrial Cancer | Jara Palomero, PhD; Carla Panisello; August Vidal, MD; Jordi Ponce, MD, PhD; Ana Vivancos, PhD; Josep Maria Piulats, MD, PhD; Xavier Matias-Guiu, MD, PhD; Alena Gros, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy;Biomarkers;Solid tumors;Tumor infiltrating lymphocytes (TILs) | |
| 62 | Poster Presentation | Applying machine vision to empower preclinical development of cell engager and adoptive cell therapeutics in patient-derived organoid models of solid tumors. | Sonal Khare, PhD; Chi-Sing Ho; Madhavi Kannan, MS; Brian M. Larsen, PhD; Brandon L. Mapes, MS; Jenna Shaxted; Jagadish Venkataraman, PhD; Ameen A. Salahudeen, MD PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy;Bispecifics;CAR T cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 66 | Oral Presentation | Prognostic and predictive value of pre-treatment T-Cell receptors (TCR) repertoire in non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy. | Afaf Abed, MBBS, FRACP; Elin S. Gray; Michael Millward, MD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Checkpoint blockade | |
| 70 | Poster Presentation | Novel Immunotherapeutic Targets in Cancer of Unknown Primary (CUP) | Mary Nesline, M.S.; Paul DePietro, PhD; Yong Hee Lee, M.S.; Zachery Bliss; R.J. J. Seager, Jr., Ph.D.; Erik Van Roey; Shuang Gao; Vincent Giamo; Blake Burgher; Sean T. Glenn, PhD; Shengle Zhang, MD; Sarabjot Pabla; Roger D. Klein, MD, JD, FACP; Jeffrey Conroy, BS | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Gene expression;Solid tumors | |
| 77 | Poster Presentation | Prevalence of Secondary Immunotherapeutic Targets in the Absence of Established Immune Biomarkers in Solid Tumors | Paul DePietro, PhD; Mary Nesline, M.S.; Yong Hee Lee, M.S.; R. J. Seager; Erik Van Roey; Shuang Gao; Vincent Giamo; Blake Burgher; Sean T. Glenn, PhD; Shengle Zhang, MD; Roger D. Klein, MD, JD, FACP; Sarabjot Pabla; Jeffrey Conroy, BS | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics;Biomarkers;Gene expression;RNA;Solid tumors;T cell;Tumor antigens | |
| 78 | Poster Presentation | Novel RNA-seq Platform Improve Patient Outcome in Clinical Oncology and enable implementation of AI in the clinic | Vy Nguyen, B.S; Gitte Pedersen, MSc; Morten Pedersen | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics;Biomarkers;Chemotherapy;Gene expression;RNA;Solid tumors | |
| 80 | Poster Presentation | Cancer testis antigen burden: A novel predictive biomarker for immunotherapy in solid tumors | Sarabjot Pabla; R. J. Seager; Yong Hee Lee, M.S.; Erik Van Roey; Shuang Gao; Vincent Giamo; Blake Burgher; Paul DePietro, PhD; Mary Nesline, M.S.; Sean T. Glenn, PhD; Shengle Zhang, MD; Jeffrey Conroy, BS | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics;Biomarkers;Gene expression;RNA;Solid tumors;Tumor antigens | |
| 86 | Poster Presentation | Extensive FAP expression analysis in 23 tumor indications and potential application in defining the patient population in FAP-targeting cancer immunotherapies | Sebastian Dziadek, PhD; Anton Kraxner; Wei-Yi Cheng; Mike Flores, PhD; Tai-Hsien tai-hsien.ou_yang@roche.com, PhD; Noah Theiss, PhD; Tsu-Shuen Tsao, PhD; Emilia Andersson; Suzana Vega Harring; Gabriele Gabriele Hoelzlwimmer, Dr.; Ann-Marie Broeske; Maurizio Ceppi; Jehad Charo; Sebastian Dziadek | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Checkpoint blockade;Clinical trial;Immune contexture;Solid tumors;Tumor antigens;Tumor evasion;Tumor microenvironment;Tumor stroma | |
| 89 | Poster Presentation | The immune marker LAG-3 increases the predictive value of CD38+ immune cells for survival outcome in immunotherapy-treated hepatocellular carcinoma | Chun Chau Lawrence Cheung, MMedSc; Yong Hock Justin Seah; Juntao Fang; Nicole HC. Orpilla; Justina Nadia Li Wen Lee; Han Chong Toh, MD; Su Pin Choo; Kiat Hon T. Lim; Wai Meng David Tai; Joe P. Yeong, MD, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Checkpoint blockade;Immune contexture;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 91 | Poster Presentation | Impact of ultra-fast 'FLASH' radiotherapy on single cell immunogenomics in diffuse intrinsic pontine glioma (DIPG) | Oscar Padilla, MD; Hanna Minns, BS; Hong-Jian Wei, PhD; Andrea Webster-Carrion, MD; Masih Tazhibi, BA; Nicholas McQuillan, BS; Xu Zhang, PhD; Zhiguo Zhang, PhD; Raul Rabadan, PhD; Peter Canoll, MD PhD; Luca Szalontay, MD; Jovana Pavisic, MD; Guy Garty, PhD; Stergios Zacharoulis, MD; Claire I. Vanpouille-Box, PhD; Vilas Menon, PhD; Marta Olah, PhD; Cheng-Chia Wu, MD PhD; Robyn D. Gartrell, MD | Biomarkers, Immune Monitoring, and Novel Technologies | Gene expression;Pediatric tumors;Radiotherapy;Tumor microenvironment | |
| 94 | Poster Presentation | Effects of chemoimmunotherapy on the peripheral blood: insights from immune monitoring of a phase Ib trial of pembrolizumab and paclitaxel or capecitabine for triple-negative breast cancer (TNBC) | Brie M. Chun, MD; Joanna Pucilowska, PhD; Shu Ching Chang, PhD; Isaac K. Kim, MD; Benjamin Nikitin; Yoshinobu Koguchi, MD, PhD; William L. Redmond, Ph.D.; Brady M. Bernard, PhD; Venkatesh Rajamanickam; Nathan W. Polaske; Paul Fields, PhD; Valerie K. Conrad, BS; Mark Schmidt; Walter J. Urba, MD, PhD; Alison K. Conlin, MD; Heather McArthur, MD; David B. Page, MD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Clinical trial;Immune monitoring;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 95 | Poster Presentation | MAGE-A1 protein expression pattern in > 5,000 tumor and healthy tissue samples: Validation of MAGE-A1 as an ideal target for TCR-based cell therapy | Jennifer D. Oduro, PhD; Ronald Simon, Prof. PhD; Natalia Gorbokon; Christoph Fraune, PD MD; Julia Bluhm, PhD; Vivian Scheuplein, PhD; Elisa Kieback, PhD; Matthias Obenaus, MD; Thomas Blankenstein, PhD; Eugen Leo, MD PhD MBA | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy;Biomarkers;Solid tumors;T cell;Targeted therapy;Tumor antigens | |
| 97 | Poster Presentation | High throughput screening of HPV-antigen peptides and expansion of tumor-specific T cells for adoptive cell therapy of HPV-associated malignancies | David Langan, PhD; Jourdain Lemaster; Lauren Suarez, PhD; Pratima Kunwar, PhD; Sojung Kim, PhD; Mathias Oelke, PhD | Cellular Therapies | Adoptive immunotherapy;T cell;Tumor antigens | |
| 98 | Poster Presentation | NX-0255, a small molecule CBL-B inhibitor, expands and enhances tumor infiltrating lymphocytes (TIL) for use in adoptive cancer immunotherapy | Sarah Whelan, PhD; Jennifa Gosling, MSc; Monisha Mani, MSc; Frederick Cohen, PhD; Austin Tenn-McClellan, BS; Janine Powers, PhD; Gwenn Hansen, PhD; Michael T. Lotze, MD; Arthur T. Sands, MD, PhD | Cellular Therapies | Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 99 | Poster Presentation | T cell immunotherapies trigger neutrophil activation to eliminate tumor antigen escape variants | Daniel Hirschhorn, PhD; Sadna Budhu, PhD; David Schröder, MD, PhD; Lukas kraehenbuehl; Anne-Laurent Flammar; Andrew Chow, MD, PhD; Isabell Schulze; Sara Schad, BS; Jacob Ricca; Billel Gasmi; Olivier De Henau; Levi M. Mangarin, BS; David Redmond; Czrina Cortez, BS; Cailian Liu, MD; Aliya Holland; Mathieu Gigoux, PhD; Asrhi Arora; Katherine S. Panageas, PhD; Gabrielle Rizzuto; Jean Albrengues, PhD; Mikala Egeblad, PhD; Jedd D. Wolchok, MD/PhD; Taha Merghoub, PhD | Cellular Therapies | Adoptive immunotherapy;Checkpoint blockade;Costimulation;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 100 | Poster Presentation | Redirecting glucose flux during in vitro expansion improves the in vivo performance of adoptive T cell therapies for cancer | Andrew Frisch, BS; Yupeng Wang, BD; Yiyang Wang, N/A; Konstantinos Lontos, MD; Dayana Rivadeneira, PhD; Greg M. Delgoffe, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 101 | Poster Presentation | Expansion of tumor-infiltrating lymphocytes (TIL) using static bag for the clinical manufacturing rapid expansion protocol (REP) process | Kenneth Onimus; Adrian Wells; Nermin Gerges; Courtney Herman; Shwetha Lakshmipathi; Viktoria Gontcharova, PhD; Joe Wypych; Arvind Natarajan; Anand Veerapathran | Cellular Therapies | Adoptive immunotherapy;Neoantigens;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 102 | Poster Presentation | The deep phenotype characterization of “Off-the-Shelf” CD19-Chimeric Antigen Receptor (CAR) T Cells allows to identify their subset complexity and to optimize their manufacturing | Cristina Maccalli, PhD; Asma Al-Sulaiti; Mohammed El-Anbari, PhD; Moza Al Khulaifi, BSc; Mohammed Toufiq; Rebecca Mathew; Chiara Cugno, MD; Sara Deola, MD; Suruchi Mohan, MD; Damilola Olagunju; Chiara Bonini, MD; Monica Casucci, PhD; Sara Tomei, PhD; Damien Chaussabel, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;T cell lineages | |
| 103 | Poster Presentation | Quality improvement of anti-CD38-JAK/STAT CAR-T cells by suppressing CD38 expression and inhibition of tyrosine kinase | Yasunori Amaishi, MS; Izumi Maki; Maiko Sugizaki; Kenichiro Mihara, M.D., Ph.D.; Sachiko Okamoto, PhD; Junichi Mineno, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;T cell;Targeted therapy;Tumor antigens | |
| 104 | Poster Presentation | Development and characterization of human chimeric antigen receptor Monocytes (CAR-Mono), a novel cell therapy platform | Daniel Blumenthal, PhD; Linara Gabitova, PhD; Brett Menchel; Patricia Reyes-Uribe; Andrew Best, BS, MS; Michael Lynch; Sotheavy Chhum; Maggie Schmierer; Sascha Abramson, PhD; Michael Klichinsky, PharmD, PhD | Cellular Therapies | Adoptive immunotherapy;Cytokine;Monocyte/Macrophage;Myeloid cells;Solid tumors | |
| 105 | Poster Presentation | 4-1BB and optimized CD28 co-stimulation enhances function of human mono- and bi-specific third-generation CAR T cells | Emiliano Roselli, Ph.D.; Justin C. Boucher; Gongbo Li; Hiroshi Kotani; Kristen Spitler; Kayla M. Reid, M.S.; Yannick Bulliard; Nhan Tu; Sae Bom Lee; Bin Yu; Frederick L. Locke, M.D.; Marco L. Davila, M.D., Ph.D. | Cellular Therapies | Adoptive immunotherapy;Bispecifics;CAR T cells | |
| 107 | Poster Presentation | Armoring NKG2D CAR T cells with IL-18 improves in vivo anti-tumor activity | Eytan Breman, MSc; Ann-Sophie Walravens; Isabelle Gennart; Amelie Velghe; Thuy Nguyen; Benjamin Violle; Fanny Huberty; Nancy Ramelot; Laure Twyffels; Emilie Gauthy; Hannes Iserentant; David E. Gilham, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Solid tumors;T cell | |
| 110 | Poster Presentation | IL-2 variant improves CAR-T functionality and efficacy against solid tumors | Qi Dong, Msc; Wenjie Yin, Ph.D.; Pengfei Jiang, Ph.D.; Manli Yin; Tao Wang; Ping Wang; Xinxin Wang, Ph.D.; William Wei Cao, Ph.D.; Lianjun Shen, Ph.D. | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Immune suppression;Solid tumors;T cell;Targeted therapy;Tumor microenvironment | |
| 111 | Poster Presentation | Armored CAR T Cells Secreting 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor for Enhanced Solid Tumor Efficacy | Zachary S. Dunn, MS; Yun Qu, Doctorate; Melanie MacMullan; Xianhui Chen, Doctorate; Gunce Cinay; Pin Wang, Doctorate | Cellular Therapies | Adoptive immunotherapy;Antibody;Bispecifics;CAR T cells;Checkpoint blockade;Costimulation;Solid tumors;T cell;Tumor microenvironment | |
| 112 | Poster Presentation | Tumor-specific Reactivity and Effector Function of Chimeric Antigen Receptor Engineered Macrophages Targeting MUC1 | Seth H. Eisenberg; Amy A. Powers, MS; Jason C. Lohmueller, PhD; James D. Luketich, MD; Rajeev Dhupar, MD; Adam C. Soloff, PhD | Cellular Therapies | Adoptive immunotherapy;Antigen presenting cells;Monocyte/Macrophage;Tumor antigens | |
| 117 | Oral Presentation | FT536 Path to IND: Ubiquitous targeting of solid tumors with an off-the-shelf, first-of-kind MICA/B-specific CAR-iNK cellular immunotherapy. | John Goulding, PhD; Bryan Hancock, PhD; Robert Blum, MS; Moyar Ge, PhD; Svetlana Gaidarova, MS; Paul Rogers, PhD; Sajid Mahmood, PhD; Rina Mbofung, PhD; Wen-I Yeh, PhD; Bi-Huei Yang, PhD; Chia-Wei Chang, PhD; Brian Groff, BS; Soheila Shirinbak, PhD; Joy Grant; Martin Hosking, PhD; Mochtar Pribadi; Yijia Pan; Hui-Yi Chu; Shohreh Sikaroodi, PhD; Lauren Fong, PhD; Nicholas Brookhouser, PhD; Fernanda Rodrigues Cugola, PhD; Ramzey Abujarour, PhD; Janel Huffman, MS; Pei-Fang Tsai, PhD; Antonio Fernandez-Perez, PhD; Karina Palomares, PhD; Natalie Marquez-Solorzano, MS; Riya Kanherkar, PhD; Andrew Burns, PhD; Aidan Keefe, MS; Samvel Nazaretyan, BS; Christine Chen, PhD; Raedun Clarke, PhD; Thomas Dailey, BS; Miguel Meza, BS; Jason O'Rouke, PhD; Jerome Bressi, PhD; Tom Lee; Ryan Bjordahl, PhD; Lucas Ferrari de Andrade, PhD; Kai W. Wucherpfennig, MD, PhD; Bahram Valamehr, PhD | Cellular Therapies | Adoptive immunotherapy;Chemotherapy;Clinical study;Leukemia/Lymphoma;NK/NKT cell;Radiotherapy;Solid tumors;Targeted therapy;Tumor antigens;Tumor evasion | |
| 118 | Poster Presentation | Development of Claudin 18.2 TAC T cells for the treatment of gastric cancer | christopher CW. Helsen, PhD; Tania Benatar, PhD; Philbert IP, PhD; Stacey Xu, PhD; Laura Shaver; Thanyashanthi Nitya-Nootan, MSc; Andreas G. Bader; Prabha Lal, PhD | Cellular Therapies | Adoptive immunotherapy;Solid tumors;T cell | |
| 119 | Poster Presentation | ADI-002: an IL-15 armored allogeneic “off-the-shelf” Vδ1 gamma delta CAR T cell therapy for solid tumors targeting glypican-3 (GPC3) | Amani Makkouk, PhD; Xue (Cher) Yang; Taylor Barca; Anthony Lucas; Mustafa Turkoz; Jonathan Wong; Kevin P. Nishimoto; Mary M. Brody; Maryam Tabrizizad; Smitha Gundurao; Lu Bai; Arun Bhat; Zili An; Stewart Abbot; Daulet Satpayev; Marissa Herrman | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Cytokine;Solid tumors;T cell;Tumor antigens | |
| 120 | Poster Presentation | Chemokine receptor engineering enhances trafficking and homing of primary and iPSC-derived CAR-T cells to solid tumors | Martin Hosking, PhD; Soheila Shirinbak, PhD; Joy Grant; Yijia Pan; Angela Gentile; Amit Mehta; Bjoern Gaertner, PhD; Bishwas Shrestha, PhD; Mochtar Pribadi; Jason ORourke, PhD; Alec Witty; Tom Lee; Bob Valamehr, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Chemokine;Chemotherapy;Radiotherapy;Solid tumors;T cell;Tumor microenvironment | |
| 121 | Poster Presentation | ICAM-1-specific affinity tuned CAR T cells expressing SSTR2 for real-time imaging | Jingmei Hsu, MD, PhD; Eric von Hofe, PhD; Michael Hsu, MD, PhD; Koen Van Besien, MD; Thomas Fahey, MD; Jana Ivanidze, MD, PhD; Janusz Puc, PhD; Karrie Du, PharmD; Moonsoo M. Jin, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Solid tumors;T cell | |
| 122 | Poster Presentation | A powerful, precise targeting system controlled by tumor deletions transforms CEA and MSLN CAR-T cells into tumor-selective agents | Agnes Hamburger; Han Xu, PhD; Yuta Ando; Grace Asuelime; Kristian Bolanos-Ibarra; Mark Daris, PhD; Kiran Deshmukh; Breanna DiAndreth; Fernando Fisher; Grant Gabrelow; Maria Imun; David Ju; Wen-Hua Lee; Chuck Li; Edwin Liu; Aaron D. Martin, M.A.; Michele Mcelvain; Jee-Young Mock; Daniel Nampe; Martin Naradikian; Mark Sandberg, PhD; Sanam Shafaattalab; Shruti Sharma; Talar Tokatlian; Dora Toledo-Warshaviak; Xueyin Wang, PhD; Lu-Min Wong; Alexander Kamb, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Solid tumors;T cell;Tumor antigens | |
| 123 | Poster Presentation | P-MUC1C-ALLO1: A Fully Allogeneic Stem Cell Memory T Cell (TSCM) CAR-T Therapy with Broad Potential in Solid Tumor | Yan Zhang, Ph.D.; Anna K. Kozlowska, Ph.D.; Jacqueline Fritz; Yingying Zhao; Claudia Palomino La Torre; Stacey Cranert, Ph.D.; Steven Wang; Rebecca Codde; Elvira Argus, Ph.D.; Samad Ibitokou, Ph.D.; Vanitra Richardson; Sumiti Jain, Ph.D.; Maximilian Richter, Ph.D.; Deepak Patil, Ph.D.; Yening Tan; Min Tong; Lu Yao, Ph.D.; Majid Ghoddusi, Ph.D.; Eric M. Ostertag, Ph.D. M.D.; Julia Coronella, Ph.D.; Devon J. Shedlock, Ph.D. | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Solid tumors;T cell | |
| 125 | Poster Presentation | Co-opting IL-8 to enhance efficacy of B7H3 CAR T cells against pediatric sarcoma | Jessica Lake, MD MPH; Kevin Winkler, BA; Alexander Harrant, BS; Ashley Yingst, MS; Kristin Schaller, PhD; Eric Hoffmeyer, BS; Madeline Larson, BS; Dejene Tufa, PhD DVM; Laura Cobb, MD; Dallas Jones, PhD; Michael Verneris, MD | Cellular Therapies | CAR T cells;Chemokine;Pediatric tumors;Radiotherapy;Solid tumors;T cell | |
| 126 | Poster Presentation | Regional administration of IL-12 endowed CAR T cells effectively targets systemic disease | Hee Jun Lee, BA; Cody Cullen; John P. Murad; Jason Yang; Wen-Chung Chang; Stephen J. Forman; Saul Priceman, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Cytokine;Solid tumors;T cell | |
| 130 | Oral Presentation | Engineered natural killer cells reactively block TIGIT and CD73 in the GBM microenvironment | Kyle B. Lupo, BS; Sandro Matosevic, PHD | Cellular Therapies | Adoptive immunotherapy;Immune suppression;NK/NKT cell;Solid tumors;Targeted therapy;Tumor microenvironment | |
| 131 | Poster Presentation | Genetic disruption of negative immune regulators to enhance CAR-T efficacy against solid tumors | David Mai, BS; Omar S. Johnson; Carl H. June, MD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Solid tumors;T cell | |
| 132 | Oral Presentation | HLA-independent T cell receptors effectively target low abundance antigens | Jorge Mansilla-Soto, PhD; Justin Eyquem; Sascha Haubner; Mohamad Hamieh; Judith Feucht; Noémie Paillon; Andres E. Zucchetti; Zhuoning Li; Maria Sjöstrand; Pieter L. Lindenbergh; Michelle Saetersmoen; Mathieu Maurin; Archana Iyer; Anton Dobrin; Andreina Garcia Angus; Matthew M. Miele; Zeguo Zhao; Theodoros Giavridis; Sjoukje JC. van der Stegen; Fella Tamzalit; Morgan Huse; Ronald C. Hendrickson; Claire Hivroz; Michel Sadelain | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Leukemia/Lymphoma;T cell | |
| 135 | Poster Presentation | Identification and Characterization of an allogeneic iNKT-CAR targeting BCMA | Xavier Michelet, PhD; Eleni Chantzoura, PhD; Efrat Altman-Sharoni; Martyna Popis; Reed Masakyan; Paul Ibbett; Deborah Wright; Moira Pinzan Rossi; Marc A. Van Dijk, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Leukemia/Lymphoma;NK/NKT cell;Targeted therapy | |
| 136 | Poster Presentation | ATA3271: An Armored, Next-Generation Off-The-Shelf, Allogeneic, Mesothelin-CAR T Cell Therapy for Solid Tumors | Xianhui Chen, PhD; Jiangyue Liu; Shuai Yang; Amogh Oke; Sarah Davies; Bryan Ruiz-Juarez; Yannick Bulliard; Cokey Nguyen | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Checkpoint blockade;Solid tumors;T cell;Targeted therapy;Tumor microenvironment | |
| 138 | Poster Presentation | Synthetic re-direction of TGFβ receptors as a novel strategy to enhance the anti-tumor activity of CAR-T cells in solid tumors | Eigen Peralta; Emily Carron, PhD; Hui-Yi Chu; Lorraine Loter; Natalie Navarrete; Arvin Tam; Amit Mehta; Dan Lu; Philip Chu; Kenyon Lyon; Yijia Pan; Mochtar Pribadi; Alec Witty; Tom Lee; Bob Valamehr, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Cytokine;Immune suppression;NK/NKT cell;Solid tumors;T cell;Tumor microenvironment | |
| 139 | Poster Presentation | Chimeric antigen receptor macrophages (CAR-M) elicit a systemic anti-tumor immune response and synergize with PD1 blockade in immunocompetent mouse models of HER2+ solid tumors | Stefano Pierini, PhD; Michael Klichinsky, PharmD, PhD; Rashid Gabbasov, PhD; Alison Worth; Ilyssa Ramos; Daniel Blumenthal, PhD; Linara Gabitova, PhD; Sascha Abramson, PhD; Thomas Condamine, PhD; Michael Ball; Yumi Ohtani, PhD | Cellular Therapies | Adoptive immunotherapy;Checkpoint blockade;Monocyte/Macrophage;Solid tumors;Tumor microenvironment | |
| 143 | Poster Presentation | Mesothelin (MSLN) targeting allogeneic CAR T cells engineered to overcome tumor immunosuppressive microenvironment | Cecile Schiffer-Mannioui; Sophie Leduc; Isabelle Chion-Sotinel; Diane le Clerre; Valérie Guyot; Marco Rotondi; Roman Galetto, PhD; Agnès Gouble | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Immune suppression;Solid tumors;T cell;Targeted therapy;Tumor microenvironment | |
| 144 | Poster Presentation | SIRP⍺ deficient CAR-Macrophages exhibit enhanced anti-tumor function and bypass the CD47 immune checkpoint | Chris Sloas, PhD; Rashid Gabbasov, PhD; Nicholas R. Anderson, PhD; Sascha Abramson, PhD; Michael Klichinsky, PharmD, PhD; Yumi Ohtani, PhD | Cellular Therapies | Adoptive immunotherapy;Checkpoint blockade;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy;Tumor microenvironment | |
| 145 | Poster Presentation | Comparison of CAR-T cell manufacturing platforms reveals distinct phenotypic and transcriptional profiles | Hannah W. Song, PhD; Lipei Shao, PhD; Michaela Prochazkova; Adam Cheuk, PhD; Ping Jin, PhD; David F. Stroncek, MD; Javed Khan, MD; Steven L. Highfill, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Clinical study;Gene expression;Solid tumors;T cell | |
| 146 | Poster Presentation | Evolving Mutliplexed shRNA to generate tailored CAR T cell therapy | Mikhail Steklov; Benjamin Lecalve; Jerome Marijse; Fanny Huberty; Nancy Ramelot; Celine Jacques-Hespel; Hannes Iserentant; Eytan Breman, MSc; David E. Gilham, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;T cell | |
| 147 | Poster Presentation | Memory phenotype in allogeneic anti-BCMA CAR-T cell therapy (P-BCMA-ALLO1) correlates with in vivo tumor control | Hubert Tseng, PhD; Yan Zhang, Ph.D.; Stacey Cranert, Ph.D.; Maximilian Richter, Ph.D.; Karl Marquez; Jing Qiu; Benjamin Cho; Yening Tan; Min Tong, MS; Christine Domingo, BS; Leslie A. Weiss, M.S.; Elvira Argus, Ph.D.; Jessica Sparks; Eric M. Ostertag, Ph.D. M.D.; Julia Coronella, Ph.D.; Devon J. Shedlock, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;T cell | |
| 148 | Poster Presentation | Primary or iPSC-derived cell-based cytotoxicity assays to assess potential safety risks of engineered T cell therapies in vitro | Sophie C. Vermond, MSc; Monique Hazenoot; Rene McLaughlin; Sabrina de Munnik; Marco Guadagnoli; Gemma Moiset; Sanne Holt; Marijn Vlaming | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor antigens | |
| 149 | Poster Presentation | In vitro efficacy studies to support engineered T cell therapies | Sabrina de Munnik; Monique Hazenoot; Sophie C. Vermond, MSc; Rene McLaughlin; Marco Guadagnoli; Gemma Moiset; Sann Holt; Marijn Vlaming | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Cytokine;T cell;Targeted therapy;Tumor antigens | |
| 150 | Poster Presentation | Targeted delivery of a PD-L1-blocking scFv by CAR-NK cells shows potential as a new approach to immunotherapy for glioblastoma | Jiao Wang, PhD; Sandro Matosevic, PHD | Cellular Therapies | Adoptive immunotherapy;Checkpoint blockade;Immune suppression;NK/NKT cell;Solid tumors;Targeted therapy;Tumor microenvironment | |
| 151 | Poster Presentation | Potentiating the Large-Scale Expansion and Engineering of Peripheral Blood-Derived CAR NK Cells for Off-the-Shelf Application | Michael I. Whang, PhD; Ming-Hong Xie, MD; Kate Jamboretz, MS; Hadia Lemar, BS; Chao Guo, PhD; Nafees Rahman, PhD; Ivan Chan, PhD; Erik M. Whiteley, PhD; Ralph Brandenberger, PhD; Sasha Lazetic; James B. Trager, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;NK/NKT cell;Targeted therapy | |
| 152 | Oral Presentation | Common trajectories of highly effective anti-CD19 chimeric antigen receptor-modified T cells identified by endogenous T cell receptor lineages | Taylor L. Wilson, BS; Hyunjin Kim, PhD; Jeremy C. Crawford, PhD; Ching-Heng Chou, PhD; Deanna Langfitt, PhD; E. Kaitlynn Allen, PhD; Timothy Lockey, PhD; Michael Meagher, PhD; Aimee C. Talleur, MD; Stephen Gottschalk, MD; Paul G. Thomas, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Gene expression;T cell;T cell lineages | |
| 153 | Poster Presentation | Nanoscale, antigen-dependent, IL-12 delivery by CAR T cells plus PD-L1 blockade for cancer treatment | Zhifen Yang, Dr.; Francesco M. Marincola, MD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Checkpoint blockade;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) | |
| 154 | Poster Presentation | Context-dependent reversible modulation of cJUN expression by CAR T cells for cancer treatment | Zhifen Yang, Dr.; Francesco M. Marincola, MD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Checkpoint blockade;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 155 | Poster Presentation | CD5 knockout enhances the potency of multiplex base-edited allogeneic anti-CD5 CAR T-cell therapy for the treatment of T-cell malignancies | Yinmeng (Amy) Yang, PhD; Ryan Murray; Adam J. Camblin, PhD; Faith Musenge; Lindsey Coholan; MarkVic Naniong; David Sweezy; Scott Haskett; Lauren Young; Yingying Zhang, PhD; Amanda Costa; Hui Wu; Alden Ladd; Luis Barrera, PhD; Lisa Schlehuber, PhD; Sarah Smith; Yeh-Chuin Poh, PhD; Giuseppe Ciaramella, PhD; Jason Gehrke, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Leukemia/Lymphoma;T cell | |
| 156 | Poster Presentation | RBC-Derived, Activating Antigen Carriers (SQZ AACs) Prime Potent T Cell Responses and Drive Tumor Regression In Vivo | Katarina Blagovic, PhD; Carolyne Smith, PhD; Lindsay Moore; Emrah Ilker Ozay, PhD; Armon Sharei, PhD; Howard Bernstein, MD, PhD; Scott M. Loughhead, PhD | Cellular Therapies | Adoptive immunotherapy;Chemotherapy;Immune adjuvant;Solid tumors;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Vaccine | |
| 157 | Poster Presentation | Lymph node targeted boosting with cognate Amphiphile-peptide vaccines enhances TCR-T Cell therapy to eradicate solid tumors | Dylan J. Drakes, PhD; Abdulraouf M. Abbas, M.Sc.; Jacqueline Shields; Peter C. DeMuth, PhD | Cellular Therapies | Adoptive immunotherapy;Immune adjuvant;Solid tumors;T cell;Targeted therapy;Vaccine | |
| 158 | Poster Presentation | Chemotherapy Resistant Gamma Delta T-cell Immunotherapy can leverage synergistic ligand expression through combinational chemotherapy and PARP-inhibitor use to enhance tumor cell recognition & killing | Kate M. Rochlin, PhD; Amber Jones; Lawrence S. Lamb, Jr., PhD; Anita Hjelmeland, PhD | Cellular Therapies | Checkpoint blockade;Chemotherapy;Gene expression;Solid tumors;T cell;Tumor antigens | |
| 160 | Poster Presentation | Evaluation and development of dual and triple antigen targeting CAR-T Engager proteins for Her2-positive CNS metastases and solid tumors | Paul D. Rennert, PhD; Lan Wu, PhD; Lihe Su, PhD; Roy R. Lobb, PhD; Christine Ambrose, PhD | Cellular Therapies | Adoptive immunotherapy;Bispecifics;CAR T cells;Tumor antigens | |
| 161 | Poster Presentation | Anti-myeloid poly-pharmacy combined with FGFR4-targeted chimeric antigen receptors (CARs) effectively treats orthotopic rhabdomyosarcoma, modeling CAR effectiveness for solid tumors | Peter M. Sullivan, PhD; Rajesh Kumar, PhD; Wei Li, PhD; Lingyang Wang, PhD; Yue Zhang, MS; Adam Cheuk, PhD; Javed Khan, MD; Dimiter S. Dimitrov, PhD; Rimas J. Orentas, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Myeloid cells;Pediatric tumors;Solid tumors;Targeted therapy;Tumor microenvironment;Tumor stroma | |
| 162 | Poster Presentation | Nicotinamide rejuvenates ex-vivo expanded natural killer cells and enhances their tumor killing capacity | Aviad AP. Pato, Dr, PhD; Astar Hailu; Nurit Brickman; Dima Yackoubov; Frank S. Cichocki, PhD; Amnon Peled, PhD; Yona Geffen, PhD; Avishay Edri, PhD; Ronit Simantov, MD; Tracey Lodie, PhD; Julia Rifman, PhD; Orit Berhani-Zipori, PhD; Aviad Pato | Cellular Therapies | Adoptive immunotherapy;NK/NKT cell;Solid tumors | |
| 163 | Poster Presentation | Improved anti-tumor activity of next-generation TCR-engineered T cells through CD8 co-expression | Gagan Bajwa; Justin T. Gunesch; Inbar Azoulay-Alfaguter; Melinda Mata; Ali Mohamed; Mamta Kalra; Steffen Walter | Cellular Therapies | Adoptive immunotherapy;Antigen presenting cells;Costimulation;Cytokine;T cell;Targeted therapy;Tumor microenvironment | |
| 164 | Poster Presentation | Potent Tumor Organoid Infiltration and Killing by PBMC-Derived Effector Cells | Frank Borriello, MD, PhD; Joshua Keegan; James A. Lederer, PhD | Cellular Therapies | Adoptive immunotherapy;NK/NKT cell;T cell | |
| 166 | Poster Presentation | Genetically engineered tumor-infiltrating lymphocytes (cytoTIL15) exhibit IL-2-independent persistence and anti-tumor efficacy against melanoma in vivo | Rachel A. Burga, PhD; Mithun Khattar, PhD; Scott Lajoie; Kyle Pedro, PhD; Colleen Foley; Alonso Villasmil Ocando; Jack Tremblay; Benjamin Primack; Meghan Langley, BS; Dan Thornton; Stanley Tam; Emily Brideau; Theresa Ross; Gwen Wilmes, PhD; Sunandan Saha, PhD; Gabriel Helmlinger, PhD; Jeremy Tchaicha, PhD; Dhruv Sethi, PhD; Michelle L. Ols, PhD; Gary Vanasse, MD; Shyam Subramanian, PhD; Jan ter Meulen, MD, PhD | Cellular Therapies | Adoptive immunotherapy;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) | |
| 167 | Poster Presentation | High-efficiency capture of anti-tumor neoantigen-reactive T cell receptors from tumor digest | Praveen D. Chatani, MD; Frank J. Lowery, PhD; Neilesh B. Parikh, M.D.; Rami Yossef, PhD; Victoria Hill, PhD; Zhiya Yu, PhD; Todd D. Prickett, PhD; Jared Gartner; Biman C. Paria, M.S.; Satyajit Ray; Maria Florentin; Paul F. Robbins, PhD; Sri Krishna, PhD; Steven A. Rosenberg, MD, PhD | Cellular Therapies | Adoptive immunotherapy;Biomarkers;Clinical study;Neoantigens;T cell;T cell lineages;Tumor antigens | |
| 168 | Poster Presentation | Expanding and characterizing tumor infiltrating lymphocytes from myxofibrosarcoma and undifferentiated pleomorphic sarcoma | Jacky HK. Chen, HBSc; Jay S. Wunder, MD., MSc; Kim Tsoi, MD., PhD; Nalan Gokgoz, PhD; Irene L. Andrulis, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Costimulation;Cytokine;Immune suppression;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 169 | Poster Presentation | Off-the-shelf, engineered iPSC-derived NK cells mediate potent cytotoxic activity against primary glioblastoma cells and promote durable long-term survival in vivo | Frank S. Cichocki, PhD; Jianfang S. Ning; Zachary B. Davis, PhD; Hongbo S. Wang; Katie S. Tuininga; Ryan Bjordahl, PhD; Paul Rogers, PhD; Moyar Ge, PhD; Tom Lee; Bob Valamehr, PhD; Clark C. Chen, MD; Jeffrey S. Miller, MD | Cellular Therapies | Adoptive immunotherapy;NK/NKT cell | |
| 170 | Poster Presentation | Novel gene editing approach to enhance CD38-directed antitumor activity of primary human natural killer cells | Joseph A. Clara, MD; Emily Levy; Robert Reger; Mala Chakraborty; David Allan; Richard W. Childs, M.D. | Cellular Therapies | Adoptive immunotherapy;Antibody;NK/NKT cell;Targeted therapy | |
| 171 | Poster Presentation | Targeting the Immunomodulatory Roles of T-cell immunoglobulin– and mucin domain–containing (TIM)–3 on Natural Killer Cells in Glioblastoma | Tram N. Dao; Sandro Matosevic, PHD | Cellular Therapies | Adoptive immunotherapy;Metabolism;NK/NKT cell;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 172 | Poster Presentation | Overcoming immunosuppressive TGF-β signaling in human ovarian cancer-derived tumor infiltrating lymphocytes via non-viral CRISPR engineering | Samantha M. Fix, PhD; Marie-Andrée Forget; Donastas Sakellariou-Thompson, BS; Yunfei Wang; Ana Lucía Dominguez; Rafet Basar; Christopher Reyes; Sanjay Kumar; Larissa A. Meyer; Patrick Hwu; Chantale Bernatchez, PhD; Amir Jazaeri, MD | Cellular Therapies | Adoptive immunotherapy;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 174 | Poster Presentation | Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes | Meredith Frank, MSc; Parin Shah; Marie Andree Forget, PhD; Lorenzo Federico, PhD; Peixin Jiang; Roohussaba Khairullah; Ignacio Wistuba, MD; Chi-Wan Chow; Yan Long; Junya Fujimoto; Shiaw-Yih Lin, Ph.D.; Anirban Maitra, MBBS; Marcelo V. Negrao, MD; Kyle Mitchell, MD; Annika Weissferdt, MD; Ara A. Vaporciyan, MD; Tina Cascone, MD, PhD; Jack Roth; Jianjun Zhang, MD, PhD; Boris Sepesi, MD; Don L. Gibbons, MD, PhD; John V. Heymach, MD, PhD; Cara Haymaker, PhD; Daniel J. McGrail, PhD; Chantale Bernatchez, PhD; Alexandre Reuben, PhD | Cellular Therapies | Adoptive immunotherapy;Clinical study;Neoantigens;Solid tumors;T cell;T cell lineages;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 175 | Poster Presentation | High-dose TIL product with improved phenotype and functionality | Christina Friese, PhD; Christina Heeke, PhD; Nikolaj Kirketerp-Møller, MS; Sandra Færch; Maria Juul Nielsen; Amalie Hey, PhD; Ulrik Cordes | Cellular Therapies | Adoptive immunotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 176 | Poster Presentation | Successful generation of tumor-infiltrating lymphocyte (TIL) product from renal cell carcinoma (RCC) tumors for adoptive cell therapy | Brian Halbert, MD MPH; David Einstein, MD; David F. McDermott, MD; Emanuelle I. Andrianopoulos; Mamta Gupta, MD; Virginia Seery, MSN, RN, ANP-BC; Kenneth Onimus; Courtney Herman; Adrian Wells; Shwetha Lakshmipathi; Arvind Natarajan; Anand Veerapathran; Rupal Bhatt, MD, PhD | Cellular Therapies | Adoptive immunotherapy;Solid tumors;Tumor infiltrating lymphocytes (TILs) | |
| 177 | Poster Presentation | Treatment outcomes with unselected autologous tumor infiltrating lymphocytes in patients with checkpoint inhibition–refractory advanced cutaneous melanoma | Robert E. Hawkins, MD, PhD; Yizhou Jiang; Paul C. Lorigan; Fiona C. Thistlethwaite; Manon Pillai; Martine Thomas; Natalia Kirillova; John S. Bridgeman; Gray Kueberuwa; Ryan D. Guest; Zachary J. Roberts | Cellular Therapies | Adoptive immunotherapy;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 178 | Poster Presentation | Expansion of Tumor-Infiltrating Lymphocytes and Marrow-Infiltrating Lymphocytes from Pediatric Malignant Solid Tumors | Jonathan Metts, MD; Jonathan A. Hensel, PhD; Alejandro Alfaro; Brook Olmo; Shari A. Pilon-Thomas, PhD; John E. Mullinax, MD; Ivanna Leon | Cellular Therapies | Adoptive immunotherapy;Pediatric tumors;Solid tumors;T cell | |
| 179 | Poster Presentation | CD8+CD69+ Expanded Tumor Infiltrating Lymphocytes from Soft Tissue Sarcoma Have Increased Tumor-Specific Functional Capacity | Jonathan A. Hensel, PhD; Alejandro Alfaro; Mary Rau; Patricio Perez-Villarroel; Zachary Sannasardo; Shari A. Pilon-Thomas, PhD; John E. Mullinax, MD | Cellular Therapies | Adoptive immunotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 180 | Poster Presentation | T Cell Phenotype Drives Restructuring of Tumor Microenvironment to Balance T Cell Longevity and Tumor Control: Insights from Multiplexed Imaging and Multi-scale Agent Based Modeling | John W. Hickey, PhD; Garry P. Nolan, PhD; Markus Covert; Eran Agmon; Nina B. Horowitz, MS; John B. Sunwoo, MD | Cellular Therapies | Adoptive immunotherapy;Bioinformatics;CAR T cells;Immune contexture;Immune monitoring;Solid tumors;Systems biology;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 181 | Poster Presentation | Intraepithelial group 1 innate lymphoid cells generated in vitro exhibit enhanced cytotoxicity and infiltration into solid tumoroids | Nina B. Horowitz, MS; John W. Hickey, PhD; John B. Sunwoo, MD | Cellular Therapies | Adoptive immunotherapy;NK/NKT cell;Solid tumors;Tumor infiltrating lymphocytes (TILs) | |
| 184 | Poster Presentation | Adoptive T cell therapies targeting common p53 neoantigens in human solid cancers | Peter Kim, PhD; Steven A. Rosenberg, MD, PhD; Nolan Vale | Cellular Therapies | Adoptive immunotherapy;Neoantigens;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs) | |
| 185 | Poster Presentation | Ex vivo efficacy of adoptive T cell therapy using autologous CD8+ T cells isolated by PD-1 positivity from peripheral blood mononuclear cells in solid tumors | Sungkyu Lee, Ph.D; yong wha Moon | Cellular Therapies | Adoptive immunotherapy;Coinhibition;Neoantigens;Solid tumors;T cell;T cell lineages;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 186 | Poster Presentation | Development of KSQ-001, an engineered TIL (eTIL) therapy for solid tumors through CRISPR/Cas9-mediated editing of SOCS1 | Karrie K. Wong, PhD; Sharon Lin, PhD; Christopher Wrocklage; Katri Sofjan; Leila Williams; Mallory Brady; Nicholas Colletti, PhD; Noah Tubo; Hugh Gannon; Robert A. LaMothe; Tianlei Xu, PhD; Tracy VandenBerg; Sol Shenker, PhD; Caroline Dugopolski; Frank Stegmeier, PhD; Louise Cadzow; Michael Schlabach, PhD; Micah J. Benson, PhD | Cellular Therapies | Adoptive immunotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 187 | Poster Presentation | Multi-omic single-cell profiling demonstrates that competition for fatty acids and fatty acid oxidation enables tumor-infiltrating lymphocyte function and survival | Melisa Angela M. Paniagua, PhD; Melisa A. Martinez Paniagua, PhD; Cara Haymaker, PhD; Jay R Adolacion; Xingyue An, BS; Caitlin Creasy, MS; Mohsen Fathi; Ali Rezvan; Tamar Geiger; Michal Harel; Jonathan Robinson; Amit Amritkar; Scott Woodman; Patrick Hwu; Chantale Bernatchez, PhD; Navin Varadarajan, PhD | Cellular Therapies | Adoptive immunotherapy;Gene expression;Metabolism;Proteomics;RNA;Tumor infiltrating lymphocytes (TILs) | |
| 188 | Poster Presentation | Development of WU-NK-101, a feeder cell-free expanded allogeneic memory NK cell product with potent anti-tumor activity. | Ryan Sullivan, PhD; Mary Mathyer; Jennifer Govero; John Dean; Andrew Martens; You Zhou; Malik Darwech; Brunda Tumala; Alex Vessoni; Alexander Hamil; Tom Leedom; Corey Johnson; Melissa Berrien-Elliot; Mark Foster; Michelle Becker-Hapak; Ethan McClain; Carly Neal; Todd A. Fehniger, MD, PhD; Niraj Shrestha, PhD; Mike Dee; Hing C. Wong, PhD; Ayman Kabakibi; Matthew L. Cooper; Ken Chrobak | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Leukemia/Lymphoma;NK/NKT cell;T cell | |
| 189 | Poster Presentation | Targeting a novel shared tumor-specific antigen with T cell receptor transduced T cells for the treatment of ovarian cancer | Justyna Ogonek, PhD; Justyna Ogonek; Tiziana Franceschetti; Andreas Acs; Alexander Schmidt; Alexandra Kuhlenkamp; Krystel Vincent; Claude Perreault; Barbara Loesch; Adriana Turqueti Neves; Slavoljub Milosevic; Dolores J. Schendel; Daniel Sommermeyer | Cellular Therapies | Adoptive immunotherapy;Solid tumors;T cell;Tumor antigens | |
| 190 | Poster Presentation | Patient-derived tumor organoids reveal mechanisms of immune evasion which can guide decisions in adoptive cell therapy for common epithelial cancers | Anup Y. Parikh, MD; Maria Parkhurst, PhD; Paul F. Robbins, PhD; Steven A. Rosenberg, MD, PhD; James C. Yang, MD, PhD | Cellular Therapies | Adoptive immunotherapy;Gene expression;Neoantigens;RNA;Solid tumors;T cell;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs) | |
| 191 | Poster Presentation | GAPDH knock-in of high affinity CD16 in iPSC derived NK cells drives high-level expression and increased anti-tumor function | Rithu Pattali; Kaitlyn M. Izzo; Edward J. Goncz; Steven Sexton; Kevin M. Wasko; John A. Zuris, Ph.D.; Michael Nehil, Ph.D.; Kate Zhang, Ph.D.; Mark Shearman, Ph.D.; Kai-Hsin Chang, Ph.D.; Alexander G. Allen, Ph.D. | Cellular Therapies | Adoptive immunotherapy;NK/NKT cell;Solid tumors | |
| 192 | Poster Presentation | POoled T Cell Receptor Screening (POTS) Provides Unbiased, High-Throughput Method for TCR Discovery | Jack L. Reid, BSc; Shihong Zhang, Ph.D; Ariunaa Munkhbat; Matyas Ecsedi, MD, PhD; Megan S. McAfee, PhD; Aude Chapuis, MD | Cellular Therapies | Adoptive immunotherapy;T cell;Tumor antigens | |
| 193 | Poster Presentation | The Achilles VELOSTM Process 2 boosts the dose of highly functional clonal neoantigen-reactive T cells for precision personalized cell therapies | Eleni Kotsiou, PhD; Joe Robinson; Amber Rogers; Daisy Melandri; Amy Baker; Anabel Ramirez Aragon; Sidra Nawaz; Michael Epstein; Shreenal Patel; Jennine Mootien; Andrew W. Craig, PhD; Satwinder Kaur-Lally; Hinal Patel; Andreas Schmitt; Farah Islam; Mariam Jamal-Hanjani; David Lawrence; Martin Foster; Samra Turajlic, MD PhD; Sergio A. Quezada, PhD; Katy Newton, BSc PhD | Cellular Therapies | Adoptive immunotherapy;Dendritic cell;Neoantigens;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 195 | Poster Presentation | Stimulation of tumor infiltrating B-cells improves ex-vivo TIL expansion for melanoma immunotherapy | Renata AM. Rossetti, PhD; Leticia Tordesillas; Matthew Beatty, PhD; Yian Ann Chen; Dongliang Du; Amod A. Sarnaik; Shari A. Pilon-Thomas, PhD; Daniel Abate-Daga, PhD | Cellular Therapies | Adoptive immunotherapy;B cell;Solid tumors;Tumor infiltrating lymphocytes (TILs) | |
| 196 | Poster Presentation | TLR9-activated B cells directly license adoptively transferred CD8+ T cells with potent tumor immunity | Aubrey S. Smith, BS; Hannah M. Knochelmann, BS; Megan M. Wyatt, MS; Guillermo O. Rangel RIvera, B.S.; Brandon Ware, PhD; Amalia M. Rivera Reyes, BS; Connor J. Dwyer, PhD; David M. Neskey, MD; Mark P. Rubinstein, PhD; Bei Liu, MD MPH; Jessica E. Thaxton, PhD, MS; Eric C. Bartee, PhD; Chrystal M. Paulos, PhD | Cellular Therapies | Adoptive immunotherapy;Antigen presenting cells;B cell;Costimulation;Solid tumors;T cell;TLR;Tumor infiltrating lymphocytes (TILs) | |
| 198 | Poster Presentation | Costimulatory antigen receptor (CoStAR): a novel platform that enhances the activity of tumor infiltrating lymphocytes (TILs) | Sujita Sukumaran, PhD; Milena Kalaitsidou; Michelle Mojadidi; Clare Yarka; Yong (Stella) Ouyang; Eric Gschweng; Gray Kueberuwa; John S. Bridgeman, PhD; Bob Hawkins; Rubén Alvarez-Rodríguez | Cellular Therapies | Adoptive immunotherapy;Antibody;Costimulation;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 199 | Poster Presentation | Potent T cell costimulation mediated by a novel costimulatory antigen receptor (CoStAR) with dual CD28/CD40 signaling domains to improve adoptive cell therapies | Martina Sykorova; Leyuan Bao; Cynthia Chauvin-Fleurence; Milena Kalaitsidou; Michelle Le Brocq; Robert E. Hawkins, MD, PhD; Gray Kueberuwa; John S. Bridgeman, PhD; Rubén Alvarez-Rodríguez | Cellular Therapies | Adoptive immunotherapy;Antibody;Costimulation;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 200 | Poster Presentation | TGFβ-Armoring Boosts Potency and Persistence of Engineered TCR T Cells, Unlocking Superior Efficacy Against HPV-positive Solid Tumors | Gail D. Turner, PhD; Gabriela Diaz, BS; Andreia Costa, PhD; Yeonjoo Oh, MS; Jianguo Huang, PhD; Jenna Bailey, BS; Cyr C. De Imus, BS; Stephanie E. Busch, PhD; Teresa Foy, PhD; Pallavur Sivakumar, PhD; Ruth A. Salmon, PhD; Cédric Cleyrat, PhD | Cellular Therapies | Adoptive immunotherapy;Solid tumors;T cell;Tumor microenvironment | |
| 201 | Poster Presentation | BNT221, an autologous neoantigen-specific T-cell product for adoptive cell therapy of metastatic ovarian cancer | Christina Arieta, PhD; Diana Velez, MS; Susan B. Hannes, BS; Shirisha Meda, MS; Brian McCarthy; Divya R. Lenkala, MS; Dewi Harjanto; Prerna Suri; Jessica Kohler, PhD; Jonathan McGee; Daniel Kallin; Paul Turcott; Cynthia Nijenhuis; Maarje W. Rohaan; Gabe Sonke; John B. Haanen, MD; Mark DeMario, MD; Richard B. Gaynor, MD; Marit M. Van Buuren, PhD | Cellular Therapies | Adoptive immunotherapy;Neoantigens;RNA;T cell | |
| 203 | Poster Presentation | A Membrane-Tethered IL-15/IL-15 Receptor Fusion Protein Enhances the Persistence and Efficacy of CD70-Targeted TRuC-T Cells | Jian Ding, PhD; Lindsay Webb; Troy Patterson; Michelle Fleury, PhD; Adam Zieba, MS; Holly Horton, PhD; Robert Hofmeister, PhD; Dario Gutierrez; Robert Tighe, NN | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Cytokine;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 204 | Poster Presentation | KSQ-004: Unbiased pair-wise discovery of SOCS1 and Regnase-1 as the top CRISPR/Cas9 dual-edit combination enhancing in vivo TIL potency against solid tumors | Karrie K. Wong, PhD; Christopher Wrocklage; Sharon Lin, PhD; Isabelle Le Mercier, PhD; Caroline Bullock; Louise Cadzow; Anja Hohmann, PhD; Sol Shenker, PhD; Katri Sofjan; Leila Williams; Gregory Kryukov, PhD; Conor Calnan; Frank Stegmeier, PhD; Micah J. Benson, PhD; Michael Schlabach, PhD | Cellular Therapies | Adoptive immunotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 205 | Poster Presentation | agenT-797, a native allogeneic “off-the-shelf” iNKT cell therapy product shows anti-tumor activity in preclinical xenograft models | Burcu Yigit, PhD; Darrian Moskowitz; Xavier Michelet, PhD; Antoine Tanne, PhD; Marc A. Van Dijk, PhD | Cellular Therapies | Adoptive immunotherapy;Leukemia/Lymphoma;NK/NKT cell;Solid tumors;T cell | |
| 207 | Poster Presentation | Enhanced antigen capture, antigen-presenting cell (APC)-like function, and cytotoxic responses with chimeric engulfment receptor (CER) T cells | Daniel Corey, MD; Sunil Thomas, PhD; Brandon Cieniewicz, PhD; Linh Nguyen, PhD; Jared Clever, PhD; Josephine Brysting, BS; Remus Vezan, MD PhD; John M. Rossi, MS; Kurt Diem, PhD; Lei Jin, PhD; Lawrence Corey, MD | Cellular Therapies | Adoptive immunotherapy;Antigen presenting cells;CAR T cells;Costimulation;Dendritic cell;Leukemia/Lymphoma;Monocyte/Macrophage;T cell;TLR;Tumor evasion | |
| 209 | Oral Presentation | Genetically Engineered Myeloid Cells (GEMys) as a Platform to Enhance Antitumor Immunity | Sabina Kaczanowska, PhD; Daniel Beury, PhD; Haiying Qin, MS; Rosandra N. Kaplan, MD | Cellular Therapies | Adoptive immunotherapy;Cytokine;Immune suppression;Monocyte/Macrophage;Myeloid cells;Pediatric tumors;Solid tumors;Tumor microenvironment | |
| 210 | Poster Presentation | A novel medium for increased cytotoxicity and serum-minimal ex vivo expansion of natural killer (NK) cellular immunotherapies | Marc A. Gillig, PhD; Graeme Lambert; Donna Sonntag; Rachit Ohri, Ph.D.; Jason G. Cahoon, BS; Avishai Shemesh, PhD; Nadhim A. Mukhaiter, MS | Cellular Therapies | Adoptive immunotherapy;NK/NKT cell | |
| 213 | Poster Presentation | AB-X integrated circuit T cells demonstrate improved potency, expansion, and specificity compared to MSLN CAR T cells | Stephen Santoro, PhD; Aaron Cooper, PhD; Natalie Bezman, PhD; Jun Feng, PhD; Kanika Chawla, PhD; Jaspar Williams, PhD; John Gagnon, PhD; Jason Hall, PhD; Dina Polyak, PhD; Angela Boroughs, PhD; Michelle Nguyen; Suchismita Mohanty, PhD; Adam Litterman, PhD; Jeff Granja; David DeTomaso, PhD; Grace Zheng, PhD; Jenessa Smith, PhD; Drake LeFace, PhD; Tarjei Mikkelsen, PhD; Susie Jun, MD, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor microenvironment | |
| 214 | Poster Presentation | SIRPα-deficient macrophages activate polyclonal tissue-resident cytotoxic CD8 T cells to eliminate irradiation-refractory non-small cell lung carcinoma | Zhen Bian, PhD; Lei Shi, PhD; Koby Kidder, PhD; Yuan Liu, MD PhD | Cellular Therapies | Antigen presenting cells;Immune suppression;Monocyte/Macrophage;Myeloid cells;Radiotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine | |
| 215 | Poster Presentation | Tissue-resident natural killer cells resembling intraepithelial ILC1 have potent anti-tumor activity in human head and neck cancer and represent a novel class of effector cells for immunotherapy | JuneHo JS. Shin, Ph; Nina B. Horowitz, MS; Quan L. Tran; Chen Chen; Uriel Y. Moreno-Nieves, PhD; Joshua K. Tay, MD PhD; Saumyaa Saumyaa; John B. Sunwoo, MD | Cellular Therapies | Adoptive immunotherapy;NK/NKT cell;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 216 | Oral Presentation | Multiplex base editing of NK cell to enhance cancer immunotherapy | Minjing Wang, BSc; Mitchell G. Kluesner, BSc; Patricia N. Claudio Vázquez, BSc; Beau R. Webber, PhD; Branden S. Moriarity, PhD | Cellular Therapies | Gene expression;NK/NKT cell | |
| 217 | Poster Presentation | Cytotoxicity of nicotinamide enhanced natural killer cells GDA201 is based on metabolic modulation as demonstrated by artificial intelligence assisted analysis of NK cell transcriptome and metabolome | Dima DY. Yackoubov, MSc; Aviad Pato; Julia Rifman, PhD; Sherri Cohen; Astar Hailu; Nurit Brycman; Orit Berhani-Zipori, PhD; Avishay Edri, PhD; Boaz Buhandler; Moshe Shahor; Nathan Dinowitz; Amram Ben David; Avi Izraeli; Vered Chalifa-Caspi, PhD; Liron Levin, PhD; Joshua D. Rabinowitz, Prof.; Wenyun Lu, PhD; Tracey Lodie, PhD; Julian Adams, PhD; Yona Geffen, PhD | Cellular Therapies | Adoptive immunotherapy;Bioinformatics;Biomarkers;Gene expression;Leukemia/Lymphoma;Metabolism;NK/NKT cell;Proteomics | |
| 220 | Poster Presentation | Transfection of human adipose-derived mast cells: A characteristic study using different chemical reagents | Mona Motaghed, PhD Candidate; Christopher Kepley, Ph.D.; Kristen Dellinger, Ph.D.; Elnaz Ahani, Ph.D. Candidate; Mohammad Fereydouni, Ph.D. Candidate | Cellular Therapies | Adoptive immunotherapy;Gene expression;Monocyte/Macrophage | |
| 221 | Oral Presentation | CRISPR screen identifies loss of IFNγR signaling and downstream adhesion as a resistance mechanism to CAR T-cell cytotoxicity in solid but not liquid tumors | Rebecca C. Larson, BS; Michael Kann; Stefanie R. Bailey, PhD; Nicholas J. Haradhvala; Kai Stewart; Amanda Bouffard; Irene Scarfo; Mark Leick; Trisha R. Berger; Max Jan; Julia Joung; Tamara Ouspenskaia; Travis Law; Aviv Regev, PhD; Gad Getz, PhD; Marcela V. Maus, MD, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Leukemia/Lymphoma;Solid tumors | |
| 223 | Poster Presentation | Potent inhibition of PI3Kδ promotes enhanced T cell stemness and mitochondrial fitness | Guillermo O. Rangel RIvera, B.S.; Connor J. Dwyer, PhD; Hannah M. Knochelmann, BS; Aubrey S. Smith, BS; Anna C. Cole, BA; Megan M. Wyatt, MS; Brandon Ware, PhD; Chrystal M. Paulos, PhD | Cellular Therapies | Adoptive immunotherapy;Immune adjuvant;Metabolism;Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs) | |
| 224 | Poster Presentation | M2 macrophage-mediated immune suppression of chimeric antigen receptor T cells via PD-L1 signaling in prostate cancer | Yukiko Yamaguchi; Jackson Gibson; Kevin Ou; Saul Priceman, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Checkpoint blockade;Monocyte/Macrophage;Myeloid cells;Solid tumors | |
| 225 | Poster Presentation | Optimal-affinity MAGE-A1-specific T cell receptors (TCRs) generated using the humanized TCR-transgenic mouse platform HuTCR are superior to human donor-derived TCRs | Ioannis IG. Gavvovidis, PhD; Matthias Leisegang, Prof. Dr.; Vivian Scheuplein, PhD; Matthias Obenaus, MD; Thomas Blankenstein, PhD; Elisa Kieback, PhD | Cellular Therapies | Adoptive immunotherapy;Solid tumors;T cell;Targeted therapy;Tumor antigens | |
| 226 | Poster Presentation | Neoantigen-specific TCR-T cells targeting shared hotspot mutations for adoptive cell therapy in common epithelial cancers | Ana B. Korngold, PhD; Jean Lin-Kin Yong, PhD; Ugochi C. Ibekwe; Julissa Simmons; Phillip Eckels, MPH; Elizabeth Figueroa, PhD; Michelle Hotard; Frances Adeyemi; Thomas Hunt; Tegan Markus; Lenka V. Hurton, PhD; Yaoyao Shi, PhD; Matthew R. Collinson-Pautz, PhD; Priya Balasubramanian, PhD; Cathy Wang, PhD; Jourdan Andersson, PhD; Lauren Heese; Mariam Khalil; David Torres; Emarco Olivares; Geraldine Bardelli; Kelly O'Brien, PhD; Haroon Hashmi; Alena Chekmasova; Raffaele Baffa, MD; Tom Spencer, PhD; Eleanor De Groot, PhD; Drew C. Deniger, PhD | Cellular Therapies | Adoptive immunotherapy;Clinical trial;Neoantigens;Solid tumors;T cell;Tumor antigens | |
| 234 | Oral Presentation | Distinct efficacy and immunological responses to αPD-1, ⍺PD-L1 and ⍺PD-L2 immunotherapy in aged versus young hosts | Yilun Deng, PhD; Harshita Gupta; Myrna G. Garcia, BS; Aravind Kancharla, MS; Ryan M. Reyes; Alvaro S. Padron; Tyler J. Curiel, MD | Checkpoint Blockade Therapy | Antigen presenting cells;Checkpoint blockade;Cytokine;Myeloid cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 241 | Poster Presentation | Immune Checkpoint Blockade (ICB) in Brain Metastases (BM) from Advanced Small Cell Urothelial Cancer (aSCUC) | Nathaniel R. Wilson, MD; Omar Alhalabi, MD; Elshad Hasanov; Lianchun Xiao; John Papadopoulos, MD; Matthew T. Campbell, MD; Amishi Shah; Jianjun Gao, MD PhD; Paul G. Corn, MD, PhD; Ana Aparicio; Jennifer Wang, MD; Bogdan A. Czerniak; Charles C. Guo; Christopher J. Logothetis, MD; Jing Li; Seungtaek Choi; Chad Tang, MD, MS; Nizar M. Tannir, MD, FACP; Arlene O. Siefker-Radtke, MD | Checkpoint Blockade Therapy | Chemotherapy;Clinical study;Radiotherapy;Solid tumors | |
| 242 | Poster Presentation | Pharmacologic tumor PD-L1 depletion with chlorambucil treats ovarian cancer and melanomas in a tumor PD-L1-dependent manner and renders αPD-L1-resistant tumors αPD-L1-sensitive | Haiyan HB. Bai, PhD; Álvaro Padrón; Yilun Deng, PhD; Anand Kornepati; Srikanth R. Polusani; Suresh C. Kari, PhD; Clare E. Murray; Myrna Garcia; Ryan M. Reyes; Niannian Ji; Harshita Gupta; Matthew J. Hart; Tyler J. Curiel, MD | Checkpoint Blockade Therapy | Checkpoint blockade;Chemotherapy;NK/NKT cell;Post-translational modifications;T cell | |
| 243 | Poster Presentation | Understanding and overcoming the mechanism of resistance to anti-PD-1 monotherapy in brain metastasis | Laura Falceto Font, BS; Catherine Flores; Jack Figg; Bayli DiVita Dean; Connor Francis; Carmelle Kuizon; Ginger Moore | Checkpoint Blockade Therapy | Checkpoint blockade;Solid tumors;Tumor evasion | |
| 244 | Poster Presentation | Genomic determinants of response to chemoradiation and durvalumab consolidation for stage III non-small cell lung cancer | Matthew Z. Guo, BA; Joseph C. Murray, MD, PhD; Paola Ghanem, MD; Khinh Ranh Voong, MD, MPH; Russell K. Hales, MD; Josephine L. Feliciano, MD; Kristen A. Marrone, MD | Checkpoint Blockade Therapy | Checkpoint blockade;Chemotherapy;Radiotherapy;Solid tumors | |
| 245 | Poster Presentation | Host myeloid response to tumor and immunotherapy is associated with heterogeneity in outcomes to anti-PDL1 | Ann Hanna, PhD; Xiaopeng Sun, BS; Paula I. Gonzalez-Ericsson, MD; Violeta I. Sanchez, BS; Melinda I. Sanders, MD; Justin M. Balko, PharmD, PhD | Checkpoint Blockade Therapy | Biomarkers;Checkpoint blockade;Chemotherapy;Myeloid cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 248 | Poster Presentation | Empiric profiling of peripheral T cell recall responses to tumor mutanomes versus in silico predictions in NSCLC patients undergoing pembrolizumab treatment ± chemotherapy | Madison Milaszewski, BS; James Loizeaux; Emily Tjon, M.S.; Crystal Cabral, BS, MSc; Tulin Dadali, PhD; Justin Strickland; Jamie Foti, PhD; Kevin J. Mancini, MS; Kesi Michael; Louisa Dowal, PhD; Vijetha Vemulapalli; Alberto Visintin, PhD; Thomas A. Davis, MD; Jessica B. Flechtner, PhD; Mark Awad, MD, PhD | Checkpoint Blockade Therapy | Checkpoint blockade;Neoantigens;T cell | |
| 249 | Poster Presentation | Characterization of unresectable and/or metastatic solid tumors patients treated with systemic anticancer therapy in first-line settings: A Pan-tumor community-oncology based study | Elise Wu, PhD; Sneha Sura, MS, PhD; Alexander I. Spira, MD, PhD, FACP | Checkpoint Blockade Therapy | Checkpoint blockade;Chemotherapy;Epidemiology;Solid tumors | |
| 250 | Poster Presentation | Spatial-transcriptomic analysis of tumor-immune microenvironment in AML patients receiving pembrolizumab and decitabine | Chen Zhao, MD; Abigail Wong-Rolle, BSc; Prajan Divakar; Katherine R. Calvo, MD, PhD; Christopher S. Hourigan, MD, PhD | Checkpoint Blockade Therapy | Chemotherapy;Immune monitoring;Leukemia/Lymphoma;RNA;T cell;Tumor microenvironment | |
| 258 | Poster Presentation | AB308 is an Anti-TIGIT Antibody That Enhances Immune Activation and Anti-tumor Immunity Alone and in Combination with Other I-O Therapeutic Agents | Dana Piovesan, MSc; Alejandra Lopez, BSc; Patrick G. Schweickert, PhD; Ferdie Soriano, BS; Soonweng Cho, PhD; Ada Chen, BS; Hema Singh; Xiaoning Zhao; Stephen W. Young; Nigel P. Walker, PhD; Matthew J. Walters, PhD; Kelsey E. Sivick Gauthier, PhD | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;T cell;Tumor microenvironment | |
| 261 | Oral Presentation | A functional genetic screen uncovers regulators of intratumoral macrophage function and reveals CD24 as a novel target for cancer immunotherapy by macrophages | Amira Barkal, MD, PhD; Rachel Brewer, MS; Irving L. Weissman, MD | Checkpoint Blockade Therapy | Monocyte/Macrophage;Myeloid cells | |
| 265 | Poster Presentation | CD47xPD-L1 bispecific antibodies for cancer therapy | Xavier CHAUCHET, PhD; Elise PENARRIETA; Nicolas BOSSON; Sébastien CALLOUD; Louis HELLEQUIN; Margaux LEGRAND; Alizée VIANDIER; Françoise RICHARD; Laura CONS; Pauline MALINGE; Tereza BAUTZOVA; Jérémie BOURGUIGNON; Guillemette PONTINI; Mengzhu SUN; Ulla RAVN; Valéry MOINE; Yves POITEVIN; Stéphanie HUGUES; Nicolas FISCHER; Limin SHANG; Walter G. FERLIN; Krzysztof MASTERNAK | Checkpoint Blockade Therapy | Adoptive immunotherapy;Antibody;Bispecifics;Checkpoint blockade;Coinhibition;Monocyte/Macrophage;Solid tumors;T cell | |
| 267 | Poster Presentation | Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes anti-tumor immunity and improves therapeutic window | Shih-Hsun Chen, PhD; Pawel Dominik; Jessica Stanfield; Sheng Ding; Wenjing Yang; Ryan Llewellyn; Jonathan Heyen; Carole Wang; Zea Melton; Kevin Lindquist; Thomas Van Blarcom; Javier Chaparro-riggers; Shahram Salek-Ardakani | Checkpoint Blockade Therapy | Adoptive immunotherapy;Antibody;Bispecifics;Checkpoint blockade;Dendritic cell;Immune suppression;Monocyte/Macrophage;Solid tumors;T cell;Tumor microenvironment | |
| 268 | Poster Presentation | KVA 12.1 a novel fully human anti-VISTA antibody: Clinical trial design in monotherapy and in combination with an anti-PD1 antibody | Thierry Guillaudeux, PhD; Shawn Iadonato, PhD; Eric Tarcha, PhD; Craig Philips | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Clinical trial;Immune suppression;Inflammation;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Tumor microenvironment | |
| 270 | Oral Presentation | Anti-CD47 immunotherapy as a therapeutic strategy for the treatment of breast cancer brain metastasis | Jessica D. Mackert, PhD; Elizabeth R. Stirling, MS; Mitra Kooshki, MS; Dawen Zhao, MD; PhD; Alexandra Thomas, MD; Glenn Lesser, MD; Pierre L. Triozzi; David R. Soto-Pantoja, PhD | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Gene expression;Monocyte/Macrophage;Solid tumors | |
| 272 | Poster Presentation | A Novel Bispecific Macrophage Engager Antibody (BiME) Designed for Cancer Immunotherapy | Hongtao Lu, PhD; Dawei Sun, Ph.D.; Xiaofeng Niu, Ph.D.; Yanan Geng; Jing Wang; Haixia Jiang; Rui Gao, Ph.D.; Zhihao Wu, Ph.D; Yangsheng Qiu, PhD | Checkpoint Blockade Therapy | Antibody;Antigen presenting cells;Checkpoint blockade;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy | |
| 280 | Poster Presentation | Clinical Outcomes of Immunotherapy Continued Beyond Radiographic Progression In Older Adults with Advanced Non-Small Cell Lung Cancer | Eric K. Singhi, MD; Frank Mott; Michelle A. Worst, PharmD, BCOP, MBA; Cheuk Hong Leung; Jack J. Lee, PhD/DDS; Brett Carter; Carolyn J. Presley; Jeff Lewis; Waree Rinsurongkawong; Vadeerat Rinsurongkawong; Jianjun Zhang, MD, PhD; Don L. Gibbons, MD, PhD; Ara A. Vaporciyan, MD; John V. Heymach, MD, PhD; Mehmet Altan | Checkpoint Blockade Therapy | Checkpoint blockade | |
| 282 | Poster Presentation | Bispecific antibodies (BsAbs) targeting ABCB1/PgP and CD47 provide a multi-modal, tumor specific approach to combat drug resistant cancers. | Robert Arathoon, PhD; Raffaella Briante, PhD; Alissa O'Connor; Cindy Tan; Pamela Klein, MD; Jessica Morgan, PhD; Paul Ponath, PhD; Leonard Presta; Qianting Zhai; Suchismita Mohanty; Pinping Zhang | Checkpoint Blockade Therapy | Antibody;Bispecifics;Checkpoint blockade;Chemotherapy;Solid tumors;Targeted therapy;Tumor antigens | |
| 287 | Poster Presentation | Combined COX-2 inhibition with fish oil and aspirin as adjuncts to anti-PD-1 immunotherapy in metastatic melanoma | Alexander C. Chacon, MD; Alexa D. Melucci, MD; Shuyang S. Qin, M.S; Paul R. Burchard, MD; Katherine M. Jackson, M.D.; Rachel Jewell; Peter A. Prieto, MD, MPH | Checkpoint Blockade Therapy | Checkpoint blockade;Inflammation;Metabolism;Monocyte/Macrophage;Solid tumors;Systems biology;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 295 | Poster Presentation | Tumor cell- intrinsic expression of FGFR3 drives anti-PDL-1 immunotherapy resistance in a murine bladder cancer model | Erica Fleming-Trujillo, PhD; Jeffrey C. Bloodworth; Anthony Fernald; Aubrianna Ramsland; Thomas F. Gajewski, MD, PhD; Randy F. Sweis, MD | Checkpoint Blockade Therapy | Checkpoint blockade;Immune suppression;Solid tumors;Tumor evasion;Tumor microenvironment | |
| 298 | Poster Presentation | Tumor cell-intrinsic mTORC1 signaling through Raptor makes melanoma and ovarian cancer immunotherapy resistant by regulating interferon-gamma responsiveness and promoting tumor-initiating cells | Harshita Gupta; Suresh C. Kari, PhD; Emily L. Salinas, BS; Haiyan HB. Bai, PhD; Erica Osta, BS; Anand Kornepati; Juan Wang; Xinyue Zhang; Yidong Chen; Ratna Vadlamudi; Tyler J. Curiel, MD | Checkpoint Blockade Therapy | Biomarkers;Checkpoint blockade;Cytokine;Solid tumors;Stem cell/cancer-initiating cell;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 306 | Poster Presentation | Decr2 regulates tumor cell ferroptosis and is required for immunotherapy efficacy | Shuyin Li, PhD; Thomas F. Gajewski, MD, PhD; Emily Higgs | Checkpoint Blockade Therapy | Checkpoint blockade | |
| 308 | Poster Presentation | Transcriptomic analysis of melanoma patients in adjuvant setting treated with Anti PD1 therapy: real life study | Domenico Mallardo, MD; Claudia Trojaniello; Maria Grazia Vitale, MD; grazia d'angelo; Andrew M. White, BSc; Mariaelena Capone, MD; Antonio Sorrentino, MD; Gabriele Madonna, MS; Marilena Tuffanelli; Vito Vanella; Lucia Festino; Ester Simeone, MD; Corrado Caracò; Nicola Normanno; Sarah E. Warren, PhD; Paolo A. Ascierto, MD | Checkpoint Blockade Therapy | Adoptive immunotherapy;Antigen presenting cells;Biomarkers;Carcinogenesis;Gene expression;Immune adjuvant;Immune suppression;T cell lineages | |
| 309 | Poster Presentation | Visualizing the immunotherapy-induced spatial reorganization of the tumor-immune microenvironment by CODEX multiplex imaging | Ruan FV. MEDRANO, PhD; Fei Han; Bassem Ben Cheikh; Patrick Leinert Jr; Wm. Pat Leinert Sr; Oliver Braubach; Robert D. Schreiber, PhD | Checkpoint Blockade Therapy | Checkpoint blockade;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 313 | Poster Presentation | Stealthier mutanomes are induced after nivolumab immunotherapy | Guilhem Richard, PhD; Michael F. Princiotta, PhD; Gary D. Steinberg, MD; William Martin, BA MD; Anne S. de Groot, MD | Checkpoint Blockade Therapy | Bioinformatics;Checkpoint blockade;Immune tolerance;Neoantigens;Regulatory T cell (Treg cell);T cell;Tumor antigens;Tumor evasion | |
| 315 | Poster Presentation | Application of the SITC Immunotherapy Resistance Taskforce definitions of anti-PD-1 resistance to studies evaluating patients with advanced melanoma | Irene Shui, ScD; Emilie Scherrer, MSc; Andrew M. Frederickson, MS; Eric Druyts, MSc; Hussein A. Tawbi, MD, PhD | Checkpoint Blockade Therapy | Biomarkers;Checkpoint blockade;Epidemiology;Solid tumors;Targeted therapy | |
| 318 | Poster Presentation | Enforced tumor specific MHC-I heterogeneity in triple negative breast cancer drives immunotherapy resistance | Brandie C. Taylor, MS; Justin M. Balko, PharmD, PhD; Melinda Sanders, MD; Paula I. Gonzalez-Ericsson, MD; Violeta I. Sanchez, BS | Checkpoint Blockade Therapy | Antigen presenting cells;Checkpoint blockade;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 319 | Poster Presentation | The Tumor-intrinsic NLRP3 Inflammasome Establishes a Pulmonary Metastatic Niche via Type II Epithelial HSP70/TLR4 Signaling and Facilitates Disease Hyperprogression in Response to Immunotherapy | Balamayooran BT. Theivanthiran, PhD; Fang Liu, M.D.; Nicholas C. DeVito, MD; Michael P. Plebanek, PhD; Brent A. Hanks, MD, PhD | Checkpoint Blockade Therapy | Checkpoint blockade;Cytokine;Granulocyte;Immune suppression;Inflammation;MDSC;Myeloid cells;TLR;Tumor microenvironment;Tumor stroma | |
| 323 | Poster Presentation | Immunogenic Syngeneic Model MC38-OVA for the Preclinical Evaluation of Immune Evasion and Checkpoint Blockade | Jessie J. Wang, PhD; Kaixia Lian; Jia Zheng; Chenpan Nie; Annie An; Henry Q. Li | Checkpoint Blockade Therapy | Adoptive immunotherapy;Checkpoint blockade;Solid tumors;T cell | |
| 329 | Poster Presentation | Early blood cell count test (BCT) for survival prediction for non-small cell lung cancer patients treated with atezolizumab: Integrated analysis of 4 multicenter clinical trials | Jian-Guo Zhou, MD; Ada Hang-Heng Wong; Haitao Wang; Su-Han Jin; Fangya Tan; Yu-Zhong Chen; Si-si He; Gang Shen; Benjamin Frey; Markus Hecht; Rainer Fietkau; Bo Shen; Hu Ma; Udo S. Gaipl | Clinical Trials Completed | Bioinformatics;Biomarkers;Checkpoint blockade;Chemotherapy;Clinical study;Clinical trial;Epidemiology;Monocyte/Macrophage;Solid tumors | |
| 339 | Poster Presentation | Immune profiling to investigate improved survival in patients with metastatic triple-negative breast cancer receiving trilaciclib prior to chemotherapy | Aaron D. Stevens; Joyce O'Shaughnessy; Subing Cao; Jessica Sorrentino; Janet Horton; John S. Yi; Antoinette R. Tan | Clinical Trials Completed | Chemotherapy;Clinical study;Gene expression;Immune monitoring;RNA;Solid tumors;T cell;T cell lineages;Tumor microenvironment | |
| 343 | Poster Presentation | Multiomic biomarker signatures identify subsets of patients who may benefit from either nivolumab or sotigalimab in combination with chemotherapy in metastatic pancreatic cancer. | Deena M. Maurer, PhD; Jia Xin Yu, PhD; Kamil Sklodowski, PhD; Marco Tognetti, PhD; Lukas Reiter, PhD; Roland Bruderer, PhD; Jakob Vowinckel, PhD; Shannon M. Pfeiffer, MS; Mark H. O'Hara, MD; Eileen M. O’Reilly, MD; Robert A. Wolff, MD; Zev A. Wainberg, MD; Andrew H. Ko, MD; Osama Rahm, MD; George A. Fisher, MD; Jaclyn P. Lyman, MS; Christopher R. Cabanski, PhD; Pier Federico Gherardini, PhD; Jill O’Donnell-Tormey, PhD; Theresa M. LaVallee, PhD; Robert H. Vonderheide, MD, PhD; Lacey J. Kitch, PhD | Clinical Trials Completed | Biomarkers;Checkpoint blockade;Chemokine;Chemotherapy;Clinical trial;Costimulation;Immune suppression;Solid tumors | |
| 345 | Poster Presentation | Phase I/II trial of cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies (CAMILLA): Phase Ib safety and efficacy results | Anwaar Saeed, MD; Robin Park; Junqiang Dai; Raed Al-Rajabi; Anup Kasi; Joaquina Baranda; Stephen Williamson; Zachary Collins; Jacob Ripp; Azhar Saeed; Kelly Mulvaney; Vanna Manirad; Rashna Madan; Dharmalingam Subramaniam; Shrikant Anant; Milind Phadnis; Weijing Sun | Clinical Trials Completed | Angiogenesis;Checkpoint blockade;Clinical trial;Tumor microenvironment | |
| 348 | Poster Presentation | Interleukin 2(IL-2) Systems Immunology Modeling: Machine Learning for Cancer Immunotherapy | Jennifer Bone, PhD; Newell R. Washburn, PhD; Jian Han, PhD; Miranda Steele; Pranav Murthy, BS; Michael T. Lotze, MD | Clinical Trials Completed | B cell;Bioinformatics;Immune monitoring;Systems biology;T cell | |
| 349 | Poster Presentation | Tolerability of tivozanib vs. sorafenib in elderly and/or immunotherapy-pretreated patients with metastatic renal cell cancer (mRCC) in TIVO-3 | Vijay Kasturi, MD; Bernard J. Escudier, MD; Brian I. Rini, MD; Sumanta K. Pal, MD; David F. McDermott, MD; Camillo Porta, MD; Elena Verzoni | Clinical Trials Completed | Checkpoint blockade;Clinical trial;Targeted therapy | |
| 351 | Poster Presentation | KEYNOTE-365 cohort D: Pembrolizumab plus abiraterone acetate and prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) | Josep M. Piulats, MD, PhD; Cristiano Ferrario; Mark Linch, MD; Michael Stoeckle; Brigitte Laguerre; Jose A. Arranz; Tilman Todenhoefer; Peter Fong; William Berry; Urban Emmenegger; Loic Mourey; Nataliya Mar, MD; Leonard J. Appleman, MD, PhD; Anthony M. Joshua, MBBS, PhD; Henry Conter; Xin Tong Li; Charles Schloss; Christian H. Poehlein, MD; Johann S. De Bono, PhD; Evan Y. Yu, MD | Clinical Trials Completed | Checkpoint blockade;Clinical trial | |
| 353 | Poster Presentation | Identification of potential response predictors to maveropepimut-S (DPX-Survivac), a novel T cell activating immunotherapy, in patients with advanced recurrent ovarian cancer | Oliver Dorigo, MD, PhD; Walead Ebrahimizadeh, PhD; Barry Kennedy, PhD; Lisa MacDonald, MSc; Stephan Fiset, MSc, MBA; Jeannine Villella, DO, FACOG, FACS; Amit OZA, MD; Tanja Pejovic, MD, PhD; Prafull Ghatage, MD, FRCSC; Sharad A. Ghamande, MD; Diane Provencher, MD FRCS FACOG; Yogesh Bramhecha, PhD | Clinical Trials Completed | Biomarkers;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) | |
| 356 | Poster Presentation | Personalized immunotherapy by adoptive T cell transfer during chemotherapy with or without interferon-alpha in patients with recurrent platinum-sensitive epithelial ovarian cancer | Els M. Verdegaal, PhD; Marten Visser, MSc; Lien E. van der Minne, MSc; Linda de Bruin; Inge F. Roozen; Pauline Meij, PhD; Sjoerd H. van der Burg, Prof.Dr.; Judith R. Kroep, MD, PhD | Clinical Trials Completed | Adoptive immunotherapy;Chemotherapy;Clinical study;Clinical trial;Immune monitoring;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 357 | Poster Presentation | Toripalimab plus chemoradiotherapy in patients with recurrent or metastatic cervical cancer: A multicenter, open-label, single-arm, phase II trial | Xiaoting Xu; Jian Huan; Hui Miao; Hao Wang; Yue Wang; Hongyu Zhu; Jun Jiang; Juying Zhou, MD | Clinical Trials Completed | Antibody;Carcinogenesis;Chemotherapy;Clinical study;Clinical trial;Coinhibition;Genetic polymorphism;Immune contexture;Immune suppression;Solid tumors | |
| 362 | Poster Presentation | Association of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with clinical outcomes to tislelizumab monotherapy in patients with previously treated advanced hepatocellular carcinoma | Philippe Merle; Helena Verdaguer Mata; Congying Xie; Richard Hubner; Yong Liu; Jane Margetts; Ying Cheng, MD; Yee Chao; Cong Fei; Chen Ling; Ruiqi Huang; Xikun Wu; Zhirong Shen; Bai Li; Sandra Chica Duque; Zhenggang Ren | Clinical Trials Completed | Biomarkers;Checkpoint blockade;Immune monitoring;Solid tumors | |
| 363 | Poster Presentation | KEYNOTE-042 5-year survival update: pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1–positive, locally advanced or metastatic non–small-cell lung cancer | Gilberto De Castro, Jr., DR; Gilberto de Castro Jr, MD, PhD; Iveta Kudaba; Yi-Long Wu; Gilberto Lopes; Dariusz M. Kowalski; Hande Z. Turna; Christian Caglevic; Li Zhang; Boguslawa Karaszewska; Konstantin K. Laktionov; Vichien Srimuninnimit; Igor Bondarenko; Kaoru Kubota; Rinee Mukherjee; Jianxin Lin; Fabricio Souza; Tony S. K. Mok; Byoung Chul Cho, MD, PhD | Clinical Trials Completed | Antibody;Checkpoint blockade;Chemotherapy;Clinical trial;Solid tumors | |
| 364 | Poster Presentation | KRAS Mutations in Patients With Nonsquamous Non–Small-Cell Lung Cancer: Prevalence and Relationship With PD-L1 Expression, Tumor Mutation Burden and Smoking Status | Marina Chiara Garassino, MD; Marina C. Garassino; Delvys Rodriguez-Abreu; Shirish M. Gadgeel; Dariusz M. Kowalski; Kazuo Kasahara; Enriqueta Felip, MD, PhD; Yi-Long Wu; Gilberto de Castro Jr, MD, PhD; Byoung Chul Cho, MD, PhD; Hande Z. Turna; Hidehito Horinouchi; Martin Reck; Rina Hui; Edward B. Garon; Michael Boyer, MB BS PhD; Tony S.K. Mok; Gilberto Lopes; Julie Kobie; Yongjin Li; Mark A. Ayers; Razvan Cristescu; Bin Zhao; M. Catherine Pietanza; Roy S. Herbst | Clinical Trials Completed | Biomarkers;Checkpoint blockade;Chemotherapy;Clinical trial;Gene expression;Targeted therapy | |
| 368 | Poster Presentation | Consistent pattern of immune activation induced by oncolytic adenovirus ONCOS-102 across diverse types of solid tumors | Lukasz Kuryk, PhD; Anne-Sophie Moller; Sandeep Kumar; Alexander N. Shoushtari, MD; Luis Paz Ares, MD, PhD; Magnus Jaderberg; Erik Digman Wiklund, PhD; Victor Levitsky, MD, PhD | Clinical Trials Completed | Checkpoint blockade;Chemotherapy;Gene expression;Immune monitoring;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 369 | Poster Presentation | Clinical update of VT1021, a first-in-class CD36 and CD47 targeting immunomodulating agent, in subjects with pancreatic cancer and other solid tumors stratified by novel biomarkers | Devalingam Mahalingam, MBBCh BAO; Mary Mulcahy, MD; Dejan Juric; Manish R. Patel, MD; Shubham Pant, MD; Susanna Ulahannan, MD, MMED; Afshin Dowlati; Andrea J. Bullock, MD; Lou Vaickus, MD; Susanne Fyfe; Melanie Vincent, PhD; Suming Wang, Ph.D; Jian J. Chen, PhD; Marsha Crochiere, PhD; Randolph Watnick, Ph.D; Michael Cieslewicz, Ph.D; Jing Watnick, Ph.D | Clinical Trials Completed | Biomarkers;Clinical study;Clinical trial;MDSC;Solid tumors;Tumor microenvironment | |
| 384 | Poster Presentation | An investigation into the role of CD4+ tumor-infiltrating lymphocytes (TIL) in metastatic melanoma patients with a complete response to adoptive cell therapy | MacLean Hall, BS; Holly Branthoover; Patrick Innamarato, B.S.; Amy M. Hall; Alex Alfaro; Allison Richards; Jeani Rich; Jonathan A. Hensel, PhD; Jim Bender; Jake Ceccarelli; TJ Langer; Matthew Beatty, PhD; John E. Mullinax, MD; Jamie Teer, PhD; Amod A. Sarnaik; Shari A. Pilon-Thomas, PhD | Clinical Trials Completed | Adoptive immunotherapy;Neoantigens;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 385 | Poster Presentation | Identification and enrichment of neoantigen-reactive T cells to optimize adoptive cell transfer with tumor-infiltrating lymphocytes (TIL) | MacLean Hall, BS; Holly Branthoover; Matthew Beatty, PhD; Kwame Twumasi-Boateng; Jim Bender; Jake Ceccarelli; TJ Langer; Jamie Teer, PhD; Amod A. Sarnaik; Shari A. Pilon-Thomas, PhD | Clinical Trials Completed | Adoptive immunotherapy;Neoantigens;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 391 | Poster Presentation | Biomarker correlates of response in patients with advanced Myxoid/Round Cell Liposarcoma (MRCLS) treated with NY-ESO-1 TCR T cells (Letetresgene autoleucel) | Gurpreet S. Kapoor, PhD; Stefan Zajic; Sunil Suchindran; Jaegil Kim; Ioanna S. Eleftheriadou; Anne Huff; Michael Nathenson; Mihaela Druta; Brian A. Van Tine, MD, PhD; Neeta Somaiah, MD, MBBS; David A. Liebner, MD; Scott Schuetze; Sandra D’Angelo | Clinical Trials In Progress | Adoptive immunotherapy;Biomarkers;Chemokine;Cytokine;Gene expression;Immune monitoring;Pediatric tumors;Solid tumors;T cell;Targeted therapy | |
| 397 | Poster Presentation | A phase I/II trial of intracerebroventricular 177Lu DTPA omburtamab radioimmunotherapy for leptomeningeal metastasis from solid tumors | Elena Pentsova; Maria Düring; Charlotte Lybek Lind; John Rømer Nielsen | Clinical Trials In Progress | Antibody;Clinical study;Clinical trial;Radiotherapy;Targeted therapy | |
| 398 | Poster Presentation | neoIRX: a phase II trial of locoregional cytokine therapy to promote immunologic priming and clinical response to neoadjuvant pembrolizumab plus chemotherapy in triple negative breast cancer (TNBC) | Katherine Sanchez, MD; Alison K. Conlin, MD; Parvin Peddi, MD; Sasha E. Stanton, MD; Janet Ruzich, MD; Kelly Perlewitz, MD; Yaping Wu, MD; Nicole Moxon, RN, BSN, OCN; Staci Mellinger, RN; Zhaoyu Sun, Ph.D.; William L. Redmond, Ph.D.; David B. Page, MD | Clinical Trials In Progress | Checkpoint blockade;Clinical trial | |
| 399 | Poster Presentation | A phase II study of nivolumab, ipilimumab, plus androgen receptor blockade with bicalutamide to enhance thymic T-cell production and immunotherapy response in metastatic breast cancer | David B. Page, MD; Krystle L. Collins, MD; Brie M. Chun, MD; Zhaoyu Sun, Ph.D.; Yoshinobu Koguchi, MD, PhD; William L. Redmond, Ph.D.; Maritza Martel, MD; Yaping Wu, MD; Nicole Moxon, RN, BSN, OCN; Staci Mellinger, RN; Walter J. Urba, MD, PhD; Ayca Gucalp, MD; Tiffany A. Traina, MD | Clinical Trials In Progress | Biomarkers;Checkpoint blockade;Clinical trial;Immune adjuvant;Solid tumors;T cell;Tumor microenvironment | |
| 400 | Poster Presentation | Persistence and tissue distribution of Agent-797 – a native allogeneic iNKT cell-therapy drug product | Marco Purbhoo, PhD; Burcu Yigit, PhD; Darrian Moskowitz; Min Lim; Irina Shapiro; Ayat Alsaraby; Xavier Michelet, PhD; Marc A. Van Dijk, PhD | Clinical Trials In Progress | Adoptive immunotherapy;Clinical trial;COVID and Immunotherapy;Leukemia/Lymphoma;NK/NKT cell;T cell lineages | |
| 405 | Poster Presentation | Camrelizumab combined with paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESPRIT): a phase Ⅱ, single-arm, exploratory research | Jianqun Ma, MD; Jinfeng Zhang; Yingnan Yang; Dayong Zheng; Xiaoyuan Wang; Hao Liang; Luquan Zhang; Yanzhong Xin; Xiaodong Ling; Chengyuan Fang; Hao Jiang; Hongxue Meng; Wei Zheng | Clinical Trials In Progress | Checkpoint blockade;Chemotherapy;Surgery | |
| 406 | Poster Presentation | Camrelizumab combined with paclitaxel and nedaplatin in the first-line treatment of locally advanced/advanced esophageal squamous cell carcinoma: a phase Ⅱ, single-arm, exploratory research | Jianqun Ma, MD; Jinfeng Zhang; Yingnan Yang; Dayong Zheng; Xiaoyuan Wang; Hao Liang; Luquan Zhang; Yanzhong Xin; Xiaodong Ling; Chengyuan Fang; Hao Jiang; Wei Zheng | Clinical Trials In Progress | Checkpoint blockade;Chemotherapy | |
| 407 | Poster Presentation | A Phase 1b KEYNOTE-B79 trial evaluating non-gene edited allogeneic CAR T-cells, CYAD-101, post FOLFOX preconditioning, followed by pembrolizumab, in refractory metastatic colorectal cancer patients | Anne Flament, MD; Frédéric F. Lehmann, MD; Erik M. Alcantar-Orozco, MD, PhD; Emilie Cerf, PhD; Caroline Lonez, PhD; David E. Gilham, PhD; Charles Morris, MD | Clinical Trials In Progress | Adoptive immunotherapy;CAR T cells;Checkpoint blockade;Clinical trial;Solid tumors | |
| 410 | Poster Presentation | Phase I Interim Study Results of Nous-209, an Off-the-Shelf Immunotherapy, with Pembrolizumab, for the Treatment of Tumors with a Deficiency in Mismatch Repair/ Microsatellite Instability (dMMR/MSI) | Michael J. Overman, MD; Marwan Fakih; Dung T. Le, MD; Anthony F. Shields, MD PhD; Katrina S. Pedersen; Manish A. Shah, MD; Sarbajit Mukherjee, MD, MS; Thea Faivre; Guido Leoni, PhD; Anna Morena D'Alise; Gabriella Cotugno, PhD; Francesca Langone, PhD; Stefania Capone; Maria Rosaria Del Sorbo; Elisa Scarselli; Patricia Delaite, MD | Clinical Trials In Progress | Bioinformatics;Checkpoint blockade;Clinical study;Clinical trial;Immune monitoring;Neoantigens;Solid tumors;T cell;Vaccine | |
| 411 | Poster Presentation | INNATE: Immunotherapy during neoadjuvant therapy for rectal cancer to elucidate local and systemic therapeutic responses. | Nina N. Sanford, MD; Eslam Elghonaimy, PhD; Adel Kardosh, MD; Syed A. Kazmi, MD; Javier Salgado Pogacnik, MD; Xiaodong Yang, MD PhD; Robert Timmerman, MD; Todd A. Aguilera, MD, PhD | Clinical Trials In Progress | Antigen presenting cells;Bioinformatics;Chemotherapy;Radiotherapy;Solid tumors;Tumor microenvironment | |
| 412 | Poster Presentation | CAMrelizumab and apatiniB combIned with chemoTherapy (mFOLFOX6) as neoadjuvant therapy for locally advanced rIght-sided colON cancer (AMBITION) | Zhou Tong, master; Sen Lu; Xiaomeng Dai; Xiaobin Cheng; Xuanwen Bao; Xudong Zhu; Xiaofei Cheng; Qihan Fu; Danyang Wang; Hangyu Zhang; Qinsong Sheng; Lulu Liu; Guoliang Zhang; Yi Zheng; Fanlong Liu; Peng Zhao; Wenbin Chen; Weijia Fang, PHD; Xiangmin Xu | Clinical Trials In Progress | Checkpoint blockade;Chemotherapy;Clinical trial | |
| 413 | Poster Presentation | Toripalimab in combination with concurrent chemoradiation in patients with advanced/metastatic esophageal carcinoma: protocol for a single-arm, prospective, open-label, phase II clinical trial | Lei Wu, M.M.; Yi Wang, M.M.; Gang Wan, M.M.; Jiahua Lv, M.M.; Qifeng Wang, M.D.; Jinyi Lang, M.D.; Tao Li, M.D. | Clinical Trials In Progress | Checkpoint blockade;Chemotherapy;Clinical trial;Radiotherapy | |
| 414 | Poster Presentation | A randomized phase II study of systemic therapy plus WeiLeShu (WLS) versus systemic therapy alone in patients with metastatic colorectal cancer (mCRC). | Ruyi Zhang; Xiaoxuan Tu, MS; Zhou Tong, master; Hangyu Zhang; Xudong Zhu; Weijia Fang, PHD; Lanfang Yu; Haibo Mou | Clinical Trials In Progress | Chemokine;Chemotherapy;Clinical trial;Inflammation;Microbiome;Monocyte/Macrophage;Solid tumors;Tumor microenvironment | |
| 418 | Poster Presentation | Phase 1b/2 KEYNOTE-365 cohort I: Platinum-containing chemotherapy alone or in combination with pembrolizumab for treatment-emergent neuroendocrine prostate carcinoma | Johann S. De Bono, PhD; Neal Shore, MD, FACS; Gero Kramer, MD; Anthony M. Joshua, MBBS, PhD; Xin Tong Li; Christian H. Poehlein, MD; Charles Schloss; Evan Y. Yu, MD | Clinical Trials In Progress | Checkpoint blockade;Chemotherapy;Clinical study;Clinical trial | |
| 421 | Poster Presentation | A first-in-human (FIH) Phase I/IIa clinical trial assessing a ribonucleic acid lipoplex (RNA-LPX) encoding shared tumor antigens for immunotherapy of prostate cancer; preliminary analysis of PRO-MERIT | Mark Linch; Zsuzsanna Papai; Istvan Takacs; Esteban Rodrigo Imedio; Marie-Cristine Kühnle; Evelyna Derhovanessian; Isabel Vogler; Stephanie Renken; Philippa Graham; Ugur Sahin; Özlem Türeci | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial;RNA;T cell;Tumor antigens;Vaccine | |
| 424 | Poster Presentation | A Phase 1b/2 randomized study of AVB-S6-500 in combination with cabozantinib versus cabozantinib alone in patients with advanced clear cell renal cell carcinoma who have received front-line treatment | Kathryn E. Beckermann, MD, PhD; Nicholas J. Vogelzang, MD; Mao Shifeng; Moshe C. Ornstein; Neil Shah, MD; Hans Hammers, MD, PhD; Matthew T. Campbell, MD; Xin Gao; David F. McDermott, MD; Randy Anderson; Vanessa Esquibel, Director; Eduardo J. Pennella, MD; Reshma Rangwala, MD, PhD; Eric Jonasch, MD | Clinical Trials In Progress | Angiogenesis;Antibody;Chemotherapy;Clinical study;Clinical trial;Solid tumors;Targeted therapy;Tumor microenvironment | |
| 428 | Poster Presentation | Preliminary Clinical Results of Toripalimab Monotherapy or Combination Therapy for Recurrent or Refractory Gynecologic Cancer | Peng Diao; Qian Peng; Xingbo Luo; Qing Huang; Gaoshu Yan; Yan Tan | Clinical Trials In Progress | Checkpoint blockade;Chemotherapy;Radiotherapy | |
| 431 | Poster Presentation | First-in-human phase I clinical trial evaluating intraperitoneal administration of MOv19-BBz CAR T cells in patients with alpha folate receptor-expressing recurrent high grade serous ovarian cancer | Payal D. Shah, MD; Richard Shlanksy-Goldberg, MD; Lainie Martin, MD; Gregory Nadolski, MD; Elizabeth Hexner, MD; Susan Shamimi-Noori, MD; Wei-Ting Hwang, Ph.D.; Tina Matlawski, RN; Amanda L. Cervini; Joanne B. Shea, RN; Lauren M. Nelson; Simon F. Lacey, Ph.D.; Gabriela Plesa, MD, Ph.D.; Lester R. Lledo, DNP, RN, CRNP; Karen L. Dengel, BSN, RN; Amy E. Marshall, MPH; Rachel M. Leskowitz, Ph.D.; Lana Kandalaft, Pharm.D.; Mariangela Figini; Silvana Canevari, Ph.D.; George Coukos, MD, Ph.D.; Daniel J. Powell Jr., Ph.D. | Clinical Trials In Progress | Adoptive immunotherapy;CAR T cells;Clinical trial;Solid tumors | |
| 433 | Poster Presentation | A phase 2 study of evorpacept (ALX148) in combination with pembrolizumab and chemotherapy in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-04 | Beatriz B. Cirauqui, MD; Ezra EW. Cohen, MD; Bhumsuk Keam, MD, PhD; Jean-Pascal Machiels, MD, PhD; Sjoukje Oosting, MD, PhD; Tim Welliver, MD, PhD; Shanhong Guan, PhD; Feng Jin, PhD; Alison J. Forgie, PhD; Philip S. Fanning, PhD; Katherine Ruffner, MD; Jaume Pons, PhD; Sophia S. Randolph, MD, PhD; Kevin Harrington, PhD, FRCP, FRCR | Clinical Trials In Progress | Antigen presenting cells;Checkpoint blockade;Clinical study;Clinical trial;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Tumor evasion;Tumor microenvironment | |
| 436 | Poster Presentation | A phase II study of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy | Haiqiang Mai; haiqiang Mai; Shaojun Lin; Dongping Chen; Xiaozhong Chen; Song Qu; Qin Lin; Ying Luo; Chunhong Hu; Dehua Wu; Tianxin Qin; Feng Jin; Nianyong Chen; Yunxiu Luo; Zhifang Yao; Xiaoping Jin; Baiyong Li, Ph.D; Yu Xia; Rui-Hua Xu | Clinical Trials In Progress | Bispecifics;Checkpoint blockade;Clinical trial;Coinhibition;Solid tumors | |
| 438 | Poster Presentation | A phase 1 trial of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer | Christine H. Chung, MD; A. Dimitrios Colevas, MD; Michael K. Gibson, MD PhD; Douglas R. Adkins, MD; Ammar Sukari, MD; Lori J. Wirth, MD; Barbara A. Burtness, MD; Julie E. Bauman, MD, MPH; Cristina P. Rodriguez, MD; Francis P. Worden, MD; Nabil F. Saba, MD; Bonnie S. Glisson, MD; Lara A. Dunn, MD; Tanguy Y. Seiwert, MD; Laura Agensky; Matteo Levisetti; Reena Lynam; Steven P. Margossian, MD, PhD; Raymond J. Moniz, PhD; Steve N. Quayle, PhD; Kenneth J. Pienta, MD; Sara I. Pai, MD PhD | Clinical Trials In Progress | Adoptive immunotherapy;Checkpoint blockade;Clinical trial;Costimulation;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) | |
| 443 | Poster Presentation | Open-label, phase 2 study to assess the safety of mogamulizumab at 2 mg/kg Q4W maintenance dosing in patients with relapsed/refractory MF/SS subtypes of CTCL | Karen Dwyer, BA; Roland Meier, PhD; Matthew Hruska, PharmD, PhD; Floyd E. Fox, PhD; Takahiro Ito, MSc | Clinical Trials In Progress | Antibody;Clinical trial;COVID and Immunotherapy;Leukemia/Lymphoma;T cell;Targeted therapy | |
| 448 | Poster Presentation | Lemzoparlimab (TJ011133), an anti-CD47 antibody, with/without dexamethasone plus anti-myeloma regimens for relapsed/refractory multiple myeloma: a phase 1b dose escalation and expansion study | Edward A. Stadtmauer, MD, FACP; Lionel Karlin; Katja Weisel; Moshe Etzion Gatt; Ankit Kansagra; Gregory P. Monohan, MD; Andrew Yee; Shayna Rockow-Magnone; Jose Cordero; David Hoffman; Orlando Bueno; Kevin Y. Wu; Cristina Gasparetto, MD | Clinical Trials In Progress | Antibody;Chemotherapy;Clinical trial;Monocyte/Macrophage;Myeloid cells;Targeted therapy | |
| 452 | Poster Presentation | Preliminary analysis of a real-world study (RWS) of camrelizumab treatment in primary liver cancer (PLC) | Zhendong Chen; Nianfei Wang; Dayong Luo; Bo Jiang; Mu Yuan; Xinzhong Li; Chunmei Yao; Hong Qian; Qingsheng Kan; Erxuan Wang | Clinical Trials In Progress | Angiogenesis;Checkpoint blockade;Chemotherapy;Clinical trial;Coinhibition;Immune suppression;Targeted therapy | |
| 456 | Poster Presentation | A phase 1b/2 umbrella study of anti-PD-1 sasanlimab in combination with other therapies for patients with Stage IIIB/IV non-small cell lung cancer (NSCLC): The LANDSCAPE 1011 trial in progress | Michael Boyer, MB BS PhD; Sandip Patel; Thomas U. Marron, MD, PhD; Nick Pavlakis; Sagun Parakh; Shirish Gadgeel; Michael Shafique, MD; Robert Hoyer; D Ross Camidge; Charles M. Farber, MD, PhD; Ranee Mehra, MD; Tarek Mekhail; Prunella Blinman; Karey Kowalski; Craig B. Davis, PhD; Dmitri Pavlov; Nayra Gad; Erminia Massarelli, MD, PhD, MS | Clinical Trials In Progress | Antibody;Clinical study;Clinical trial;Solid tumors | |
| 458 | Poster Presentation | First phase 2 results of autologous tumor-infiltrating lymphocyte (TIL; LN-145) monotherapy in patients with advanced, immune checkpoint inhibitor-treated, non-small cell lung cancer (NSCLC) | Adam J. Schoenfeld, MD; Sylvia Lee, MD; Luis Paz-Ares; Bernard Doger; Scott N. Gettinger, MD; Simon Haefliger; Angela Orcurto, MD; Ammar Sukari, MD; Sophie Papa, PhD, MBBS, MRCP; Juan Francisco Rodriguez Moreno; Friedrich Graf Finckenstein, MD; Madan Jagasia; Rana Fiaz; Giri Sulur; Guang Chen; Viktoria Gontcharova, PhD; Kai He, MD, PhD | Clinical Trials In Progress | Adoptive immunotherapy;Clinical study;Clinical trial;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 459 | Poster Presentation | Phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1–positive metastatic NSCLC | Matthew D. Hellmann, MD; Byoung C. Cho, MD, PhD; Rosalyn A. Juergens, MD, PhD; Ying Cheng, MD; Gilberto de Castro, Jr; Mustafa Erman, MD; Jessica Bauman; Toshiaki Takahashi, MD, PhD; Paul Schwarzenberger, MD; Pingye Zhang, PhD; M. Catherine Pietanza; James Chih-Hsin Yang | Clinical Trials In Progress | Antibody;Checkpoint blockade;Chemotherapy;Clinical trial | |
| 461 | Poster Presentation | Updated PFS analysis of toripalimab with anlotinib and chemotherapy as first-line therapy in patients with extensive-stage small-cell lung cancer (ES-SCLC) | Hao Luo, MD; Dan Jian; Yan Feng; Li Zhong; Qian Chen; Wei Guan; Shiheng Zhang; Jiamin Luo; Xueqin Yang; Kan Gong; Yanli Xiong; Mengxia Li; Mingfang Xu; Yu Pu; Liang Zhao; Chengyuan Qian; Nan Dai; Dong Wang | Clinical Trials In Progress | Antibody;Checkpoint blockade;Chemotherapy;Clinical study;Clinical trial;Solid tumors | |
| 463 | Poster Presentation | Vibostolimab plus pembrolizumab with/without docetaxel vs docetaxel in NSCLC after platinum chemotherapy and immunotherapy | Solange Peters, MD, PhD; Dae Ho Lee, MD, PhD; Rodryg Ramlau, MD, PhD; Balazs Halmos, MD; Christian Schumann, MD, PhD; David Planchard, MD, PhD; Niyati Bhagwati, MD; Diana (Qiusheng) Chen, PhD; Debra Kush, BSN, MBA; Silvia Novello, MD, PhD | Clinical Trials In Progress | Antibody;Checkpoint blockade;Chemotherapy;Clinical trial | |
| 464 | Poster Presentation | 2SMALL (NCT04253145) phase I part: Lurbinectidine (LUR) in combination with Atezolizumab (ATZ) for second line Extensive Stage Small Cell Lung Cancer (ES-SCLC) patients (pts) | Santiago Ponce Aix, MD; Alejandro Navarro; Reyes Bernabe; Maria Eugenia Olmedo; Trigo Jose Manuel; Jon Zugazagoitia Fraile, MD; Luis Paz-Ares; Santiago Ponce Aix | Clinical Trials In Progress | Checkpoint blockade;Chemotherapy;Clinical trial;Solid tumors | |
| 465 | Poster Presentation | Bintrafusp alfa in combination with chemotherapy in patients with stage IV NSCLC: safety and pharmacokinetic results of the INTR@PID LUNG 024 study | Christian Rolfo, MD, PhD, MBA, Dr.hc.; Laurent Greillier; Remi Veillon; Firas Badin, MD; Francois Ghiringhelli; Nicolas Isambert, MD, PhD; Astrid Paulus; Marc Lambrechts; Surendra Chaudhary; Xiaoli You; Yulia Vugmeyster; Christoph Helwig, MSc; Sandrine Hiret | Clinical Trials In Progress | Bispecifics;Checkpoint blockade;Chemotherapy;Clinical study;Clinical trial;Coinhibition;Solid tumors | |
| 467 | Poster Presentation | Phase II clinical study of Toripalimab in combination with stereotactic radiotherapy as a neoadjuvant therapy for the treatment of resectable (N1-N2) non-small cell lung cancer | Zhen Wang, MD; Xi-xu Zhu; Yong Song | Clinical Trials In Progress | Clinical study;Immune suppression;Radiotherapy;Solid tumors | |
| 468 | Poster Presentation | A phase Ⅱ study of toripalimab plus anlotinib as maintenance therapy in extensive-stage small cell lung cancer | Dongqing Lv, MD; Guixian Wu | Clinical Trials In Progress | Angiogenesis;Checkpoint blockade;Chemotherapy;Clinical study | |
| 469 | Poster Presentation | A Phase 1 First in Human Study of HMBD-002, an IgG4 Monoclonal Antibody Targeting VISTA, as a Monotherapy and Combined with Pembrolizumab in Patients with Advanced Solid Malignancies | Leah DiMascio, PhD; Dipti Thakkar, PhD; Siyu Guan, PhD; Eric Rowinsky, MD; Jordi Rodon; Joshua J. Gruber, MD, PhD; Benjamin L. Musher, MD; Joseph W. Kim, MD; Alain Mita, MD; Monica Mita, MD; Piers J. Ingram, PhD; Jerome D. Boyd-Kirkup, PhD | Clinical Trials In Progress | Antibody;Checkpoint blockade;MDSC;Myeloid cells;Solid tumors;Tumor microenvironment | |
| 470 | Poster Presentation | A Phase 1/2, Open-Label, Dose Escalation and Expansion Study of GI-101 as a Single Agent and in Combination with a Pembrolizumab, Lenvatinib or Local RT in Advanced Solid Tumors (KEYNOTE-B59) | Byoung Chul Cho, MD, PhD; Sang Joon Shin, MD, PhD; Jae-Lyun Lee, MD, PhD; Byoung Yong Shim, MD, PhD; Hyung Soon Park, MD, PhD; Nari Yun, PhD; Mina Ham, MS; Young Jun Koh, PhD; Myoung Ho Jang, PhD | Clinical Trials In Progress | Bispecifics;Checkpoint blockade;Clinical trial;Cytokine;Radiotherapy;Solid tumors;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 475 | Poster Presentation | GEN-011-101 (the TiTAN-1 trial): Phase 1 study to evaluate the safety, proliferation and persistence of GEN-011, an autologous neoantigen-targeted peripheral T cell therapy in solid tumors | Thomas A. Davis, MD; Arthur P. DeCillis, MD; Richard Hernandez; Jessica Price; Craig Carey; Kevin J. Mancini, MS | Clinical Trials In Progress | Adoptive immunotherapy;CAR T cells;Clinical trial;Immune monitoring;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 477 | Poster Presentation | COM902 (Anti-TIGIT antibody) monotherapy – preliminary evaluation of safety, tolerability, pharmacokinetics and receptor occupancy in patients with advanced solid tumors (NCT04354246). | Ecaterina E. Dumbrava, MD; Drew Rasco, MD; Amita Patnaik, MD; Daniel Vaena; Kyriakos P. Papadopoulos, MD; Adam ElNaggar; Adeboye H. Adewoye, MD; Robina Smith; Pierre Ferré, Dr Vet Med, PhD; Ilan Vaknin, PhD; Srinivas Devarakonda, MD; Manish R. Sharma, MD | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial;NK/NKT cell;T cell | |
| 481 | Poster Presentation | Phase 1/2 study of THOR-707 (SAR444245), a pegylated recombinant non-alpha IL-2, as monotherapy and in combination with pembrolizumab or cetuximab in patients (pts) with advanced solid tumors | Gerald S. Falchook, MD, MS; Hui K. Gan, MBBS PhD; Siqing Fu, MD, PhD; Meredith McKean, MD; Arun Azad, MD; David Sommerhalder; Judy S. Wang, MD; Tira Tan; Chen E. Chee; Minal Barve, MD; charlotte Lemeque; Nicole Acuff; Helene Pham; Jill Mooney; Rui Wang; Neyssa Marina, MD, MS; Giovanni Abbadessa, MD; Tarek Meniawy, MBBS FRACP | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial;Cytokine;NK/NKT cell;Solid tumors | |
| 483 | Poster Presentation | Initial safety results and immune responses induced by a novel human papillomavirus (HPV)-specific gorilla adenovirus immunotherapy vaccine, PRGN-2009, in patients with advanced HPV-associated cancers | Charalampos Floudas, MD, DMSc, MS; Julius Strauss, MD; Clint T. Allen, MD; Renee N. Donahue, PhD; Caroline Jochems, MD, PhD; Seth Steinberg, PhD; Lisa Cordes, PharmD, BCACP, BCOP; Douglas E. Brough, PhD; Amy Lankford, PhD; Sheri McMahon, RN; Jenn Marte, MD, MPH; Jason M. Redman, MD; Fatima Karzai, MD; Ravi A. Madan, MD; Jeffrey Schlom, PhD; James L. Gulley, MD, PhD | Clinical Trials In Progress | Checkpoint blockade;Clinical trial;Solid tumors;T cell;Vaccine | |
| 488 | Poster Presentation | Phase 1 trial of first-in-class anti-CD96 monoclonal antibody inhibitor, GSK6097608, monotherapy and combination with anti–PD-1 monoclonal antibody, dostarlimab, in advanced solid tumors | Omid Hamid, MD; Dawn Baxter; Rachael Easton; Lilian L. Siu, MD | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial;Solid tumors;Targeted therapy | |
| 491 | Poster Presentation | BASECAMP-1: An observational study to identify relapsed solid tumor patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) and leukapheresis for future CAR T-cell therapy | Julian R. Molina, MD, PhD; William Y. Go, MD, PhD; Scott Kopetz, PhD; Diane M. Simeone, MD; Sandip Patel; Yi Lin, MD PhD; Kirstin B. Liechty; Michelle Fan-Port, PhD; Jason Perera, PhD; Armen Mardiros, PhD; Karl Beutner; Ariane Lozac’hmeur; Eric Ng, MD; David G. Maloney, MD, PhD; J. Randolph Hecht, MD | Clinical Trials In Progress | Adoptive immunotherapy;CAR T cells;Clinical study;Clinical trial;Epidemiology;Solid tumors;T cell;Tumor antigens | |
| 492 | Oral Presentation | Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-naïve patients with advanced cancers | David O'Malley; Sylvia Lee, MD; Amanda Psyrri; Ammar Sukari, MD; Sajeve S. Thomas; Robert Wenham, MD, MS, FACS, FACOG; Helen Gogas, MD, PhD; Amir Jazaeri, MD; Bradley J. Monk, MD FACOG FACS; Peter Rose; Antonio Reuda; Friedrich Graf Finckenstein, MD; Madan Jagasia; Rana Fiaz; Brigid Garelik, MD, MPH; Wen Shi, MD, PhD; Anjali Desai; Giri Sulur; Guang Chen; Xiao Wu; Antonio Jimeno, MD, PhD | Clinical Trials In Progress | Adoptive immunotherapy;Checkpoint blockade;Clinical study;Clinical trial;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 498 | Poster Presentation | Evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with head and neck squamous cell carcinoma (HNSCC) and with gastric/gastroesophageal cancer (GC); ASPEN-01 | Keun-Wook Lee, MD; Hyun C. Chung, MD, PhD; Tae Min Kim, MD, PhD; Nehal J. Lakhani, MD; Wells A. Messersmith, MD; Rafael Santana-Davila, MD; Won Seog Kim, MD; Patricia LoRusso; Yung-Jue Bang, MD PhD; Laura QM. Chow, MD; Philip S. Fanning, PhD; Pierre Squifflet, MS; Feng Jin, PhD; Alison J. Forgie, PhD; Hong I. Wan, PhD; Jaume Pons, PhD; Sophia S. Randolph, MD, PhD; Justin Gainor, MD | Clinical Trials In Progress | Antigen presenting cells;Checkpoint blockade;Chemotherapy;Clinical trial;Dendritic cell;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Targeted therapy | |
| 499 | Poster Presentation | A first-in-human, phase 1/2 clinical trial of TK-8001, a MAGE-A1 directed T cell receptor in patients with advanced-stage solid tumors (The „IMAG1NE“-trial) | Fiona Thistlethwaite, MD, PhD; Antonia Busse, MD, PhD; Emiliano Calvo, MD, PhD; Marie-Luise Goebeler, MD; Martin Wermke; Sylvie Rottey, MD; Nuria Kotecki, MD; Matthias Obenaus, MD; Vivian Scheuplein, PhD; Ralf Wolter, PhD; Carolina Perdomo-Ortiz, PhD; Ioannis IG. Gavvovidis, PhD; Elisa Kieback, PhD; Thomas Blankenstein, PhD; Eugen Leo, MD PhD MBA | Clinical Trials In Progress | Adoptive immunotherapy;Antigen presenting cells;Biomarkers;Clinical study;Clinical trial;Solid tumors;T cell;Targeted therapy;Tumor microenvironment | |
| 501 | Poster Presentation | Survival and Immune Response Data from Intratumoral INT230-6 Alone (IT-01) and with Pembrolizumab [KEYNOTE-A10] in Subjects with Locally Advanced, Unresectable and Metastatic Solid Tumors | Jacob Thomas, MD; Anthony El-Khoueiry, MD; Anthony J. Olszanski, MD, RPh; Nilofer Azad, MD; Giles F. Whalen, MD; Diana Hanna, MD; Matthew Ingham, MD; Syed Mahmood, MD; Lewis H. Bender, MS, MA, MBA; Ian B. Walters, MD, MBA; Lilian L. Siu, MD | Clinical Trials In Progress | Biomarkers;Checkpoint blockade;Chemotherapy;Clinical study;Clinical trial;Solid tumors | |
| 502 | Poster Presentation | Recommended phase 2 dose, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the IL-15 superagonist SO-C101 as monotherapy in patients with advanced/metastatic solid tumors | Aurelien Marabelle; Stéphane Champiat; Vladimir Galvao, MD; Aung Naing, MD; Filip Janku; Patricia LoRusso; Peter Grell; Richard Sachse; David Bechard; Joachim Kiemle-Kallee; Ellena Garralda | Clinical Trials In Progress | Clinical trial;Costimulation;Cytokine;Solid tumors | |
| 530 | Poster Presentation | A first-in-human phase I study of M6223 (TIGIT inhibitor) as monotherapy or in combination with bintrafusp alfa in patients with metastatic or locally advanced solid unresectable tumors | Geoffrey A. Watson; Meredith McKean, MD; Anthony W. Tolcher, MD; Anja Victor; Sen Zhang; Vadryn Pierre; Emilia Richter; Aung Naing, MD | Clinical Trials In Progress | Antibody;Checkpoint blockade;Clinical trial;Coinhibition;Immune suppression;NK/NKT cell;Regulatory T cell (Treg cell);Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 536 | Poster Presentation | Intratumoral INT230-6 shows a favorable safety profile and early signs of efficacy in advanced soft tissue sarcoma with monotherapy and in combination with Ipilimumab [Intensity IT-01; BMS#CA184-592] | Matthew Ingham, MD; James Hu, MD; Giles F. Whalen, MD; Jacob Thomas, MD; Anthony El-Khoueiry, MD; Diana Hanna, MD; Anthony J. Olszanski, MD, RPh; Christian F. Meyer; Nilofer Azad, MD; Syed Mahmood, MD; Lewis H. Bender, MS, MA, MBA; Ian B. Walters, MD, MBA; Lilian L. Siu, MD; Albiruni R. Razak | Clinical Trials In Progress | Biomarkers;Checkpoint blockade;Chemotherapy;Clinical study;Clinical trial;Solid tumors | |
| 537 | Poster Presentation | OPTIMIZE-1, an open-label phase 1b/2 study assessing the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma | Yago Pico de Coaña, PhD; Yago Pico de Coaña; Karin Enell Smith, PhD, MS; Anette Fält; Maria Flärdh; Peter Ellmark, PhD; Philippe Cassier, MD; Jean-Luc van Laethem, MD; Malin Carlsson | Clinical Trials In Progress | Antibody;Antigen presenting cells;Chemotherapy;Clinical trial;Coinhibition;Costimulation;Dendritic cell;Monocyte/Macrophage;Myeloid cells;Tumor stroma | |
| 543 | Poster Presentation | Sensitive quantification and tracking of the active components of a Clonal Neoantigen T cell (cNeT) therapy: From manufacture to peripheral circulation | Samra Turajlic, MD PhD; Mariam Jamal-Hanjani, MD PhD; Andrew Furness, MD PhD; Ruth Plummer; Judith Cave, MD MD(Res); Fiona Thistlethwaite, MD, PhD; Emma Leire, PhD; Jen Middleton, BSc PGCert; Eloise Williams, BSc MSc; Amy Baker; Chloe Maine, BA MA; Michael Epstein; Monica Sassi, PhD; Katy Newton, BSc PhD; Michael Grant, MD BSc PGCert; Matilde Saggese, MD MD(Res); Sergio Quezada, BSc PhD; Martin Forster | Clinical Trials In Progress | Adoptive immunotherapy;Clinical study;Clinical trial;Neoantigens;T cell;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 544 | Poster Presentation | DELTA-1: A global, multicenter phase 2 study of ITIL-168, an unrestricted autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in adult patients with advanced cutaneous melanoma | Brian Gastman, MD; Omid Hamid, MD; Pippa Corrie; Geoffrey Gibney; Gregory A. Daniels; Bartosz Chmielowski; Sajeve S. Thomas; Evidio Domingo-Musibay; Donald P. Lawrence; Yizhou Jiang; Audrey Kennedy; Jeff Aycock; Ruben Alvarez-Rodriguez; Paul B. Robbins; John Le Gall; Zachary J. Roberts; Robert E. Hawkins, MD, PhD; Amod A. Sarnaik; Brian Gastman | Clinical Trials In Progress | Adoptive immunotherapy;Clinical trial;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 552 | Poster Presentation | Amphiphile-peptide boosting with FMC63-binding surrogate peptide mimotopes induces activation and potent effector function in CAR-T cells targeting CD19 | Ana Castano, MD; Peter C. DeMuth, PhD; Amy Tavares | Combination Immunotherapies | CAR T cells;Dendritic cell;T cell | |
| 553 | Poster Presentation | First-in-class inhibitors of ERAP1 alter the immunopeptidome of cancer, driving a differentiated T cell response leading to tumor growth inhibition | Peter I. Joyce, PhD; Martin Quibell, PhD; Jason Shiers, PhD; Carmen Tong, PhD; Kristopher Clark, PhD; Nicola Ternette, PhD; Kate Anderton, BSc; Jessica Sette, BSc; Wayne Paes, PhD; Andrew J. Leishman, PhD | Combination Immunotherapies | Checkpoint blockade;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 554 | Poster Presentation | The panorama of tumor intrinsic immune regulators exhibited by genome-wide CRPISR immune screen integrated with comprehensive clinical dataset analysis | Jiakai Hou, Ph.D; Yunfei Wang; Leilei Shi, PhD; Yuan Chen; Chunyu Xu; Arash Saeedi; Ke Pan; Ritu Bohat; Nicholas A. Egan; Jodi A. McKenzie; Rina M. Mbofung; Leila Williams; Zhenhuang Yang; Ming Sun; Xiaofang Liang; Jordi Rodon Ahnert; Navin Varadarajan, PhD; Cassian Yee; Yiwen Chen; Patrick Hwu; Weiyi Peng, PhD | Combination Immunotherapies | Bioinformatics;Epigenetics;Systems biology;Tumor microenvironment | |
| 555 | Poster Presentation | A high-throughput in situ screen to identify synergistic combinations of immune-oncology drugs with targeted and cytotoxic agents in a patient-derived humanized mouse model of renal cancer | Oliver Jonas, PhD; Eva Oswald, PhD; Kanstantsin Lashuk; Sebastian Ahn, PhD; Julia Schuler, DVM PhD | Combination Immunotherapies | Antibody;Checkpoint blockade;Proteomics;Solid tumors;T cell;Tumor microenvironment | |
| 556 | Poster Presentation | Chemo-immunotherapy to treat bone-metastatic prostate cancer | Shreya Kumar, MS; Marxa L. Figueiredo, Ph.D. | Combination Immunotherapies | Chemotherapy;Cytokine;Solid tumors;Tumor microenvironment | |
| 557 | Poster Presentation | Neoadjuvant Camrelizumab in combination with albumin paclitaxel and cisplatin for patients with locally advanced esophageal squamous cell carcinoma (ESCC) | Huilai Lv; Yang Tian; Zhenhua Li; Chao Huang; Yanzhao Xu; Ziqiang Tian | Combination Immunotherapies | Antibody;Checkpoint blockade;Chemotherapy;Clinical study;Immune tolerance;Immune toxicity;Surgery;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 559 | Poster Presentation | Preclinical evaluation of pegylated liposomal Doxorubicin or Doxorubicin with mATRC-101 in the EMT6 syngeneic mouse model | Erin Wechsler, PhD; Nikhil Vad, PhD; Danhui Zhang, MD PhD | Combination Immunotherapies | Antibody;Chemotherapy;Costimulation;Solid tumors;Targeted therapy;Tumor antigens | |
| 560 | Poster Presentation | Immunotherapeutic and antimetastatic activity of LTX-315 in preclinical models of ICI-resistant breast cancer | Takahiro Yamazaki, PhD; Erik Wennerberg, PhD; Michal Hensler; Aitziber Buqué Martinez, PhD; Jeffrey Kraynak; Jitka Fucikova; Xi Zhou; Baldur Sveinbjornsson, PhD; Oystein Rekdal, PhD; Sandra Demaria, MD; Lorenzo Galluzzi, PhD | Combination Immunotherapies | Antigen presenting cells;Chemotherapy;Dendritic cell;NK/NKT cell;Radiotherapy;Solid tumors;Tumor infiltrating lymphocytes (TILs) | |
| 561 | Oral Presentation | Triple checkpoint blockade, but not anti-PD1 alone, enhances the efficacy of engineered adoptive T cell therapy in advanced ovarian cancer | Kristin G. Anderson, PhD; Yapeng Su; Madison G. Burnett; Breanna Bates, BS; Magdalia Rodgers Suarez; Susan L. Ruskin; Aesha Vakil; Valentin Voillet, PhD; Raphael Gottardo, PhD; Philip D. Greenberg, MD | Combination Immunotherapies | Checkpoint blockade;Immune suppression;Solid tumors;T cell;Tumor microenvironment | |
| 562 | Poster Presentation | Real-world assessment of current treatment patterns and clinical outcomes among patients with EGFR and ALK wild type non-small cell lung cancer (NSCLC) in the US | Lyudmila Bazhenova, MD; Jonathan K. Kish, PhD MPH; Beilei Cai; Nydia Caro; Bruce Feinberg | Combination Immunotherapies | Checkpoint blockade;Solid tumors | |
| 563 | Poster Presentation | ICT01, an anti-BTN3A mAb, and NL-201, an alpha-independent IL-2/IL-15 agonist, combine to elicit a potent anti-tumor response by synergistically stimulating Vg9Vd2 T cell activation and proliferation | Aude De Gassart, PhD; Patrick Brune; Maelle Mairesse; Sophie Agaugué; Ryan Swanson, BS; Loui Madakamutil; Carl Walkey; Paul A. Frohna, MD, PhD, PharmD; Aude de Gassart, PhD | Combination Immunotherapies | Antibody;Cytokine;T cell | |
| 564 | Poster Presentation | Single-cell transcriptomic analysis of immune compartments following combination immunotherapy treatment in poorly immunogenic tumors | Ang Cui, PhD; Kelly D. Moynihan, PhD; Shuqiang Li, PhD; Chensu Wang, PhD; Jackson Southard; Nir Hacohen, PhD; Darrell J. Irvine, Ph.D. | Combination Immunotherapies | Bioinformatics;Solid tumors;Systems biology;Tumor microenvironment | |
| 565 | Poster Presentation | Combinatorial HSCs and anti-PD-1 therapy in microsatellite stable colorectal cancer | Bayli DiVita Dean, PhD; John Figg; Laura Falceto Font, BS; Connor Francis; Duane Mitchell; Catherine Flores | Combination Immunotherapies | Checkpoint blockade;Dendritic cell;Solid tumors | |
| 566 | Poster Presentation | ATOR-1017, a second generation 4-1BB antibody with potential to enhance efficacy of PD-1 therapies | Karin Enell Smith, PhD, MS; Anneli Nilsson; Peter Ellmark, PhD | Combination Immunotherapies | Antibody;Costimulation;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 567 | Poster Presentation | Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of stroma poor cancers | Sadna Budhu, PhD; Aditi Gupta, MD; Kelly J. Fitzgerald, MD/PhD; Rachel A. Giese, MD; Adam O. Michel, DVM, MVSc, Dr.med.vet., DACVP; Aliya Holland; Luis Felipe F. Campesato, PhD, MS; Jacques Van Snick, PhD; Catherine Uyttenhove, PhD; Gerd Ritter, PhD; Jedd D. Wolchok, MD/PhD; Taha Merghoub, PhD | Combination Immunotherapies | Checkpoint blockade;Cytokine;Immune suppression;Tumor microenvironment | |
| 568 | Poster Presentation | Tumor-derived GDF-15 prevents therapy success of checkpoint inhibitors by blocking T-lymphocyte recruitment | Markus Haake, PhD; Tina Schäfer, PhD; Beatrice Haack; Neha Vashist, PhD; Sabrina Genßler, PhD; Patrick Harter, MD; Alexander Martens, PhD; Kilian Wistuba-Hamprecht, PhD; Florian Wedekink; Birgitt Fischer; Michel Mittelbronn, MD; Mitchell Levesque, PhD; Phil Cheng, PhD; Reinhard Dummer, MD; Benjamin Weide, MD; Kathrin Klar, PhD; Eugen Leo, MD, PhD, MBA; Falk Nimmerjahn, PhD; Christine Schuberth-Wagner, PhD; Jörg Wischhusen, PhD | Combination Immunotherapies | Antibody;Checkpoint blockade;Cytokine;Immune suppression;Immune tolerance;Solid tumors;T cell lineages;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 569 | Poster Presentation | A novel microbiome-derived peptide reverses resistance to anti-PD-1 therapy | Dhwani D. Haria, MS; Jayamary Divya Ravichandar; Jill Desnoyer; Sabina Lau; Jina Lee; Erica Rutherford; Preeti Lal; Karim Dabbagh; Helena Kiefel, PhD | Combination Immunotherapies | Antigen presenting cells;Checkpoint blockade;Chemokine;Cytokine;Dendritic cell;Microbiome;Myeloid cells;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 570 | Poster Presentation | Blockade of the inhibitory collagen receptor LAIR-1, PD-L1, and TGF-β promotes anti-tumor activity through T cell activation and myeloid cell polarization | Lucas A. Horn, PhD; Haiyan Qin; Kristen N. Fousek, PhD; Masafumi Iida, MD, PhD; Dallas B. Flies, PhD; Ronald Copeland; Zachary Cusumano, Ph.D.; Han Myint; Solomon Langermann; Jeffrey Schlom, PhD; Claudia M. Palena, PhD | Combination Immunotherapies | Monocyte/Macrophage;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 571 | Poster Presentation | IL-2 combination with ImmTAC overcomes CD163+ TAM-like M2 macrophage inhibition of ImmTAC-mediated T cell killing of tumor cells | Rahul Khanolkar; Revashnee Naidoo; Esra Güç; Emma Leach; Sarah Stanhope; Duncan Gascoyne; Laura Collins; Koustubh Ranade; Adel Benlahrech | Combination Immunotherapies | Cytokine;Immune suppression;Monocyte/Macrophage;T cell;Tumor microenvironment | |
| 572 | Poster Presentation | Combination therapy of exoSTING, exoIL-12 activates systemic anti-tumor immunity | Katherine Kirwin; Su Chul Jang, PhD; Christine Sia; Kevin Dooley; Tong Zi; Kelvin Zhang, PhD; Yanyan Liu, PhD; Kyriakos Economides, PhD; Shil Patel, PhD; Sriram Sathyanaryanan, PhD | Combination Immunotherapies | Checkpoint blockade;Extracellular vesicles/exosomes;T cell | |
| 573 | Poster Presentation | FS120, an OX40/CD137 tetravalent bispecific dual agonist antibody, synergistically increases the antitumor activity of anti-PD-1 in preclinical studies | Matthew A. Lakins, PhD; Wenjia Liao; Emma McConnell; Quincy Kaka; Jennifer Ofoedu; Cristian Gradinaru; Raffaella Giambalvo; Miguel Gaspar; Edmund Poon; Michelle Morrow, PhD; Neil Brewis | Combination Immunotherapies | Antibody;Bispecifics;Checkpoint blockade;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 574 | Poster Presentation | Multiplex microscopy reveals unique spatiotemporal effects of cancer immunotherapies | Vivien I. Maltez, PhD; Katelyn Byrne, PhD; Ronald N. Germain, MD, PhD | Combination Immunotherapies | Checkpoint blockade;Dendritic cell;Regulatory T cell (Treg cell);Solid tumors;Systems biology;T cell;T cell lineages;Tumor microenvironment | |
| 575 | Poster Presentation | Dual blockade of LAG3 and TIGIT improves the treatment efficacy of a nanoparticle-mediated immunoradiation in anti-PD1 resistant lung cancer in mice | Yun Hu, PhD; James Welsh; Sebastien Paris; Genevieve Bertolet; Hampartsoum Barsoumian; Lily Schuda; Kewen He; Duygu Sezen; Mark Wasley; Joylise Mitchell; Tiffany Voss; Fatemeh Masrorpour; Jordan SILVA; Claudia Kettlun Leyton; Liangpeng Yang; Nahum Puebla-Osorio; Saumil Gandhi; Quynh-Nhu Nguyen; Angelica Cortez | Combination Immunotherapies | Antibody;Radiotherapy;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine | |
| 576 | Poster Presentation | Tumor Targeted Superantigen (TTS), Naptumomab Estafenatox (NAP), enhances CAR-T cells potency and can boost CAR-T efficacy against solid tumors | yael Sagi, PhD; Michal Shahar, PhD; Marina Pinsker, MSc | Combination Immunotherapies | Adoptive immunotherapy;CAR T cells;Solid tumors;T cell;Tumor microenvironment | |
| 577 | Poster Presentation | Non-clinical efficacy, pharmacokinetics, and pharmacodynamics of a novel bi-functional anti-CD73-TGFβRII-trap molecule in combination with immune checkpoint therapy | Susanna Y. Stinson, MS; Jianhua He; Kyung-Hoon Kim; Becky Yang; Marianna Zavodovskaya, M.S.; Ping Yi; Federico Campigotto; Monika Sobczyk; Rutwij Dave; Brian Carr; In Kyoung Mah; Shiva Zaboli; Jens Brodbeck; Scott Turner; Vivian Barry; Kelli Boyd; Valeria Fantin | Combination Immunotherapies | Immune suppression;Tumor microenvironment | |
| 578 | Oral Presentation | CD8-targeted IL-2 drives potent anti-tumor efficacy and promotes action of tumor specific vaccines | Hussein Sultan, Ph.D.; Kelly D. Moynihan, Ph.D.; Yuang Song, B.A.; Samuel Ameh, B.A.; Ton N. Schumacher, PhD; Yik Andy Yeung, Ph.D.; Ivana Djuretic, Ph.D.; Robert D. Schreiber, PhD | Combination Immunotherapies | Checkpoint blockade;Cytokine;Immune adjuvant;Neoantigens;T cell;Tumor antigens;Vaccine | |
| 579 | Poster Presentation | Exploiting tumor neoantigen-targeted immunotherapy in immunologically hot versus cold murine lung cancer models | Changbo Sun, MD; Koji Nagaoka, PhD; Yukari Kobayashi, BS; Jun Nakajima, MD, PhD; Kazuhiro Kakimi, MD, PhD | Combination Immunotherapies | Adoptive immunotherapy;Checkpoint blockade;Immune suppression;Neoantigens;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor microenvironment;Vaccine | |
| 580 | Poster Presentation | Glutamine blockade in combination with immune checkpoint blockade remodels the myeloid landscape in mouse models of soft tissue sarcomas | Aditya A. Suru, BTech; Marwa Islam; Ada Tam; Dr. John Gross, MD; Nicolas J. Llosa, MD | Combination Immunotherapies | Checkpoint blockade;Immune suppression;MDSC;Metabolism;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy;Tumor microenvironment | |
| 581 | Poster Presentation | Multi-dimensional Synergy of Combinations (MuSYC) Algorithm Optimizes Combinatorial STING and TLR Adjuvant Cancer Vaccines | David R. Taylor, B.S. in Chemistry; Michael J. Korrer, PhD | Combination Immunotherapies | Antigen presenting cells;Costimulation;Dendritic cell;Immune adjuvant;Myeloid cells;T cell;TLR;Tumor antigens;Tumor microenvironment;Vaccine | |
| 582 | Poster Presentation | Immune correlates from QuEST1 in men with castration-resistant prostate cancer | Nicole J. Toney, Ph.D; Yo-Ting Tsai, PhD; Jason M. Redman, MD; James L. Gulley, MD, PhD; Jeffrey Schlom, PhD; Renee N. Donahue, PhD | Combination Immunotherapies | Checkpoint blockade;Clinical study;Clinical trial;Immune monitoring;NK/NKT cell;Proteomics;Solid tumors;T cell;Tumor antigens;Vaccine | |
| 583 | Poster Presentation | Exploring the Potential of T Cell Acute Lymphoblastic Leukemia (T-ALL) for Generating Leukemia-Specific T cell Responses that can be Therapeutically Harnessed with Immunotherapy | Todd A. Triplett, PhD; Joshua F. Rios; Alexander Somma; Sarah E. Church, PhD; Khrystyna North; Andrew M. White, BSc; Nisha Holay, B.S.; Andrew D. Weinberg, PhD | Combination Immunotherapies | Checkpoint blockade;Immune contexture;Leukemia/Lymphoma;T cell;T cell lineages;Tumor microenvironment;Tumor stroma | |
| 584 | Poster Presentation | Powerful synergistic effects of a STING agonist and the IL-2 superkine, H9, in eliciting NK and T cell responses against MHC I- and MHC I+ tumors | Natalie K. Wolf, BS; Cristina Blaj, PhD; Lora Picton; Gail Snyder; Li Zhang; Christopher J. Nicolai; Chudi Ndubaku; Kelsey E. Sivick Gauthier; Sarah McWhirter, PhD; K. Christopher Garcia; David Raulet, PhD | Combination Immunotherapies | Checkpoint blockade;Cytokine;NK/NKT cell;T cell | |
| 585 | Poster Presentation | LIGHT (TNFSF14) co-stimulation enhances myeloid cell activation and anti-tumor immunity in the setting of PD-1 and TIGIT checkpoint blockade | George J. Fromm, Jr., Ph.D.; Kyung Jin Yoo; Kellsey Johannes; Casey Shuptrine; Zach Opheim; Arpita Patel; Haley Andreasen; Jaya Miriyala; Suresh De Silva, Ph.D.; Taylor H. Schreiber, MD, PhD | Combination Immunotherapies | Bispecifics;Checkpoint blockade;Costimulation;NK/NKT cell;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs) | |
| 586 | Poster Presentation | Monitoring the impact of MDSC targeting drugs in combination with nivolumab on activation and proliferation of tumor resident effector immune cells in patient-derived 3D-EXplore platform | Jared C. Ehrhart, PhD; Brittany Bunch; Kelly Sussman; Kelly Guzman; Soner Altiok, MD, PhD | Combination Immunotherapies | Checkpoint blockade;Costimulation;Immune suppression;MDSC;Solid tumors;Tumor evasion;Tumor microenvironment;Tumor stroma | |
| 587 | Poster Presentation | Inducing mismatch repair deficiency in combination with anti-CTLA4 therapy is highly effective against non-immunogenic neuroblastoma tumors | Mikal El-Hajjar, MSc; Lara Gerhardt, BSc; Mithunah Krishnamoorthy, PhD; Rene Figueredo, MSc; Xiufen Zheng, PhD; James Koropatnick, PhD; Saman Maleki, PhD | Combination Immunotherapies | Bioinformatics;Checkpoint blockade;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 588 | Poster Presentation | Caloric restriction sensitizes melanoma to anti-PD-1 immune checkpoint inhibition | Alexa D. Melucci, MD; Shuyang S. Qin, M.S; Alexander C. Chacon, MD; Rachel Jewell; Peter A. Prieto, MD, MPH | Combination Immunotherapies | Checkpoint blockade;Immune suppression;Inflammation;T cell | |
| 589 | Poster Presentation | Enhancement of the anti-tumor effects of CD47 blockade in solid tumors by combination with targeted radioimmunotherapy | Denis Beckford, PhD; Sagarika Pachhal; Emily Greer; Jesse Hwang; Qing Liang; Mary Chen; Eileen Geoghegan; Helen Kotanides; Dale Ludwig | Combination Immunotherapies | Antibody;Checkpoint blockade;Radiotherapy;Solid tumors;Targeted therapy | |
| 590 | Poster Presentation | Anti-CD33 actinium-225 targeted radioimmunotherapy enhances the biologic activity of anti-CD47 antibody immunotherapy in preclinical models of acute myeloid leukemia | Denis Beckford, PhD; Sagarika Pachhal; Emily Greer; Jesse Hwang; Qing Liang; Mary Chen; Eileen Geoghegan; Helen Kotanides; Dale Ludwig | Combination Immunotherapies | Antibody;Radiotherapy;Targeted therapy | |
| 591 | Poster Presentation | Survival rates in Stage IV melanoma patients treated with radiation and immunotherapy differ depending on age and radiation treatment site | Catherine Colonna, MS; Nasreen A. Vohra, MD; Aiden Burke, MD; Matthew S. Peach, MD; Andrew W. Ju, MD | Combination Immunotherapies | Checkpoint blockade;Radiotherapy | |
| 592 | Oral Presentation | ATR-mediated CD47 and PD-L1 upregulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer | Rodney Cheng-En Hsieh, MD; Sunil Krishnan; Ren-Chin Wu; Akash R. Boda, MS; Arthur J. Liu, BS; Michelle Winkler, BS; Wen-Hao Hsu; Steven H. Lin; Mien-Chie Hung; Li-Chuan Chan; Krithikaa R. Bhanu; Anupallavi Srinivasamani, MS; Ricardo A. De Azevedo; Yung-Chih Chou; Ronald Depinho; Matthew M. Gubin, PhD; Eduardo Vilar-Sanchez, MD, PhD; Chao-Hsien Chen; Ravaen Slay; Priyamvada Jayaprakash, PhD; Shweta M. Hegde; Genevieve P. Hartley, PhD; Spencer T. Lea, BA; Rishika Prasad, MS; Brittany Morrow; Coline A. Couillault, PhD; Madeline Steiner; Chun-Chieh Wang; Bhanu P. Venkatesulu; Cullen Taniguchi; Betty Y. Kim; Junjie Chen; Nils-Petter Rudqvist, PhD; Michael A. Curran, PhD | Combination Immunotherapies | Antigen presenting cells;Checkpoint blockade;Coinhibition;Immune suppression;Radiotherapy;T cell;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 593 | Poster Presentation | PI3Kγδ inhibitor combined with radiation enhances the antitumor immune effect of PD-1 blockade in syngenic murine breast cancer model and humanized patient-derived xenograft model | MIn Guk Han, PHD student; Bum Sup Jang, PHD; Mi Hyun Kang, MS; Deukchae Na, PhD; In Ah Kim, MD, PhD | Combination Immunotherapies | Checkpoint blockade;Immune tolerance;MDSC;Monocyte/Macrophage;Radiotherapy;Regulatory T cell (Treg cell);Tumor microenvironment | |
| 594 | Poster Presentation | Combination of antigen-specific vaccination and targeted radionuclide therapy improves anti-tumor efficacy in a murine prostate model | Hemanth K. Potluri, BA; Carolina A. Ferreira, PhD; Joseph Grudzinski, PhD; Christopher Massey; Reinier Hernandez, PhD; Jamey Weichert, PhD; Douglas G. McNeel, MD, PhD | Combination Immunotherapies | Dendritic cell;Radiotherapy;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine | |
| 595 | Poster Presentation | Inhibition of integrin αvβ8 in combination with low dose radiation induces antitumor effect in advanced immune checkpoint blockade refractory tumor model | Natalia J. Reszka-Blanco, PhD; Megan Krumpoch; Michaela Mentzer; Vinod Yadav Yadav; Brianna Bannister; Dan Cui; Elizabeth Konopka; Dooyoung Lee; Fu-Yang Lin; Terence I. Moy; Eugene Nebelitsky; Qi Qiao; Inese Smutske; Charlotte A. Root; Patrick Allison; Sarah A. Krueger; Dawn Troast; Blaise Lippa; Bruce N. Rogers; Adrian S. Ray | Combination Immunotherapies | Antigen presenting cells;Costimulation;Dendritic cell;Immune suppression;Immune tolerance;Radiotherapy;Solid tumors;Tumor evasion;Tumor infiltrating lymphocytes (TILs) | |
| 596 | Poster Presentation | Combining Bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) pairs local innate activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity | Annah S. Rolig, Ph. D; Daniel C. Rose, BS in biology; Grace Helen C. McGee; Saul Kivimae, PhD; Werner Rubas, PhD; William L. Redmond, Ph.D. | Combination Immunotherapies | Cytokine;Immune adjuvant;Radiotherapy;T cell;TLR;Tumor infiltrating lymphocytes (TILs) | |
| 597 | Poster Presentation | The role of CCL20 in mediating regulatory T cell infiltration and resistance to radiotherapy in head and neck squamous cell carcinoma | Cleopatra Rutihinda, BSc; Leanié Moreau, BSc; Safia Chelighem, BSc; Ayman J. Oweida, PhD | Combination Immunotherapies | Antibody;Chemokine;Cytokine;Radiotherapy;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 598 | Poster Presentation | Local radiation in combination with CpG and anti-OX40 induces enhanced T cell activation and proliferation | Dan Spiegelman, BS; Alexander Pieper, B.S.; Luke M. Zangl, BS; Arika S. Feils, BS; Anna Hoefges, MS; Mildred A. Felder, BS; Sritha Moram, BS; Alexander L. Rakhmilevich, MD, PhD; Amy K. Erbe, PhD; Jacquelyn A. Hank, PhD; Ravi Patel, MD, PhD; Zachary S. Morris, MD, PhD; Paul M. Sondel, MD, PhD | Combination Immunotherapies | Costimulation;Radiotherapy;T cell;Vaccine | |
| 599 | Poster Presentation | Cyclophosphamide augments the efficacy of an in situ vaccine in a mouse melanoma model | Noah Tsarovsky, BS; Mildred A. Felder, BS; Mackenzie Heck; Jacob Slowinski; Kayla Rasmussen; Sabrina VandenHeuvel; Zachary S. Morris, MD, PhD; Amy K. Erbe, PhD; Paul M. Sondel, MD, PhD; Alexander L. Rakhmilevich, MD, PhD | Combination Immunotherapies | Chemotherapy;Cytokine;Immune adjuvant;Radiotherapy;T cell;Vaccine | |
| 600 | Poster Presentation | BR101801 stimulates anti-tumor immunity and enhances the efficacy of radiation in a syngeneic model | Seungho Wang, MS; Yi Na Yoon; Mi kwon Son; Soo Jung Kim; Bo Ram Lee; Eun hee Yang; Byeongwook Jeon; Seung Hyun Lee; Tae-Jin Kim; Jae-Sung Kim; Joo Han Lee | Combination Immunotherapies | Immune adjuvant;MDSC;Myeloid cells;Radiotherapy;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 601 | Oral Presentation | Sequencing Immunotherapy Before Lymphatic Ablation Unleashes cDC1-Dependent Antitumor Immunity in HNSCC | Robert Saddawi-Konefka, MD PhD; Aoife E. O'Farrell, BS; Farhoud Faraji, MD PhD; Michael Allevato, BA; Zhiyong Wang, PhD; Victoria H. Wu, BA; Bryan S. Yung, MA; Nana-Ama A. Anang, BS; Ida Franiak-Pietryga, PhD; Aaron B. Simon, MD PhD; Shawn Jensen, PhD; Bernard A. Fox, PhD; Andrew Sharabi, MD, PhD, FACS; Ezra EW. Cohen, MD; Joseph Califano, MD; J. Silvio Gutkind | Combination Immunotherapies | Checkpoint blockade;Dendritic cell;Solid tumors;Surgery;Systems biology;Tumor evasion | |
| 602 | Poster Presentation | AXL targeting with bemcentinb restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through innate immune cell mediated expansion of TCF1+ CD8 T cells | Huiyu Li, BS; Zhida Liu, PhD; Longchao Liu, PhD; Hongyi Zhang; Chuanhui Han, PhD; Luc Girard, Ph.D.; Hyunsil Park; Anli Zhang, PhD; Chunbo Dong; Jianfeng Ye; Austin Rayford, MS; Michael Peyton, Ph.D.; Xiaoguang Li; Kim Avila; Xuezhi Cao; Shuiqing Hu; Esra Akbay, PhD; Luisa M. Solis, MD; Carmen Behrens, MD; Sharia Hernandez-Ruiz; Lu Wei; Ignacio Wistuba, MD; John V. Heymach, MD, PhD; Michael Chisamore, PhD; David Micklem, PhD; Hani Gabra, MD, PhD, FRCP; Gro Gausdal, PhD; James B. Lorens, PhD; Bo Li; Yang-Xin Fu, MD, PhD; John D. Minna, M.D.; Rolf A. Brekken, PhD | Combination Immunotherapies | Checkpoint blockade;Dendritic cell;Immune contexture;Immune suppression;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 603 | Poster Presentation | Targeted STAT3 degradation leads to remodeling of an immunosuppressive tumor microenvironment and subsequent sensitization to immune checkpoint therapy | Joyoti Dey, PhD, MPH; Phillip CC. Liu, PhD; Michele Mayo; Rahul Karnik, PhD; Bin Yang, PhD; Vaishali Dixit, PhD; Jieun Jeong, PhD; Jared Gollob, MD; Chris De Savi, PhD | Combination Immunotherapies | Checkpoint blockade;Gene expression;Immune suppression;Leukemia/Lymphoma;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 604 | Poster Presentation | Combining a novel dual RAF/MEK inhibitor with immunomodulation to promote an anti-tumor response. | Lauren Dong, BS; Hyejin Choi, PhD; Sadna Budhu, PhD; Isabell Schulze; Nezar Mehanna; Neal Rosen; Taha Merghoub, PhD; Jedd D. Wolchok, MD/PhD | Combination Immunotherapies | Checkpoint blockade;Costimulation;Targeted therapy | |
| 605 | Poster Presentation | NHS-IL12 plus Entinostat combination effectively targets anti-PD-1/PD-L1 checkpoint resistant murine tumors harboring MHC Class I and antigen processing machinery deficiency | Christine M. Minnar, PhD; Paul L. Chariou, PhD; Kristin C. Hicks, PhD; Jeffrey Schlom, PhD; Sofia R. Gameiro, PharmD, PhD | Combination Immunotherapies | Antigen presenting cells;Cytokine;Epigenetics;Solid tumors;Targeted therapy;Tumor microenvironment | |
| 606 | Poster Presentation | SAR444245 (THOR-707), an engineered non-alpha IL-2, enhances NK mediated antibody-dependent cellular cytotoxicity | Julie-Ann Gavigan; Nicole V. Acuff; Christen Buetz; Michael Lampa; Chaomei Shi; Yu-an Zhang; Liqing Chen; Kelly Balko; Virna Cortez-Retamozo; Jill Mooney; Carolina Caffaro; Marcos Milla; Joachim Theilhaber; Donald Jackson; Timothy Wagenaar; Giovanni Abbadessa; Donald Shaffer; Xiangming Li | Combination Immunotherapies | Antibody;Cytokine;NK/NKT cell;Solid tumors | |
| 607 | Poster Presentation | Regional delivery of a TLR9 agonist to boost checkpoint inhibitor responsiveness in liver metastases | Chandra C. Ghosh, PhD; Kyle O’Connell, BS; Kara Heatherton, BS; Jason Laporte, MS; Prajna Guha, PhD; Bryan Cox; Steven C. Katz, MD | Combination Immunotherapies | Checkpoint blockade;MDSC;Solid tumors;TLR;Tumor microenvironment | |
| 608 | Poster Presentation | Synergistic effect of the combination of ATG-017, an ERK1/2 inhibitor, and immune checkpoint inhibitor in preclinical cancer models | Bing Hou, Ph.D; Peng Chen; Yun Liu; Min Deng; Jian Wang; Dirk Hoenemann; Kevin Lynch; Jay Mei; Bo Shan | Combination Immunotherapies | Checkpoint blockade;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 609 | Poster Presentation | Combining bintrafusp alfa with abituzumab enhances suppression of the TGF-β signaling pathway | Feng Jiang, PHD; Hong Wang; Tsz-Lun Yeung; Guozhong Qin; Bo Marelli; Hui Huang, Ph.D.; Kin-Ming Lo; Yan Lan, MD | Combination Immunotherapies | Bispecifics;Checkpoint blockade;Cytokine;Tumor microenvironment | |
| 610 | Poster Presentation | Sustainable regression of disseminated solid tumors mediated by in situ combinational treatment with adoptive T cell therapy and oncolytic adenovirus Delta-24-RGDOX | Hong Jiang, PhD; Dong Ho Shin; Sagar s. Sohoni, PhD; Teresa T. Nguyen, PhD; Yanhua Yi; Xuejun Fan, BS; Joy Gumin; Sanjay k. Singh, PHD; Frederick Lang, MD; Candelaria Gomez-Manzano; Juan Fueyo | Combination Immunotherapies | Adoptive immunotherapy;Solid tumors;T cell;Targeted therapy | |
| 611 | Poster Presentation | Exploiting T cells as vehicles of liposomal SHP2i to enhance adoptive cell therapy | Xin Li, MSc; Hólmfridur R. Halldórsdóttir; Sven Weller; Anna Colliander; Ditte Jæhger, PhD; Martin Bak; Gael Clergeaud, PhD; Thomas L. Andresen, PhD | Combination Immunotherapies | Adoptive immunotherapy;Checkpoint blockade;T cell;Targeted therapy | |
| 612 | Poster Presentation | Human ribonucleases act as potential plasma biomarkers for targeted therapy and immunotherapy in hepatocellular carcinoma | Zhengyu Zha; Chenhao Zhou; Dihua Yu; Mien-Chie Hung; Chunxiao Liu, PhD; Ning Ren | Combination Immunotherapies | Biomarkers;Checkpoint blockade;Targeted therapy;Tumor microenvironment | |
| 613 | Poster Presentation | 9-ING-41, a selective small molecule inhibitor of Glycogen Synthase Kinase-3 beta (GSK-3beta), may enhance neuroblastoma immunogenicity | Angela Markovska, MSc; Marianne Boes, PhD; Francis Giles, MD | Combination Immunotherapies | Checkpoint blockade;Metabolism;Pediatric tumors;Solid tumors;T cell;Targeted therapy | |
| 614 | Poster Presentation | Investigating immune mediated mechanisms of PARPi resistance in BRCA1-associated triple negative breast cancer (TNBC) | Anita K. Mehta, PhD; Madeline G. Townsend; Madisson Oliwa; Patrice A. Lee, PhD; Nicholas A. Saccomano, PhD; Filipa Lynce, MD; Geoffrey I. Shapiro, MD, PhD; Elizabeth A. Mittendorf, MD, PhD; Jennifer L. Guerriero, PhD | Combination Immunotherapies | Checkpoint blockade;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy;Tumor microenvironment | |
| 615 | Poster Presentation | Reactivating antitumor immunity in gliomas with osteopontin/integrin blocking peptide | Paulina Pilanc-Kudlek, MSc; Katarzyna Poleszak, PhD; Aleksandra Ellert-Miklaszewska, PhD; Adria-Jaume Roura Canalda, MSc; Salwador Cyranowski, MSc; Julian Swatler, MSc; Bartlomiej Gielniewski, PhD; Bozena Kaminska, Prof. | Combination Immunotherapies | Angiogenesis;Checkpoint blockade;Immune suppression;Monocyte/Macrophage;Myeloid cells;Tumor microenvironment | |
| 616 | Poster Presentation | CD47 blockade modulates immunosuppressive checkpoint molecules and cellular metabolism to sensitize triple-negative breast cancer tumors to immune checkpoint blockade therapy | Elizabeth R. Stirling, MS; Adam Wilson, .; Katherine L. Cook, PhD; Alexandra Thomas, MD; Pierre L. Triozzi; David R. Soto-Pantoja, PhD | Combination Immunotherapies | Biomarkers;Checkpoint blockade;Immune suppression;Metabolism;Solid tumors;Tumor microenvironment | |
| 617 | Poster Presentation | Trastuzumab and Pertuzumab combination therapy activates complement-dependent cytotoxicity and phagocytosis against HER2+ breast cancer | Li-Chung Tsao, PhD; Zachary C. Hartman, PhD | Combination Immunotherapies | Antibody;Coinhibition;Monocyte/Macrophage;Solid tumors;Targeted therapy | |
| 618 | Poster Presentation | Expanding Cancer Immunotherapy by Exploiting Recall Immunity – A New Co-Therapy Option for Checkpoint Inhibitors | Indu Venugopal, PhD; Kathlynn C. Brown; Michael J. McGuire; Anuja Pande | Combination Immunotherapies | Antigen presenting cells;Checkpoint blockade;Solid tumors;T cell;Targeted therapy | |
| 619 | Poster Presentation | Pharmacologic modulation of tumor glycolysis to improve responses to immune checkpoint blockade therapy | Svena Verma, BS; Rachana Maniyar, PhD; Myat K. Ko; Sadna Budhu, PhD; Inna Serganova; Roberta Zappasodi, PhD; Ronald Blasberg; Taha Merghoub, PhD; Jedd D. Wolchok, MD/PhD; Levi M. Mangarin, BS | Combination Immunotherapies | Metabolism | |
| 620 | Poster Presentation | Onco-immunological mechanisms of focal ablation and localized IL-12 immunotherapy | Maura R. Vrabel, B.S.; David A. Zaharoff, PhD; Siena M. Mantooth, BS | Combination Immunotherapies | Immune adjuvant;Solid tumors;Surgery;Targeted therapy | |
| 621 | Poster Presentation | NKG2A and HLA-E define a novel mechanism of resistance to immunotherapy with M. bovis BCG in non-muscle-invasive bladder cancer patients | Amir Horowitz, PhD; Jorge Daza, MD; Y. Alice Wang, PhD; Daniel Ranti; Berengere Salome, PharmD, PhD; Elliot Merritt, PhD; Julie-Ann Cavallo-Fleming, PhD; Everado Hegewisch-Solloa; Emily M. Mace, PhD; Adam M. Farkas, PhD; Sanjana Shroff, PhD; Michelle Tran, MD PhD Candidate; Jingjing Qi, PhD; Manishkumar Patel, PhD; Daniel Geanon; Geoffrey Kelly; Ronaldo de Real; Brian Lee; Seunghee Kim-Schulze, PhD; Tin Htwe Thin, PhD; Monica Garcia-Barros; Kristin G. Beaumont; Ying-Chih Wang; Li Wang, PhD; Dominic LaRoche, PhD; Yong Lee; Robert Sebra; Rachel Brody, MD, PhD; Reza Mehrazin, MD; Jun Zhu, PhD; Anna Tocheva, PhD; Benjamin Hopkins, PhD; Peter Wiklund, MD; Matthew D. Galsky, MD; Nina Bhardwaj, MD, PhD; John P. Sfakianos, MD | Combination Immunotherapies | Checkpoint blockade;Inflammation;NK/NKT cell;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 622 | Poster Presentation | Disrupted oxygen supply and tumor hyper- oxygen consumption contribute independently to prostate cancer immune privilege | Priyamvada Jayaprakash, PhD; Meghan Rice; Krithikaa Rajkumar Bhanu; Brittany Morrow; Joseph R. Marszalek, PhD; Jason P. Gay, PhD; Christopher P. Vellano, PhD; Benjamin R. Cowen, PhD, MBA; Dean J. Welsch, PhD; Michael A. Curran, PhD | Combination Immunotherapies | Checkpoint blockade;Immune suppression;MDSC;Metabolism;Myeloid cells;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 623 | Poster Presentation | Notch Orchestrates A Multifaceted Immune Evasion Program in Hepatocellular Carcinoma | Katherine E. Lindblad, BS; Marina Ruiz de Galarreta, PhD; Romain Donne, PhD; Marina Bárcena-Varela, PhD; Ian Liebling; David Repáraz; Melissa Yao, B.S.; Maxime Dhainaut, PhD; Brian Brown, PhD; Alice O. Kamphorst, PhD; Amaia Lujambio, PhD | Combination Immunotherapies | Checkpoint blockade;T cell;Targeted therapy;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 624 | Poster Presentation | Targeting Type I arginine methyltransferases promotes T cell mediated antitumor immune responses | Leilei Shi, PhD; Andrew Fedoriw; Shane O'Brien; Kimberly Smitheman; Yunfei Wang; Jiakai Hou, Ph.D; Christian Sherk; Satyajit Rajapurkar; Jenny Laraio; Leila Williams; Chunyu Xu; Guangchun Han; Qin Feng; Mark T. Bedford; Linghua Wang, PhD; Olena Barbash; Ryan G. Kruger; Patrick Hwu; Helai P. Mohammad; Weiyi Peng, PhD | Combination Immunotherapies | Checkpoint blockade;Gene expression;Immune suppression;Post-translational modifications;T cell;Tumor evasion;Tumor microenvironment | |
| 625 | Oral Presentation | COVID-19 vaccination in patients with renal cancer or melanoma receiving immune checkpoint inhibitors | Joyce K. Hwang, MD PhD; Hannah E. Dzimitrowicz, MD; Riddhishkumar Shah, MD PhD; Kathleen Ashcraft, PhD; Daniel J. George, MD; April Salama, MD; Tian Zhang, MD | COVID and Immunotherapy | Checkpoint blockade;COVID and Immunotherapy;Vaccine | |
| 626 | Oral Presentation | Dissecting the spatial heterogeneity of SARS-CoV-2-infected tumour microenvironment reveals a lymphocyte-dominant immune response in a HBV-associated HCC patient with COVID-19 history | Benedict Tan, PhD; Yi Yang, PhD; Chun Chau Lawrence Cheung, MMedSc; Denise Goh, BBiomedSc (Hons); Mai Chan Lau, PhD; Xinru Lim; Jeffrey C. Lim; Li Wen Justina Nadia Lee; Tracy Z. Tien; Shirin Kalimuddin; Wai Meng David Tai; Jenny G. Low; Cedric Chuan Young Ng; Wei Qiang Leow; Thuan Tong Tan; Tony KH. Lim; Jin Liu; Joe P. Yeong, MD, PhD | COVID and Immunotherapy | B cell;Bioinformatics;COVID and Immunotherapy;Gene expression;Immune contexture;NK/NKT cell;RNA;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 629 | Poster Presentation | Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors | Priyanka V. Chablani, MD; Theodore Karrison, PhD; Walter Stadler, MD | Education and Treatment Management | Checkpoint blockade;Chemotherapy;Clinical study;Solid tumors | |
| 630 | Poster Presentation | Oncologists’ perspectives on evolution of first-line immune checkpoint inhibitor maintenance therapy in management of advanced urothelial carcinoma in the US | Petros Grivas; Phani Veeranki; Kevin Chiu; Vivek Pawar; Jane Chang; Murtuza Bharmal, PhD, MS, BPharm | Education and Treatment Management | Checkpoint blockade;Chemotherapy;Clinical study;Solid tumors | |
| 631 | Poster Presentation | Deep, durable response to PD-1 inhibitor monotherapy in microsatellite-stable, tumor mutational burden-high colorectal cancer | Samuel J. Schellenberg, BS; Leeseul Kim, MD; Young Kwang Chae, MD, MPH, MBA | Education and Treatment Management | Biomarkers;Checkpoint blockade;Neoantigens;Solid tumors;Tumor antigens | |
| 632 | Poster Presentation | Toripalimab combined with platinum-based chemotherapy as a second-line treatment for small cell lung cancer (SCLC) with brain metastases: A case report | Jieqiong Fan; Yao Zhang; Xiaofei Mo; Jing Guo | Education and Treatment Management | Antibody;Checkpoint blockade;Solid tumors | |
| 635 | Poster Presentation | Online CME improves the interprofessional team’s ability to manage patients with malignant pleural mesothelioma | Michelle A. Worst, PharmD, BCOP, MBA; Emily Van Laar; Megan Whitney, DMD; Anne Tsao, MD; Hossein Borghaei, MS, DO | Education and Treatment Management | Checkpoint blockade;Chemotherapy;Epidemiology;Immune toxicity;Solid tumors;Targeted therapy;Tumor microenvironment | |
| 636 | Poster Presentation | Patient-Reported Distress with Immunotherapy-Based First-Line Treatment for mNSCLC: a Real-World Evidence Study | Monica H. Bodd, BA; Susan C. Locke, PhD; Scott Antonia, MD, PhD; Jeffrey Crawford, MD; John Hartman, PhD; Kris Herring, PhD; Neal Ready, MD, PhD; Thomas E. Stinchcombe, MD; Jesse D. Troy, PhD; Chakita Williams, PhD; Steven Wolf, MS; Jeffrey M. Clarke, MD; Thomas W. LeBlanc, MD MA MHS FAAHPM FASCO | Education and Treatment Management | Chemotherapy;Clinical study;Solid tumors | |
| 637 | Poster Presentation | Exploring the Impact of Immunotherapy on Cancer Patients’ Real World Experience | Helen M. Nichols, PhD; Helen M. Nichols, PhD, MSW; Elise Wu | Education and Treatment Management | Targeted therapy | |
| 647 | Poster Presentation | Possibility of immunotherapy for the glioblastoma patients with O6-methyl-guanine DNA methyltransferase (MGMT) expression or promoter unmethylated. | Yoshihiro Kushihara; Yukari Kobayashi, BS; Koji Nagaoka, PhD; Kazuhiro Kakimi, MD, PhD | Immune Cell Biology | Immune suppression;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 651 | Oral Presentation | Molecular signature of neoantigen-reactive CD4+ and CD8+ T cells from metastatic human cancers enables prospective antitumor TCR prediction | Frank J. Lowery, III, Ph.D.; Sri Krishna, PhD; Rami Yoseph, PhD; Neilesh B. Parikh, M.D.; Praveen D. Chatani, MD; Yong-Chen William W. Lu, PhD; Nikolaos Zacharakis, PhD, MS; Paul F. Robbins, PhD; Maria Parkhurst, PhD; Steven A. Rosenberg, MD, PhD | Immune Cell Biology | Adoptive immunotherapy;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 659 | Poster Presentation | T cell receptor exchange by zygote engineering results in physiological T cell responses for therapeutic use in pancreatic ductal adenocarcinoma | Meagan R. Rollins, BA; Jackson F. Raynor; Ebony A. Miller; Ellen J. Spartz, M.D.; Walker S. Lahr; Adam L. Burrack, Ph.D.; Yun You, Ph.D.; Branden S. Morarity, Ph.D.; Beau R. Webber, PhD; Ingunn M. Stromnes, Ph.D. | Immune Cell Biology | Adoptive immunotherapy | |
| 660 | Oral Presentation | Targeting T cell fates: converting exhaustion to memory to improve immunotherapeutic responses to cancer | Nicole E. Scharping, PhD; Allison Cafferata; Maximilian Heeg; Quynhanh Nguyen; Ananda W. Goldrath | Immune Cell Biology | Adoptive immunotherapy;Checkpoint blockade;Solid tumors;T cell;T cell lineages;Targeted therapy;Tumor infiltrating lymphocytes (TILs) | |
| 662 | Poster Presentation | Dissecting the CD226 immune axis in the tumor microenvironment using CyTOF-based high-dimensional immunophenotyping | Katie Vowell, PhD; Michael Conner; Florence Perrin; Paul Bojczuk; Kenneth Hance, PhD, MPH; Iris Roth, PhD; Christine Donahue, PhD; James Smothers, PhD; Jeremy Waight, PhD | Immune Cell Biology | Checkpoint blockade;NK/NKT cell;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 668 | Oral Presentation | Lipid-instructed metabolic rewiring unleash the anti-tumor potential of CD8+ T cells. | Teresa Manzo, PhD; Carina Nava Lauveson; Teresa Maria Frasconi; Silvia Tiberti; Ignazio Caruana; Luigi Nezi; Philip D. Greenberg, MD | Immune Cell Biology | Adoptive immunotherapy;Metabolism;T cell;Tumor microenvironment | |
| 671 | Poster Presentation | Biological Impacts of Standard of Care Chemotherapies on Immune Effector Cells from AML Patients | Dmitry Zhigarev, MD; Alexander W. MacFarlane, PhD; Christina Drenberg, PhD; Reza Nejati, MD; Asya Varshavsky, MD PhD; Kerry S. Campbell, PhD | Immune Cell Biology | Biomarkers;Chemotherapy;Clinical study;Immune monitoring;Immune suppression;Leukemia/Lymphoma;NK/NKT cell;Regulatory T cell (Treg cell);T cell | |
| 672 | Poster Presentation | The effect of ChemoRadioTherapy and Tumor Histology on the Immune Contexture of Tumor-Draining Lymph Nodes in NSCLC | Marieke F. Fransen, PhD; Famke L. Schneiders, MD, PhD; Vinitha Kandiah; Teodora Radonic, MD, PhD; Idris Bahce, MD, PhD; Chris Dickhoff, MD, PhD; Tanja D. de Gruijl, PhD | Immune Cell Biology | Checkpoint blockade;Chemotherapy;Dendritic cell;Immune contexture;Monocyte/Macrophage;Radiotherapy;Surgery;T cell | |
| 688 | Poster Presentation | Knockout of the inhibitory receptor TIGIT enhances anti-tumor response of ex vivo expanded NK cells | Tayler J. Croom-Perez, PhD; Md Faqrul Hasan, Masters; Thomas A. Dieffenthaller; Liza D. Robles-Carrillo; Jonathan E. Eloriaga; Alicja J. Copik, PhD | Immune Cell Types | Adoptive immunotherapy;NK/NKT cell | |
| 690 | Poster Presentation | TIGIT blockade improves anti-tumor activity of ex vivo expanded NK cells | Md Faqrul Hasan, Masters; Alicja J. Copik, PhD | Immune Cell Types | Adoptive immunotherapy;Checkpoint blockade;NK/NKT cell | |
| 691 | Poster Presentation | Identification of shared tumor epitopes from endogenous retroviruses inducing high avidity cytotoxic T cells for cancer immunotherapy | Paola Bonaventura, PhD; Vincent Alcazer, MD; Virginie Mutez; Laurie Tonon; Juliette Martin, PhD; Nicolas Chuvin, PhD; Rasha Boulos, PhD; Yann Estornes, PhD; Jenny Valladeau-Guilemond, PhD; Alain Viari, PhD; Christophe Caux, PhD; Stephane Depil, MD, PhD | Immune Cell Types | Antigen presenting cells;Bioinformatics;Dendritic cell;Neoantigens;Solid tumors;T cell;TLR;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Vaccine | |
| 695 | Poster Presentation | Combination of click chemistry-based SQ3370 with immunotherapies enhances antitumor effect in murine tumors with minimized systemic toxicity | Amir Mahmoodi, MS; Sangeetha Srinivasan, PhD; Michael Zakharian, MS; Nathan A. Yee, PhD; Jesse M. McFarland, PhD; Jose M. Mejia Oneto, MD, PhD | Immune-stimulants and immune modulators | Antigen presenting cells;Dendritic cell;Inflammation;Monocyte/Macrophage;Solid tumors;Tumor infiltrating lymphocytes (TILs) | |
| 701 | Poster Presentation | Activating CD73 on B cells as a target for immunotherapy of COVID-19 and viral associated cancers: Clinical activity in human papilloma virus positive (HPV) head and neck squamous cell cancers (HNSCC) | Jason J. Luke; Jaime R. Merchan, MD; Brett GM. Hughes, MD; Jeffrey A. Sosman, MD; Abhishek Tripathi, MD; Igor Puzanov, MD, MSCI; Thomas U. Marron, MD, PhD; Kristen A. Marrone, MD; Craig M. Hill, PhD; James Janc, PhD; Jenny Rudnick, BS, PhD; Shenshen Hu, PhD; Mehrdad Mobasher, MD, MPH; Suresh Mahabhashyam, MD, MPH; Richard A. Miller, MD | Immune-stimulants and immune modulators | Antibody;B cell;Clinical study;Clinical trial;COVID and Immunotherapy;Tumor antigens | |
| 708 | Poster Presentation | Novel ways to exploit IL-21 to augment adoptive T cell transfer therapy against tumors | Anna C. Cole, BA; Guillermo O. Rangel RIvera, B.S.; Aubrey S. Smith, BS; Megan M. Wyatt, MS; Brandon Ware, PhD; Hannah M. Knochelmann, BS; Chrystal M. Paulos, PhD | Immune-stimulants and immune modulators | Adoptive immunotherapy;Cytokine;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 714 | Poster Presentation | Selective expansion of antigen-specific CD8 T cells with engineered Antigen Presenting Exosome | Tomoyoshi Yamano, phD; Xiabing Lyu; Rikinari Hanayama, M.D., phD | Immune-stimulants and immune modulators | Adoptive immunotherapy;Costimulation;Dendritic cell;T cell;Tumor antigens | |
| 721 | Poster Presentation | Intratumoral immunotherapy with aluminum hydroxide-tethered IL-12 induces potent local and systemic immunity with minimal toxicity | Michael M. Schmidt, PhD; Gregory Papastoitsis; Howard L. Kaufman, MD; Darrell J. Irvine, Ph.D.; K. D. Wittrup | Immune-stimulants and immune modulators | Costimulation;Cytokine;Immune adjuvant;Immune toxicity;Solid tumors;Tumor microenvironment | |
| 722 | Poster Presentation | INBRX-121 is an NKp46-targeted detuned IL-2 with antitumor activity as a monotherapy or in combination with multiple cancer immunotherapy modalities | Florian J. Sulzmaier, PhD; Heather Kinkead, PhD; Anya Polovina; Nadja Kern; Angelica Sanabria; Chelsie Macedo; Abrahim Hussain; Sae Jeong Ahn; Rajay Pandit; William Crago; John C. Timmer, PhD; Analeah B. Heidt, PhD; Brendan P. Eckelman, PhD | Immune-stimulants and immune modulators | Antibody;Bispecifics;Cytokine;NK/NKT cell;Targeted therapy | |
| 729 | Poster Presentation | Immunologic tumor cell intrinsic effects of standard of care therapies for ovarian cancer | Nicole E. James, PhD; Melih A. Ozsoy; Payton De La Cruz; Morgan Woodman; Jennifer Ribeiro | Immune-stimulants and immune modulators | Chemotherapy;Cytokine;Solid tumors | |
| 731 | Poster Presentation | Concurrent immunotherapy and dipeptidyl peptidase-4 inhibition among patients with solid tumors | Kayla W. Miranda, MD; Matthew D. Tucker, MD; Yu-Wei Chen, MD; Kathryn E. Beckermann, MD, PhD; Brian I. Rini, MD | Immune-stimulants and immune modulators | Checkpoint blockade;Clinical study;Immune toxicity;Solid tumors;Tumor microenvironment | |
| 733 | Poster Presentation | Immunological mechanisms of resistance to CDK4/CDK6 inhibitors in breast cancer | Giulia Petroni, PhD; Kenneth Gouin; Aitziber Buqué Martinez, PhD; Simon Knott; Silvia C. Formenti, MD; Lorenzo Galluzzi, PhD | Immune-stimulants and immune modulators | Immune contexture;Monocyte/Macrophage;Radiotherapy;Regulatory T cell (Treg cell);T cell;Tumor microenvironment | |
| 736 | Poster Presentation | Treatment with decitabine (DAC) induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer | Nassiba Taib, Mater's degree; Maysaloun Merhi; Varghese Inchakalody; Sarra Mestiri; Afsheen Raza, PhD; Shahab Uddin; Cristina Maccalli; Mohammed Ussama AlHomsi; Said Dermime | Immune-stimulants and immune modulators | Chemotherapy;Epigenetics;Neoantigens | |
| 740 | Poster Presentation | Radiotherapy-activated NBTXR3 nanoparticles Increase CD8+ T cell infiltration and diversity in tumors, and modulate the immunopeptidome of cancer cells | Audrey Darmon, BS; Ping Zhang, PhD; Jordan Da silva; Sebastien Paris | Immune-stimulants and immune modulators | Biomarkers;Radiotherapy;Surfaceome;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 747 | Poster Presentation | CodaLytic™, a novel codon-pair deoptimized influenza virus creates an immune-stimulatory tumor microenvironment leading to monotherapy efficacy in a preclinical model of breast cancer | Marcin Stawowczyk, PhD; Katie Pfeffer; Juliana Tafrova, PhD; Charles B. Stauft, PhD; Anna Kushnir, PhD; Sybil A. Tasker, MD, MPH, FIDSA; Steffen Mueller, PhD; J Robert Coleman, PhD, MBA; Johanna K. Kaufmann, PhD | Immune-stimulants and immune modulators | B cell;NK/NKT cell;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 750 | Poster Presentation | AK119, A CD73 Targeting Antibody with Dual Mechanism of Action | Zhaoliang Huang, BSc; Xinghua Pang, BSc; Tingting Zhong, MS; Chunshan Jin; na chen, MD; Xinrong He; Dennis Xia, Ph.D; Xiaoping Jin, PhD; Zhongmin Wang; Xu Xia; Baiyong Li, Ph.D | Immune-stimulants and immune modulators | Antibody;B cell;COVID and Immunotherapy;Immune suppression;T cell | |
| 753 | Poster Presentation | InhibigenTM administration promotes aberrant T cell responses in cancer but may be beneficial for amelioration of autoimmune disease | Victoria L. DeVault, PhD; Hanna Starobinets, PhD; Julie N. Arnold; Stephanie Rinaldi; Charley Hubbard, PhD; Osaruese Odeh; Cindy Nguyen; Laura Apolloni; Dimitry Lineker; Jessica B. Flechtner, PhD; Hubert Lam, PhD | Immune-stimulants and immune modulators | Adoptive immunotherapy;Checkpoint blockade;Immune suppression;Neoantigens;T cell;Targeted therapy;Tumor antigens;Vaccine | |
| 755 | Poster Presentation | Pharmacologic tumor PD-L1 depletion reduces Chk2 content and sensitizes tumors to small molecule Chk1 DNA damage repair inhibitors | Clare E. Murray; Anand V. Kornepati; Alvaro S. Padron; Myrna G. Garcia, BS; Haiyan HB. Bai, PhD; Yilun Deng, PhD; Tyler J. Curiel, MD | Immune-stimulants and immune modulators | Biomarkers;Checkpoint blockade;Chemotherapy;Coinhibition;Immune monitoring;Solid tumors;Targeted therapy;Tumor antigens;Tumor evasion;Tumor microenvironment | |
| 756 | Poster Presentation | Identifying the role of B7-H4 as a suppressor of tumor infiltrating lymphocytes and a target for immunotherapy in breast cancer | Elizabeth Wescott, BS; Paula I. Gonzalez-Ericcson, MD; Violeta I. Sanchez, BS; Melinda Sanders, MD; Justin M. Balko, PharmD, PhD | Immune-stimulants and immune modulators | Checkpoint blockade;Immune suppression;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 762 | Poster Presentation | STING agonism combined with arginase, NOS2, and PTGES/COX2 inhibitors for improved anti-tumor immunotherapeutic benefit | Jessica Filderman, BS; Manoj Chelvanambi, BS; Walter J. Storkus, PhD | Immune-stimulants and immune modulators | Angiogenesis;Inflammation;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 769 | Poster Presentation | A Single Dose of Intratumoral TransCon™ TLR7/8 Agonist Monotherapy Promoted Sustained Activation of Antigen Presenting Cells Resulting in CD4+ and CD8+ T cell Activation and Tumor Growth Inhibition | Luis Zuniga, PhD; Karan Uppal, PhD; Kathy Bang; Enping Hong, PhD; Simran Sabharwal, PhD; Yuchi Lee, PhD; Solomon Martinez; David Rosen, PhD; Amer M. Mirza, PhD; Juha Punnonen, MD, PhD; Luis A. Zuniga, PhD | Immune-stimulants and immune modulators | Antigen presenting cells;Inflammation;MDSC;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;TLR;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 771 | Poster Presentation | Novel lipid nanoparticle vaccine platform for efficient delivery of high- and low-affinity epitopes | Unnur Jóna Björgvinsdóttir; Laura Stentoft Carstensen; Anna Colliander; Ditte Elisabeth Jæhger; Gael Clergeaud Veiga; Hólmfríður Rósa Halldórsdóttir; Matilde Smærup Jørgensen; Esben Christensen; Sara Vangsgaard; Aristeidis Koukos; Martin Bak; Paul Kempen; Thomas Lars Andresen; Unnur Jóna Ms. Björgvinsdóttir, MSc | Immune-stimulants and immune modulators | Adoptive immunotherapy;Antigen presenting cells;Immune adjuvant;T cell;TLR;Vaccine | |
| 773 | Poster Presentation | A novel cancer immunotherapy; vaccination against tumor vascular extracellular vimentin | Elisabeth J. Huijbers, PhD; Karlijn van Loon; Judy R. van Beijnum; Arjan W. Griffioen | Immune-stimulants and immune modulators | Angiogenesis;Solid tumors;Vaccine | |
| 783 | Poster Presentation | SGN-PDL1V, a novel, investigational PD-L1-directed antibody-drug conjugate for the treatment of solid tumors | Byron Kwan, PhD; Megan Ramirez; Steven Jin; Changpu Yu; Serena W. Wo; Priyanka Gupta; Sean Allred; Jessica K. Simmons; Kelly M. Hensley; Christina Zuch de Zafra; Haley Neff-LaFord; Shawna Hengel; Andres Forero-Torres, MD; Heather Van Epps | Immuno-conjugates and chimeric molecules | Antibody;Chemotherapy;Solid tumors;Targeted therapy | |
| 790 | Poster Presentation | DSP502 — A Novel Approach For Targeting TIGIT And PD1 Pathways For Cancer Immunotherapy | Ayelet Chajut; Shirley Greenwald; Matthew C. Weber, PhD; Ami Tamir, PhD; Iris Pecker, PhD; Rinat Tabakman, PhD; Lucy Ganthous; Liat Tamir, PhD; Roy Kahn, PhD; Jasmine Avichzer; Alexandra Aronin; Elina Zorde-Khvalevsky; Amnon Peled, PhD; Michal Michal Elhalel Dranitzki, Dr.; Adam Foley-Comer, Dr.; Mark L. Tykocinski, Dr. | Immuno-conjugates and chimeric molecules | Bispecifics;Checkpoint blockade;Coinhibition;NK/NKT cell;Targeted therapy;Tumor microenvironment | |
| 799 | Poster Presentation | Neoantigen-cytokine-chemokine Multifunctional Natural Killer Cell Engager for Immunotherapy of Solid Tumors | Xue Yao, Master; Sandro Matosevic, PHD | Immuno-conjugates and chimeric molecules | Bispecifics;Chemokine;Cytokine;Immune suppression;Neoantigens;NK/NKT cell;Solid tumors;Tumor antigens;Tumor microenvironment | |
| 802 | Poster Presentation | An electronic health record-based approach to identify and characterize patients with immune checkpoint inhibitor-associated arthritis | Steven Tran, BS; Luke Rasmussen, MS; Jennifer Pacheco, MS; Carlos Galvez, MD; Kyle Tegtmeyer, MD; Yuan Luo, PhD; Jeffrey A. Sosman, MD; Abel Kho, MD; Theresa Walunas, PhD, MS | Immunotherapy Toxicities | Checkpoint blockade;Immune toxicity | |
| 803 | Poster Presentation | Immune-related adverse events correlate with improved outcomes in patients with advanced non-small cell lung cancer treated with combinations of immune-checkpoint inhibitors and chemotherapy | Lindsey Shantzer, MD; Sean C. Dougherty, MD; Wendy Novicoff, PhD; John W. Melson, MD; Daniel R. Reed, MD; Alia C. Lynch, PharmD; Ryan D. Gentzler, MD, MS; Richard D. Hall, MD, MS | Immunotherapy Toxicities | Chemotherapy;Immune toxicity;Solid tumors | |
| 804 | Poster Presentation | Real-world incidence and impact of pneumonitis in lung cancer patients treated with immune checkpoint inhibitors | Bruce C. Tiu, BS; Leyre Zubiri; James Iheke; Vartan Pahalyants, MD, MBA; Nicholas Theodosakis, MD; Pearl O. Ugwu-Dike; Jayhyun Seo; Kimberly Tang; Ryan J. Sullivan, MD; Meghan J. Mooradian, MD; Yevgeniy R. Semenov, MD; Kerry L. Reynolds, MD | Immunotherapy Toxicities | Checkpoint blockade;Clinical study;Epidemiology;Immune toxicity;Solid tumors;T cell;Targeted therapy | |
| 805 | Oral Presentation | Clonal, activated CD8+ T cells recognizing cardiac alpha-myosin drive immune checkpoint inhibitor associated myocarditis in mice | Margaret L. Axelrod, BS; Wouter C. Meijers, MD,PhD; Elie Tannous, MD; Xiaopeng Sun, BS; Juan Qin, PhD; Ayaka Sugiura, BS; Elizabeth Wescott, BS; Elles M. Screever, BS; Spencer C. Wei, PhD; Susan Opalenik, BS, PhD; Yueli Zhang; Douglas B. Johnson, M.D.; James P. Allison, PhD; Javid Moslehi; Justin M. Balko, PhD, PharmD | Immunotherapy Toxicities | Autoimmunity;Checkpoint blockade;Immune tolerance;Immune toxicity;Inflammation;Neoantigens;T cell;Tumor antigens | |
| 806 | Oral Presentation | PD-1 blockade affects inflammation and metabolic flexibility to potentially mediate cardiac immune-related adverse events | Steven M. Bronson, DVM; Elizabeth R. Stirling, MS; Brian Westwood, MS; Pierre L. Triozzi; David R. Soto-Pantoja, PhD | Immunotherapy Toxicities | Checkpoint blockade;Immune toxicity;Inflammation;Metabolism | |
| 807 | Poster Presentation | Immunotherapy Related Adverse Events: A Single Center Experience | Wei Yang, MD; Sophia Lee, MD; Julie Rowe, MD; Jing Zhang; Mohammad Rahbar | Immunotherapy Toxicities | Chemotherapy;Immune toxicity | |
| 808 | Poster Presentation | Tertiary lymphoid structure gene signature detected in immune checkpoint inhibitor-associated renal immune related adverse event | Jamie S. Lin, MD; Amanda Tchakarov; Noha Abdel-Wahab; Houssein Safa, MD; Salah-Eddine Bentebibel; Maen Abdelrahim, MD, PhD; Cassian Yee, MD; Adi Diab, MD; Ala Abudayyeh, MD | Immunotherapy Toxicities | Checkpoint blockade;Gene expression;Immune toxicity | |
| 810 | Poster Presentation | Impact of immune-related adverse event development on overall survival in hospitalized lung cancer patients | Eric Olson, MD; Greg Russell; Jeffrey Lantz, DO; Andy Dothard, MD; Vanya Aggarwal, MD; Thomas W. Lycan, Jr., DO | Immunotherapy Toxicities | Checkpoint blockade;Immune monitoring;Immune toxicity;Solid tumors | |
| 811 | Poster Presentation | Allelic variation in Human Leukocyte Antigen class II genes is associated with pneumonitis risk in cancer patients treated with immune checkpoint inhibitors | Ashis Saha, PhD; Christine N. Spencer, PhD; Zia Khan, PhD; Jonathan Carroll, PhD; Claudia Yanez Arellano; Julie Hunkapiller, PhD; Nicholas L. Bayless; Leonardo Nissola, MD; Roslyn Wallace, MBBS; Ira Mellman; Rajat Mohindra, MD; Samantha Bucktrout, PhD; Shahneen Sandhu, MBBS FRACP; G. Scott Chandler, MD; Christian Hammer, PhD | Immunotherapy Toxicities | Antigen presenting cells;Checkpoint blockade;Genetic polymorphism;Immune toxicity;Solid tumors;Systems biology;T cell | |
| 812 | Poster Presentation | Erythema nodosum-like toxicity in an immunotherapy treated patient is accompanied by oligoclonal memory activated CD4 T cells | Xiaopeng Sun, BS; Margaret L. Axelrod, BS; Yu Wang, PhD; Sanchez Violeta; Paula I. Gonzalez-Ericsson, MD; Douglas B. Johnson, M.D.; Justin M. Balko, PhD, PharmD | Immunotherapy Toxicities | Checkpoint blockade;Immune toxicity;T cell | |
| 813 | Poster Presentation | CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect | Mingyue Liu, PhD; Xu Wang; Peng Zhang; Juanjuan Su; Xuexiang Du; Yan Zhang; Yang Liu, PhD; Pan Zheng, MD, PhD | Immunotherapy Toxicities | Immune toxicity | |
| 814 | Oral Presentation | Cutaneous Immune-related Adverse Events are Protective of Mortality in Patients Treated with anti-PD1 and anti-PDL1 therapy in a multi-institutional cohort study | Yevgeniy R. Semenov, MD; Kimberly Tang; Jayhyun Seo; Kerry L. Reynolds, MD; Bruce Tiu; Thomas Le; Vartan Pahalyants; Neel Raval; Pearl O. Ugwu-Dike; Leyre Zubiri; Vivek Naranbhai; Alexander Gusev; Nicole LeBoeuf; Maryam Asgari; Shawn Kwatra | Immunotherapy Toxicities | Biomarkers;Checkpoint blockade;Immune toxicity | |
| 815 | Poster Presentation | Single-center retrospective cohort of all patients suspected to have immunotherapy-mediated diarrhea and colitis | Vanya Aggarwal, MD; Ella M. LePage, M.D.; Andrew Faucheux, M.D.; Hiral S. Patel, M.D.; Gregory B. Russell, M.S.; Eric Olson, MD; Jared J. Rejeski, M.D.; Thomas W. Lycan, Jr., DO | Immunotherapy Toxicities | Autoimmunity;Checkpoint blockade;Clinical study;Immune monitoring;Immune tolerance;Immune toxicity;Inflammation | |
| 816 | Poster Presentation | Selective Immune Suppression using Interleukin-6 blockade in Immune Related Adverse Events | Faisal Fa'ak, MD; Faisal Fa'ak; Chrystia M. Zobniw; Maryam Buni; Linda Lu; Adewunmi Falohun; VanAnh Trinh; Muhammad Osama Awiwi; Khaled M Elsayes; Kaysia Ludford; Maya Dimitrova; Sabina Sandigursky; Amy Cunningham-Bussel; Jeffrey A. Sparks; Osama Abu-Shawer; Uma Thanarajasingam; Ashley M. Zeman; Rafee Talukder; Namrata Singh; Sarah H. Chung; Petros Grivas; May Daher; Ala Abudayyeh; Daniel Johnson; Maria Suarez-Almazor; Osama E. Rahma; Jeffrey S. Weber; Jean Tayar; Adi Diab; Noha Abdel-Wahab | Immunotherapy Toxicities | Checkpoint blockade;Cytokine;Immune suppression;Immune toxicity | |
| 817 | Poster Presentation | Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study | Pankti Reid, MD, MPH; David F. Liew; Rajshi Akruwala; Anne Bass, MD; Karmela K. Chan, MD | Immunotherapy Toxicities | Checkpoint blockade;Immune monitoring;Immune toxicity | |
| 820 | Poster Presentation | Machine learning significantly improves neoantigen-HLA predictions utilizing > 26,000 data points from the PACTImmuneTM Database | Vinnu Bhardwaj, PhD; Amin Momin; Jonathan Johnston; Elizabeth Speltz; Tyler Borrman; Stefanie Mandl; Olivier Dalmas, Ph.D.; Zheng Pan, PhD; Ashish Kheterpal; Eric Stawiski | Machine Learning, Artificial Intelligence, and Computational Modeling | Adoptive immunotherapy;Bioinformatics;Neoantigens;Solid tumors;T cell;Tumor antigens | |
| 827 | Poster Presentation | Streamlining design of safe and effective TCR therapies with AI | Mikolaj Mizera, PhD; Anna Sanecka-Duin, PhD, MS; Maciej Jasinski, PhD; Paulina Król; Giovanni Mazzocco, M.Sc.; Victor Murcia Pienkowski, PhD; Alexander Myronov; Iga Niemiec; Piotr Skoczylas, M.Sc.; Slawomir Stachura, PhD; Piotr Stepniak; Daniel Wojciechowski; Lukasz Grochowalski; Oskar Gniewek; Jan Kaczmarczyk, PhD; Agnieszka Blum, PhD, MD | Machine Learning, Artificial Intelligence, and Computational Modeling | Adoptive immunotherapy;Bioinformatics;Clinical study;Immune monitoring;Immune toxicity;Neoantigens;T cell;T cell lineages;Targeted therapy;Tumor antigens | |
| 829 | Poster Presentation | Spatial arrangement and density of tumor-infiltrating lymphocytes (TILs) predicts response to immunotherapy in head and neck squamous cell carcinoma patients | Reetoja Nag, PhD; Germán Corredor; Vidya S. Viswanathan; Pingfu Fu, PhD; James Lewis Jr.; Jay Wasman; Theodoros N. Teknos; Monaliben Patel, MD; Quintin Pan; Anant Madabhushi, PhD | Machine Learning, Artificial Intelligence, and Computational Modeling | Biomarkers;Tumor infiltrating lymphocytes (TILs) | |
| 832 | Oral Presentation | Deep learning reveals predictive sequence concepts within immune repertoires to immunotherapy | John-William Sidhom, M.D., PhD.; Petra B. Ross-Macdonald, PhD; Megan Wind-Rotolo, PhD; Andrew M. Pardoll, MD, PhD; Alexander Baras, M.D., Ph.D. | Machine Learning, Artificial Intelligence, and Computational Modeling | Bioinformatics;Biomarkers;Checkpoint blockade;Immune monitoring;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 835 | Poster Presentation | Harnessing the microbiota to increase response rates to immunotherapy. | Valentina Ferrari, BA; Alessia Melacarne; Francesca Algieri; Maria Rescigno, PhD | Microbiome and other environmental factors | Checkpoint blockade;Microbiome;Solid tumors | |
| 836 | Poster Presentation | Murine fecal microbiota transfer models colonize human microbes selectively and reveal transcriptional pathways associated with response to neoadjuvant checkpoint inhibitors | Fyza Y. Shaikh, MD, PhD; Joell Gills; Fuad Mohammad; James R. White; Courtney Stevens; Hua Ding; Juan Fu; Ada Tam; Richard Blosser; Tatianna Larman; Jarushka Naidoo, MD, MHS; Patrick Forde; Sudipto Ganguly; Franck Housseau; Drew M. Pardoll; Cynthia L. Sears | Microbiome and other environmental factors | Biomarkers;Checkpoint blockade;Microbiome;Solid tumors;T cell;Tumor microenvironment | |
| 837 | Poster Presentation | Preliminary insights into the impact of tumor microbiome in head and neck squamous cell carcinoma | Vidhya Karivedu, MD; Rebecca Hoyd; Caroline Wheeler; Sachin Jhawar; Priyanka Bhateja; Marcelo Bonomi, MD; Daniel Spakowicz, PhD, MS | Microbiome and other environmental factors | Biomarkers;Microbiome | |
| 838 | Poster Presentation | The role of microbiota in metastatic brain tumors | Sarah B. Johnson; Golnaz Morad, DDS, PhD; Nadim J. Ajami, PhD; Jennifer A. Wargo, MD, MMSc; Matthew C. Wong; Matthew Lastrapes | Microbiome and other environmental factors | Immune suppression;Microbiome;Solid tumors;T cell;Tumor microenvironment | |
| 839 | Oral Presentation | Microbiota-specific T follicular helper cells drive tertiary lymphoid structure formation and anti-tumor immunity in colorectal cancer. | Abigail E. Overacre-Delgoffe, PhD; Hannah J. Bumgarner, BS; Anthony R. Cillo, PhD; Ansen H. Burr; Justin Tometich; Amrita Bhattacharjee; Tullia C. Bruno, PhD; Dario A. Vignali, PhD; Timothy W. Hand, PhD | Microbiome and other environmental factors | B cell;Microbiome;NK/NKT cell;Regulatory T cell (Treg cell);T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 840 | Poster Presentation | A therapeutic humanized anti-carcinoma monoclonal antibody (mAb) can also identify immunosuppressive regulatory T (Tregs) cells and down regulate Treg-mediated immunosuppression | Kwong Y. Tsang, PhD; Massimo Fantini, PhD; Christopher B. Cole, MD; Christina M. Annunziata, MD, PHD; Philip Arlen | Novel Single-Agent Immunotherapies | Antibody;Immune monitoring;Immune suppression;Regulatory T cell (Treg cell);T cell;Tumor antigens | |
| 841 | Poster Presentation | Targeting the intersection of immunology and redox biology: therapeutic potential of an anti-Thioredoxin antibody | Gabriella Willman; Max Davidson; Carolina Trkulja; Owe Orwar; Sreesha P. Srinivasa, PhD | Novel Single-Agent Immunotherapies | Chemokine;Cytokine;Immune suppression;Regulatory T cell (Treg cell);T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 842 | Poster Presentation | Exosome mediated reprogramming of tumor associated macrophages by exoASO-STAT6 for the treatment of Hepatocellular Carcinoma (HCC) | Sushrut Kamerkar, PhD; Charan Leng; Kelvin Zhang, PhD; Olga Burenkova; Su Chul Jang, PhD; Samuel Kasera; Tong Zi; Kyriakos Economides, PhD; Timothy J. Soos; Dalia Burzyn, PhD; Sriram Sathyanaryanan, PhD | Novel Single-Agent Immunotherapies | Extracellular vesicles/exosomes;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor microenvironment | |
| 843 | Poster Presentation | Development and engineering of human sialidase for degradation of immunosuppressive sialoglycans to treat cancer | Li Peng, PhD; Lizhi Cao; Sujata Nerle; Robert LeBlanc; Abhishek Das, Ph.D.; Sandip Shelke; Autumn Turner; Jenny Che; Zakir Siddiquee; Hui Xu; Lihui Xu, BS; Wayne Gatlin; James Broderick, M.D. | Novel Single-Agent Immunotherapies | Checkpoint blockade;Dendritic cell;Immune suppression;Immune tolerance;T cell;Tumor evasion | |
| 844 | Poster Presentation | A trispecific ROR1 x CD3 T cell engager mediates in vitro tumor cell killing and in vivo tumor eradication | Bithi Chatterjee, PhD; Daniel Snell, PhD; Christian Hess, PhD; Matthias Brock, PhD; Fabio Spiga, PhD; Alexandre Simonin, PhD; Tea Gunde, PhD; Stefan Warmuth, PhD; Christopher Weinert, PhD; Nicole Bassler; Niels Kirk; Nina Schumacher; Dana Mahler; Yasemin Yaman; Bettina Bommer; Giorgio Gambino; Noreen Giezendanner; Benjamin Kuettner; Naomi Flueckiger; Robin Heiz; Sandro Wagen; Dania Diem; Julia Zeberer; David Urech, PhD | Novel Single-Agent Immunotherapies | Antibody;Bispecifics;T cell;Targeted therapy;Tumor antigens | |
| 845 | Poster Presentation | A colony stimulating factor 1 receptor-blocking bifunctional protein simultaneously targets tumor-associated macrophages and exhausted T cells for the treatment of triple-negative breast cancer | Pandelakis Koni; Hung-Kai Chen; Yao-Wen Chang; Huey-Wen Hsiao; Chih-Lun Hsiao; Jing-Yi Huang; Ju-Pei Chen; Muh-Hwa Yang | Novel Single-Agent Immunotherapies | Antibody;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 846 | Poster Presentation | Pre-clinical validation of a FLT3L-fusion protein for dendritic cell expansion and anti-tumor efficacy | Michelle R. Kuhne, PhD; Hamlet Chu; Sarah Ng; Christopher Clarke, PhD; Brian Carr; Manuel Baca, PhD; Magdeleine Hung; Mark R. Nagel; Alexandre Ambrogelly, PhD; Nicholas Wilson, PhD | Novel Single-Agent Immunotherapies | Antigen presenting cells;Dendritic cell;Tumor infiltrating lymphocytes (TILs) | |
| 847 | Poster Presentation | Pharmacokinetics and pharmacodynamics of GS-3583 in cynomolgus monkeys | Michelle R. Kuhne, PhD; Hamlet Chu; Christopher Clarke, PhD; Brian Carr; Manuel Baca, PhD; Magdeleine Hung; Mark R. Nagel; Alexandre Ambrogelly, PhD; Nishanathan Rajakumaraswamy | Novel Single-Agent Immunotherapies | Antibody;Antigen presenting cells;Dendritic cell | |
| 848 | Poster Presentation | Novel small molecule HPK1 inhibitor PCC-1 induces strong anti-tumor activity | Sanjib Das, PhD; Sravan Mandadi, PhD; Jagmohan Saini, PhD; Sachin S. Chaudhari, PhD; Ameya Deshpande; Murugan Chinnapattu, PhD; Malini Bajpai, PhD; Priyanka Pangre; Varada Potdar; Megha Marathe; Pooja Sawant; Atul Akarte, PhD; Chandrasekhar Misra, PhD; Subhadip Das, PhD; Anuj Singh; Avratanu Das; Pandurang Lambade; Chaitanya Tirumalasetty; Raju Patole; Nilanjana Biswas, PhD; Vikas Karande; Heta Shah; Dayanidhi Behera; Nagaraj Gowda, PhD; Pravin S. Iyer, PhD | Novel Single-Agent Immunotherapies | Checkpoint blockade;Cytokine;Immune suppression;Solid tumors;T cell;Tumor microenvironment | |
| 849 | Poster Presentation | ReSTORE T cell engager platform depletes MDSC in parallel with antigen-specific solid tumor cytotoxicity | Sterling C. Eckard, PhD; Bianca Rojo, PharmD; Li Mei; Alberto Ponce; Patrick Chun, MD; Victoria Smith, PhD | Novel Single-Agent Immunotherapies | Immune suppression;MDSC;Myeloid cells;Solid tumors;T cell;Targeted therapy;Tumor microenvironment | |
| 850 | Poster Presentation | Dual blockade of the EP2 and EP4 PGE2 receptors with TPST-1495 is an optimal approach for drugging the prostaglandin pathway | Brian Francica, PhD; Justine Lopez; Anja Holtz; Dave Freund; Dingzhi Wang, PhD; Amanda Enstrom; Sam H. Whiting, MD, PhD; Chan C. Whiting, PhD; Thomas W. Dubensky, Jr., PhD | Novel Single-Agent Immunotherapies | Immune suppression;NK/NKT cell;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 851 | Poster Presentation | Harnessing innate immunity in cancer therapies: the example of Natural Killer Cell Engagers | Olivier Demaria, PhD; Eric Vivier, PhD; Marie Vetizou, PhD; Audrey Blanchard Alvarez; Guillaume Habif, PhD; Cécile Bonnafous, PhD; Sivan Bokobza, PhD; Agnès Represa; Benjamin Rossi, PhD; Luciana Batista, PhD; Constance Vagne, PhD; Sabrina Carpentier; Stéphanie Cornen, PhD; Ariane Morel, PhD; Ivan Perrot, PhD; Yannis Morel, PhD; Laurent Gauthier, PhD | Novel Single-Agent Immunotherapies | Antibody;Bispecifics;Cytokine;NK/NKT cell;Targeted therapy;Tumor antigens;Tumor microenvironment | |
| 852 | Poster Presentation | Trifunctional NKp46/CD16a-NK cell engager targeting CD123 overcomes acute myeloid leukemia resistance to ADCC | Laurent Gauthier, PhD; Angela Virone-Oddos; Jochen Beninga, PhD; Benjamin Rossi; Céline Nicolazzi; Céline Amara; Audrey Blanchard-Alvarez; Nicolas Gourdin; Jacqueline Courta; Alexandra Basset; Franceline Guillot; Gwendoline Grondin; Hélène Bonnevaux; Anne-Laure Bauchet; Ariane Morel, PhD; Yannis Morel, PhD; Marielle Chiron, PhD; Eric Vivier, PhD | Novel Single-Agent Immunotherapies | Antibody;Bispecifics;Leukemia/Lymphoma;NK/NKT cell;Targeted therapy;Tumor antigens | |
| 853 | Poster Presentation | ACTM-838: A microbial-based immunotherapy that delivers combination IL-15 + engineered STING to tumor-resident APCs After IV dosing in T-cell excluded solid tumors | Haixing Kehoe, M.S.; Alexandre Iannello, PhD; Keith Cheung, PhD; Bret Peterson, PhD; Marie Marotel, PhD; Sara Tribble, B.S.; Hailey He, B.S.; Jonathan J. Hodgins, B.S.; Michele Ardolino, PhD; Christopher Rae, PhD; Christopher D. Thanos, PhD; Laura H. Glickman, PhD | Novel Single-Agent Immunotherapies | Antigen presenting cells;Cytokine;Immune adjuvant;Monocyte/Macrophage;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 854 | Poster Presentation | SGN-B7H4V, a novel, investigational vedotin antibody-drug conjugate directed to the T cell checkpoint ligand B7-H4, shows promising activity in preclinical models | Elizabeth Gray, PhD; Angela D. Epp; Michelle Ulrich, BS; Disha Sahetya; Kelly M. Hensley; Julie Hahn; Sean Allred; Jane Haass; Katie Snead; Sasha Lucas; John Gosink; Rogely Boyce; Esther Trueblood; Piper Treuting; Chris Frantz; Alyson J. Smith, PhD; Jason Schrum; Natalya Nazarenko; Shyra J. Gardai, PhD | Novel Single-Agent Immunotherapies | Antibody;Checkpoint blockade;Solid tumors;Targeted therapy;Tumor antigens | |
| 855 | Poster Presentation | Development of a Novel Anti-Multiple Myeloma Chimeric Antigen Receptor T Cell Therapy | Chuck Hay, PhD; Mary Faber, PhD; Kemi Adeyanju, PhD; Jeffrey A. Medin, PhD | Novel Single-Agent Immunotherapies | Adoptive immunotherapy;Antibody;CAR T cells;Granulocyte;T cell;T cell lineages;Targeted therapy;Tumor antigens | |
| 856 | Poster Presentation | INBRX-106: A novel hexavalent anti-OX40 agonist for the treatment of solid tumors | Emily Rowell, Ph.D.; Heather Kinkead, PhD; Elisabeth Torretti; Bryan R. Becklund, PhD; Florian J. Sulzmaier, PhD; William Crago; Kyle Jones; John C. Timmer, PhD; Quinn Deveraux, PhD; Brendan P. Eckelman, PhD; Analeah B. Heidt, PhD | Novel Single-Agent Immunotherapies | Costimulation;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 857 | Poster Presentation | SELECTIVE TREG DEPLETION IN SOLID TUMORS WITH ALD2510, A NOVEL HUMANIZED CD25-SPECIFIC, IL-2 SPARING MONOCLONAL ANTIBODY. | Jemila Houacine; Anne Marie-Cardine; Aude Le Roy; Jérôme Giustiniani; Riad Abes; Anne-Sophie Chrétien; Stéphane Fattori; Laurent Gorvel; Armand Bensussan; Daniel Olive; Arnaud Foussat | Novel Single-Agent Immunotherapies | Antibody;Immune suppression;Immune tolerance;Regulatory T cell (Treg cell);T cell | |
| 858 | Poster Presentation | TILKine-2: A novel best-in-class tumor infiltrating lymphocyte (TIL) targeting engineered IL-2 with superior pre-clinical efficacy and safety for immunotherapy of cancer. | Sreerupa Challa, PhD; Yao-Te Hsieh, PhD; Jonathan M. Carnino; Andrea Umana; Yuesheng Li; Jing Xu; Lingyun Rui | Novel Single-Agent Immunotherapies | Antibody;Bispecifics;Checkpoint blockade;NK/NKT cell;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 859 | Poster Presentation | Tuning the tumor microenvironment by reprogramming TREM1+ myeloid cells to unleash anti-tumor immunity in solid tumors | Nadine Jahchan, PhD; Hanna Ramoth; Vladi Juric, PhD; Erin Mayes; Shilpa Mankikar; Ranna Mehta; Mikhail Binnewies, PhD; Subhadra Dash; Rachael Palmer; Joshua L. Pollack; Joshua Rudolph; Pamela Canaday; Linnea Haeggblom; Carlos Santamaria; xiaoyan Du, PhD; Leonard Reyno, MD; Kevin P. Baker, PhD; Linda Liang, PhD | Novel Single-Agent Immunotherapies | Antibody;Biomarkers;Checkpoint blockade;Cytokine;Immune suppression;MDSC;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor microenvironment | |
| 860 | Poster Presentation | The anti-tumor activity of HSP-90 therapeutic cancer vaccine (AST-021p) combine with TLR2/3 agonist in a MMTV-neu transgenic model | Jinho Kang; Eunkyo Joung, MD; Hunwoo Shin; Byung cheol Ahn; Eunjung Jung; Hun JH. Jung, MD./PhD.; Kyong Hwa Park | Novel Single-Agent Immunotherapies | Clinical study;Immune adjuvant;Immune monitoring;T cell;Targeted therapy;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor stroma;Vaccine | |
| 861 | Poster Presentation | Reprogramming regulatory T cells (Treg) using a MALT1 inhibitor for cancer therapy | Peter Keller; Irina Mazo; Yun Gao; Vijayapal Reddy; Francisco Caballero; Sam Kazer; Amina Fu; Yi Sun; Dannah Miller; Roberto Gianani, MD, FCAP; James E. Marvin; Bret Stephens; Gregory L. Beatty, MD, PhD; Russell W. Jenkins; Ulrich Von Andrian, MD, PhD; Daniel Krappmann; Thorsten Mempel, MD, PhD | Novel Single-Agent Immunotherapies | Clinical study;Clinical trial;Cytokine;Immune tolerance;Regulatory T cell (Treg cell);Solid tumors;Tumor microenvironment | |
| 862 | Poster Presentation | Dectin-2, a novel target for tumor macrophage reprogramming in cancer immunotherapy | Justin A. Kenkel, PhD; Po Y. Ho; Sameera Kongara, PhD; Karla A. Henning, PhD; Cindy L. Kreder; Jess L. Nolin; Steven J. Chapin, PhD; Marcin Kowanetz, Ph.D.; Michael N. Alonso, PhD; Shelley E. Ackerman; Edgar G. Engleman, MD; David Dornan, PhD | Novel Single-Agent Immunotherapies | Antibody;Antigen presenting cells;Dendritic cell;Immune adjuvant;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 863 | Poster Presentation | In vitro and in vivo studies establish DuoBody®-CD3xB7H4 as a novel drug candidate for the treatment of solid cancers | Louise A. Koopman, PhD; Laura Smits-de Vries; Frederikke Lihme Egerod; Sebastiaan Wubben; Mischa Houtkamp, PhD; Stefanie A. De Poot; Madelon Paauwe; Edward van den Brink; Andrea Gorlani; Dennis Verzijl; Kate Sasser, PhD; Esther Breij, PhD | Novel Single-Agent Immunotherapies | Antibody;Biomarkers;Bispecifics;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) | |
| 864 | Poster Presentation | Identification of A Novel Allosteric Oral Cbl-b Inhibitor that Augmented T Cell Response and Enhanced NK Cell Killing in vitro and in vivo | Jun Kuai, Ph D; Yingzhi Bi; Yilin Qi; Deborah G. Conrady; Rajiv G. Govindaraj; Graham Hone; R. Aldrin Denny; Ken Carson; Geraldine Harriman; Fang Wang | Novel Single-Agent Immunotherapies | Checkpoint blockade;Costimulation;Immune suppression;Immune tolerance;NK/NKT cell;T cell;Targeted therapy | |
| 865 | Poster Presentation | iosH2 exerts potent anti-tumor activity by blocking LILRB1/2 and KIR3DL1 receptor signaling | Osiris Marroquin Belaunzaran, PhD; Anahita Rafiei; Anil Kumar; Marco Gualandi; Magdalena Westphal; Lorenz Vogt; Sean R. Smith; Michael A. Curran, PhD; Christoph Renner | Novel Single-Agent Immunotherapies | Checkpoint blockade;Monocyte/Macrophage;Myeloid cells;NK/NKT cell;Solid tumors | |
| 866 | Poster Presentation | RBN-2397, a novel, potent, and selective PARP7 inhibitor, induces tumor-intrinsic Type I interferon responses and adaptive immunity in preclinical models and patient tumors | Kristy G. Kuplast-Barr, Bachelor of Science; Melissa L. Johnson, MD; Manish R. Patel, MD; Timothy A. Yap, MD; Gerald S. Falchook, MD, MS; Patricia LoRusso; Ryan Abo, PhD; Chang Liu, PhD; Erika Manyak; Lisa Cleary; Viviana Bozon; Sudha Parasuraman, MD; Heike Keilhack; Kristen McEachern, PhD | Novel Single-Agent Immunotherapies | Biomarkers;Clinical study;Gene expression;Monocyte/Macrophage;Solid tumors;T cell;Targeted therapy;Tumor microenvironment;Tumor stroma | |
| 867 | Poster Presentation | TriTAC-XR is an extended-release T cell engager platform designed to minimize cytokine release syndrome by reducing Cmax in systemic circulation | Kathryn S. Kwant, Ph.D.; Sony S. Rocha; Katrina Stephenson; Maria R. Dayao; Subramanian Thothathri; Rose Banzon; Wade H. Aaron, BS; Golzar Hemmati; Evan Callihan; Timothy Yu; Jessica O'Rear; Eric Bragg; Willis Kwong; Hubert Situ; Avneel Hundal; Stephen Yu; Taggra Jackson; Kevin J. Wright, Ph.D.; Yinghua Xiao, Master Degree; Linh To; Richard Austin, Ph.D.; Bryan Lemon, Ph.D.; Holger Wesche, Ph.D.; S. Jack Lin, Ph.D. | Novel Single-Agent Immunotherapies | Antibody;Immune toxicity;Solid tumors;T cell;Targeted therapy | |
| 868 | Poster Presentation | Overall survival on tebentafusp in metastatic uveal melanoma (mUM) across the range of tumor gp100 expression levels | Emma Leach; Sarah Stanhope; Revashnee Naidoo; Shaad E. Abedin, MD, FACP; Laura Collins; Koustubh Ranade | Novel Single-Agent Immunotherapies | Bispecifics;Clinical trial;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 869 | Poster Presentation | Locally administered immunotherapy self-delivering RNAi PH-762 results in abscopal clearance of untreated distal tumors, suggesting systemic immune response, in a murine hepatocarcinoma model | Benjamin Cuiffo, PhD; Melissa Maxwell, MS; Dingxue Yan, PhD; Brianna Rivest, BS; James Cardia, PhD; Simon P. Fricker, PhD | Novel Single-Agent Immunotherapies | Checkpoint blockade;RNA;Solid tumors;Tumor microenvironment | |
| 870 | Poster Presentation | Targeting GCN2 kinase-driven stress response inactivation to restore tumor immunity in metastatic triple negative breast cancer | Hariprasad Vankayalapati, Ph.D.; Kyle Medley, MS; Zhaoliang Li, PhD; Dongqing Yan, PhD; David Bearss, PhD; Alana Welm, PhD | Novel Single-Agent Immunotherapies | Biomarkers;MDSC;Myeloid cells;Solid tumors;T cell;T cell lineages;Targeted therapy;Tumor microenvironment | |
| 871 | Poster Presentation | Construction and Evaluation of Interleukin 3 (IL3)-Zetakine Redirected Cytolytic T Cells for the Treatment of CD123 Expressing Acute Myeloid Leukemia | Rebecca Moeller, MSc; Julian Scherer, PhD; Sadik H. Kassim, PhD | Novel Single-Agent Immunotherapies | CAR T cells;Cytokine;Leukemia/Lymphoma;T cell;Targeted therapy;Tumor antigens | |
| 872 | Poster Presentation | PD1 x TGFbR2 and CD5 x TGFbR2 bispecifics selectively block TGFbR2 on target-positive T cells, promote T cell activation, and elicit an anti-tumor response in solid tumors | Gregory L. Moore, PhD; Suzanne Schubbert, PhD; Christine Bonzon, PhD; Kendra N. Avery, PhD; Rumana Rashid, PhD; Erik Pong, BS; Lukasz J. Ochyl, BS; Alex Nisthal, PhD; Seung Chu, PhD; James Ernst, PhD; John R. Desjarlais, PhD | Novel Single-Agent Immunotherapies | Antibody;Bispecifics;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 873 | Poster Presentation | S-531011, a novel anti-human CCR8 antibody: anti-tumor responses through depletion of tumor-infiltrating CCR8-positive Tregs | Ryohei Nagai, Ph.D.; Ryohei Nagai; Morio Nagira; Wataru Nogami; Michinari Hirata; Azumi Ueyama; Mai Yoshikawa, Ph.D.; Naganari Ohkura; Hisashi Wada; Yoji Nagira | Novel Single-Agent Immunotherapies | Antibody;Chemokine;Regulatory T cell (Treg cell);Targeted therapy;Tumor infiltrating lymphocytes (TILs) | |
| 874 | Poster Presentation | Development of BCA101, a bifunctional antibody capable of simultaneously disabling EGFR and TGFβ signaling, as novel single-agent immunotherapy | Srinivas R. Boreddy, Ph. D; Reshmi Nair; Arindam Banerjee; Anshu Kuriakose; Prashant Kumar Pandey; Chaitali Dey; Meena Shri; Shruthi Rao; Bhadravathi Marigowda Shivakumar; Moni Abhram Kuriakose; Ram Bhupal Reddy; Amritha Suresh; Praveen Reddy Moole; Usha Bughani; Seng-Lai Tan, PhD; Pradip Nair | Novel Single-Agent Immunotherapies | Angiogenesis;Antibody;Bispecifics;Coinhibition;Cytokine;Immune suppression;Regulatory T cell (Treg cell);Solid tumors;Targeted therapy;Tumor microenvironment | |
| 875 | Poster Presentation | AL009, a fusion protein and multi-Siglec inhibitor, repolarizes suppressive myeloid cells and potentiates anti-cancer effects | Sam Nalle, PhD; Helen Lam; Ling Leung; Spencer Liang; Daniel Maslyar, MD | Novel Single-Agent Immunotherapies | Checkpoint blockade;MDSC;Monocyte/Macrophage;Myeloid cells;Solid tumors | |
| 876 | Poster Presentation | Intratumoral administration and local retention of IL-2/IL-12 fusion proteins drive a potent systemic anti-tumor immune response | Mehta K. Naveen, PhD; Bochong Li; Dane Wittrup; Patrick A. Baeuerle; Jennifer S. Michaelson | Novel Single-Agent Immunotherapies | Cytokine;Solid tumors;Tumor microenvironment | |
| 877 | Poster Presentation | PSGL-1 blocking antibodies repolarize tumor associated macrophages, reduce suppressive myeloid populations and induce inflammation in the tumor microenvironment, leading to suppression of tumor growth | Phuong A. Nguyen, PhD; Jessica Ritter, PhD; Mohammad Zafari; Denise Manfra, PhD; Veronica Komoroski; Brian O'Nuallain, PhD; Ryan Phennicie; Kevin Kauffman, PhD; Dominika Nowakowska, PhD; Joe Wahle, PhD; Steve Sazinsky, PhD; Michael A. Brehm, PhD; Igor Feldman, PhD; Tatiana Novobrantseva, PhD | Novel Single-Agent Immunotherapies | Antibody;Antigen presenting cells;Immune suppression;MDSC;Monocyte/Macrophage;Myeloid cells;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 878 | Poster Presentation | Novel microbial immunotherapy approach for the treatment of bladder cancer | Nicholas Glanville, PhD; Tobi Oke, BSc; Sonia Domingos-Pereira; Lenka Polak; Denise Nardelli-Haefliger, PhD; Livija Deban, PhD | Novel Single-Agent Immunotherapies | Dendritic cell;Monocyte/Macrophage;Myeloid cells;NK/NKT cell;Solid tumors;T cell;Targeted therapy | |
| 879 | Poster Presentation | A promising cancer immunotherapy target: Novel fully human agonist antibodies against the human T-cell costimulatory receptor CD27 | Thierry Guillaudeux, PhD; Yulia Ovechkina; Shaarwari Sridhar; David Jurchen; David Peckham; Emily Frazier; Eric Tarcha, PhD; Shawn Iadonato, PhD | Novel Single-Agent Immunotherapies | Antibody;Costimulation;Cytokine;T cell;Targeted therapy;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 880 | Poster Presentation | Tetravalent, bispecific innate cell engager AFM24 enhances macrophage mediated tumor cell phagocytosis | Sheena Pinto, PhD; Susanne Wingert, PhD; Jens Pahl, PhD; Armin Beez; Sabrina Purr; Uwe Reusch, PhD; Arndt Schottelius, MD, PhD; Joachim Koch, Prof. | Novel Single-Agent Immunotherapies | Bispecifics;Monocyte/Macrophage;Solid tumors | |
| 881 | Poster Presentation | Enhanced antibody-mediated phagocytosis and antibody-mediated cell cytotoxicity using tetravalent, bispecific innate cell engagers (ICE®) in 3D spheroids | Sheena Pinto, PhD; Savannah Jackson; Julia Knoch; Christian Breunig, PhD; Arndt Schottelius, MD, PhD; Joachim Koch, Prof. | Novel Single-Agent Immunotherapies | Bispecifics;Monocyte/Macrophage;Solid tumors | |
| 882 | Poster Presentation | Selective affinity-enhanced T cell receptor bispecific targeting of KRAS G12D neoantigen driven cancers | Andrew D. Whale, PhD; Andrew Poole; Vijaykumar Karuppiah; Annabelle Hartt; Jaafar N. Haidar; Sylvie Moureau; Aimee Bence Lin; Marc Van der Kamp; Gregory D. Plowman; Annelise Vuidepot; David K. Cole; Chandramouli Chillakuri | Novel Single-Agent Immunotherapies | Bispecifics;Neoantigens;Solid tumors;T cell;Targeted therapy;Tumor antigens | |
| 883 | Poster Presentation | An anti-carcinoma monoclonal antibody (mAb) NEO-201 can also target human acute myeloid leukemia (AML) cell lines in vitro. | Alessandra Romano, M.D., PhD; Nunziatina Parrinello; Sara Marino; Enrico La Spina1; Massimo Fantini, PhD; Philip Arlen; Kwong Tsang; Francesco Di Raimondo | Novel Single-Agent Immunotherapies | Antibody;Leukemia/Lymphoma;Myeloid cells;Regulatory T cell (Treg cell);Targeted therapy;Tumor antigens | |
| 884 | Poster Presentation | Engineered Toxin Body mediated depletion of TIGIT expressing immune cells for cancer immunotherapy | Elizabeth Saputra; Garrett Cornelison; Jennifer Mitchell; Karia Williams; Andrea Mendiola; Rachael Orlandella; John Majercak; Joseph D. Dekker, Ph.D.; Chris B. Moore; Swati Khanna, Ph.D. | Novel Single-Agent Immunotherapies | Checkpoint blockade;Immune suppression;Regulatory T cell (Treg cell);T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 885 | Oral Presentation | Targeting FPR2 as a novel approach for immunotherapy in pancreatic cancer female patients – Studies of sexual immune dimorphism in the tumor microenvironment | Dhifaf Sarhan, PhD; Fei D. He; Ahmed D. Calandigary; Enana Malki; Carlos Fernández Moro; Marina Kaisso; Peter Olofsson-Sahl; Marit Melssen; Matthias Löhr; Mikael Karlsson; Rainer Heuchel | Novel Single-Agent Immunotherapies | Immune suppression;Monocyte/Macrophage;T cell;Tumor microenvironment | |
| 886 | Poster Presentation | Targeting VSIG4, a novel macrophage checkpoint, repolarizes suppressive macrophages which induces an inflammatory response in primary cell in vitro assays and fresh human tumor cultures | Steve Sazinsky, PhD; Phuong A. Nguyen, PhD; Mohammad Zafari; Ryan Phennicie; Joe Wahle, PhD; Veronica Komoroski; Kathryn Rooney; Craig Mizzoni; Boris Klebanov; Denise Manfra, PhD; Jessica Ritter, PhD; Igor Feldman, PhD; Tatiana Novobrantseva, PhD | Novel Single-Agent Immunotherapies | Antibody;Antigen presenting cells;Immune suppression;MDSC;Monocyte/Macrophage;Myeloid cells;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 887 | Poster Presentation | Repolarization of T cells by AMV564 in patients progressing on checkpoint blockade | Victoria Smith, PhD; Sterling C. Eckard, PhD; Bianca Rojo, MSc; Patrick Chun, MD | Novel Single-Agent Immunotherapies | Bispecifics;Clinical trial;Immune contexture;Immune monitoring;Immune suppression;MDSC;Myeloid cells;Regulatory T cell (Treg cell);T cell | |
| 888 | Poster Presentation | An integrative approach to optimize a synthetic EphA2/CD137 agonist: balancing potency, physiochemical properties, and pharmacokinetics to achieve robust anti-tumor activity | Punit Upadhyaya, PhD; Gemma Mudd, .; Kristen Hurov; Johanna Lahdenranta; Elizabeth M. Repash, MSc; Julia Kristensson, .; Kevin McDonnell; Philip E. Brandish; Phil Jeffrey; Nicholas Keen | Novel Single-Agent Immunotherapies | Bispecifics;Costimulation;Solid tumors;T cell;Targeted therapy | |
| 889 | Poster Presentation | DuoBody®-CD3x5T4 induces efficient T-cell activation and killing of patient-derived head and neck cancer cells in vitro and ex vivo | Rieneke van de Ven; Sonja H. Ganzevles, B.Sc; Myrthe Veth, B.sc; Patrick Franken; Esther Breij, PhD; Ruud H. Brakenhoff, Prof. dr.; Kristel Kemper, PhD | Novel Single-Agent Immunotherapies | Antibody;Biomarkers;Bispecifics;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor antigens | |
| 890 | Poster Presentation | Manipulation of epithelial-to-mesenchymal transition reveals metastatic breast cancers support immune suppression via heme metabolism | Michelle M. Williams, Ph.D.; Jessica L. Christenson, Ph.D.; Sabrina A. Hafeez, B.S.; Nicole S. Spoelstra, B.S.; Jill E. Slansky, PhD; Jennifer K. Richer, Ph.D. | Novel Single-Agent Immunotherapies | Immune suppression;Metabolism;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy;Tumor evasion;Tumor microenvironment | |
| 891 | Poster Presentation | S-531011, a novel anti-human CCR8 antibody: Antibody screening and evaluation of biological profiles | Mai Yoshikawa, Ph.D.; Yoji Nagira; Morio Nagira; Tetsuya Yoshida; Shinpei Yoshida; Tetsuyoshi Soh; Hisashi Wada; Naganari Ohkura; Tatsuya Takahashi | Novel Single-Agent Immunotherapies | Antibody;Chemokine;Regulatory T cell (Treg cell);Targeted therapy;Tumor infiltrating lymphocytes (TILs) | |
| 892 | Poster Presentation | ABL503 (TJ-L14B), PD-L1x4-1BB bispecific antibody induces superior anti-tumor activity by PD-L1-dependent 4-1BB activation with the increase of 4-1BB+CD8+ T cells in tumor microenvironment | Gihoon You, Ph.D.; Uijung Jung; Jaehyoung Jeon; Shinai Lee; Hyung-Seung Jin; Youngkwang Kim; Eunsil Sung, Ph.D.; Hyunjoo Kim, Ph.D.; Yangmi Lim, Ph.D.; Jonghwa Won, Ph.D.; Zhengyi Wang, PhD; Wenqing Jiang, PhD; Jaeho Jung, PhD | Novel Single-Agent Immunotherapies | Antibody;Biomarkers;Bispecifics;Checkpoint blockade;Costimulation;T cell | |
| 893 | Poster Presentation | ATG-101, a novel PD-L1/4-1BB bispecific antibody, augments anti-tumor immunity through immune checkpoint inhibition and PDL1-directed 4-1BB activation | Hui Yuwen; Tengteng Li; Yijing Ren; Dirk Hoenemann; Jay Mei; Bo Shan; Bing Hou, Ph.D | Novel Single-Agent Immunotherapies | Bispecifics;Checkpoint blockade;Costimulation;NK/NKT cell;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 894 | Poster Presentation | The bispecific innate cell engagers AFM13 (CD30/CD16A) and AFM24 (EGFR/CD16A) increase the fraction of tumor target-responsive NK cells and boost serial killing | Chiara Zambarda, PhD; Karolin Guldevall, PhD; Christian Breunig, PhD; Damien Toullec, PhD; Jacopo Fontana, PhD; Sheena Pinto, PhD; Jens Pahl, PhD; Susanne Wingert, PhD; Joachim Koch, Prof.; Björn Önfelt, Prof. | Novel Single-Agent Immunotherapies | Antibody;Antigen presenting cells;Bispecifics;Leukemia/Lymphoma;NK/NKT cell;Solid tumors;Tumor antigens | |
| 895 | Poster Presentation | Discovery of a safer 4-1BB agonist by targeting a membrane-proximal epitope combined with bispecific-mediated cross-bridging | Andy Tsun, PhD; Tianhang Zhai; Xiaoniu Miao; Weifeng Huang; Chao Wang; Yifeng Xu; Zhijun Yuan; Tao Wang; Shuang Dai; Shaogang Peng; Tuling Pang; Wenchao Jiang; Yuhua Huang; Yuefeng Zou; Yingda Xu; Joanne Sun; Xinjiang Gong; Bin Li | Novel Single-Agent Immunotherapies | Antibody;Bispecifics;Checkpoint blockade;Immune toxicity;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 896 | Poster Presentation | Fighting the war against COVID-19: administration of Bamlanivimab (BAM) or Bamlanivimab + Etesivimab (BAM + E); a cooperative effort between a community cancer center and an urgent care (UC) facility | Patrick J. Skeffington, PharmD; Robert Aisenberg, MD; janice Dallacosta, RN, BSN; Ian Donaghy, RN; Dani Hackner, MD; Kelly Houde, RN, BSN; Kathy Moraes, MHA, RN, OCN; Annemarie Santos, RPh | Nursing/Pharmacy | COVID and Immunotherapy;Immune suppression | |
| 897 | Poster Presentation | Infusion episode-related benefits of pembrolizumab Q6W dosing schedule for patients with melanoma treated in the adjuvant and metastatic settings in the United States (US). | Raquel A. Aguiar-Ibanez, MSc; Emilie Scherrer, MSc; Dmitri D. Grebennik; Anvi A. Khandelwal; John J. Cook; Shalini S. Bagga; Baanie B. Sawhney; Scott S. Soefje, Pharm.D., R.Ph | Other | Checkpoint blockade;COVID and Immunotherapy;Immune adjuvant | |
| 898 | Poster Presentation | Intratumoral administration of NL-201, an alpha-independent IL-2/15 receptor agonist, inhibits the growth of both injected and uninjected tumors in preclinical models | Laurie Tatalick, DVM, PhD, DAC; Kevin Yu, BS, MS; Justin Huard, BS; Marianne Riley, BS; Ryan Swanson, BS; Carl Walkey, PhD | Other | Cytokine;Immune toxicity;Solid tumors | |
| 899 | Poster Presentation | Population coverage of HLA-A*02:01, *02:05, *02:06 across selected cancer types in the United States | Nashita Patel, MBBS PhD MSc BSc (Hons); Charlotte Carroll; Ken Culver; Shibani Pokras | Regulatory, Financial, and Access Considerations | Adoptive immunotherapy;Biomarkers;Epidemiology;Solid tumors;T cell | |
| 900 | Oral Presentation | Depleting non-canonical, cell-intrinsic PD-L1 signals induces synthetic lethality to small molecule DNA damage response inhibitors in an immune independent and dependent manner | Anand V. Kornepati; Clare E. Murray; Barbara Avalos, PhD; Cody Rogers; Kavya Ramkumar; Harshita Gupta; Yilun Deng, PhD; Zexuan Liu; Alvaro Padron; Ratna Vadlamudi; Eloise Dray; Weixing Zhao; Patrick Sung; Lauren A. Byers; Tyler J. Curiel, MD | Tumor and Stromal Cell Biology | Checkpoint blockade;Chemotherapy;Immune suppression;Post-translational modifications;Solid tumors;Targeted therapy;Tumor evasion;Tumor microenvironment | |
| 904 | Poster Presentation | Repurposing CD26 (DPP4) inhibitors to enhance immunotherapy response in pancreatic ductal adenocarcinoma | Maggie J. Phillips, BS; Michael B. Ware, PhD; Cameron Herting, PhD; Thomas A. Mace, PhD; Shishir K. Maithel, MD; Juan M. Sarmiento, MD; Bassel El-Rayes, MD; Chrystal M. Paulos, PhD; Megan M. Wyatt, MS; Gregory B. Lesinski, PhD | Tumor and Stromal Cell Biology | Checkpoint blockade;Gene expression;Immune suppression;Tumor evasion;Tumor microenvironment;Tumor stroma | |
| 905 | Poster Presentation | FASN prevents immunogenicity of irradiated glioblastoma by inhibiting ER stress | Mara De Martino, PhD; Camille Daviaud; Claire I. Vanpouille-Box, PhD | Tumor and Stromal Cell Biology | Dendritic cell;Immune contexture;Immune suppression;Metabolism;Radiotherapy;Solid tumors;T cell;Targeted therapy;Tumor evasion;Tumor infiltrating lymphocytes (TILs) | |
| 912 | Poster Presentation | Preferential recognition of neoantigens over non-canonical peptides in cancer patients | Maria Lozano-Rabella, MsC; Andrea Garcia-Garijo, MsC; Jara Palomero, PhD; Florian Erhard; Juan Martín-Liberal, MD; Ignacio Matos, MD; Jared Gartner; Steven A. Rosenberg, MD, PhD; Michael Ghosh; Francesc Canals, PhD; August Vidal, MD; Josep Maria Piulats, MD; Xavier Matias-Guiu; Irene Braña, MD; Eva Muñoz, MD; Elena Garralda; Andreas Schlosser, PhD; Alena Gros, PhD | Tumor and Stromal Cell Biology | Adoptive immunotherapy;Neoantigens;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 913 | Poster Presentation | A murine gastric cancer YTN16 model for the rational design of combination immunotherapy | Koji Nagaoka, PhD; Changbo Sun, MD; Yukari Kobayashi, BS; Kazuhiro Kakimi, MD, PhD | Tumor and Stromal Cell Biology | Neoantigens;T cell;Tumor antigens;Vaccine | |
| 915 | Poster Presentation | Molecular characterization of AXL in solid tumor malignancies using real-world data | Han Si, PhD; Maria Jure-Kunkel; Nora Pencheva; Steven Xu; Brandon Higgs; Kate Sasser, PhD; Hisham Hamadeh, PhD; Phaedra Agius; Kristina Grigaityte | Tumor and Stromal Cell Biology | Bioinformatics;Biomarkers;Checkpoint blockade;Chemotherapy;Gene expression;Solid tumors;Tumor antigens | |
| 922 | Poster Presentation | A novel autotaxin inhibitor, IOA-289, modulates tumor, immune and stromal cell function and has monotherapy activity in fibrotic cancer models | Marcel Deken; Karolina Niewola, PhD; Elisa Matas-Rico, PhD; Ragini Medhi, PhD; Alan Carruthers, PhD; Anne Cheasty, PhD; Olivier Peyruchaud, PhD; Amy Fraser, PhD; Pritom Shah, PhD; Wouter Moolenaar, PhD; Lars van der Veen, PhD; Michael Lahn, PhD, MD; ZOE JOHNSON, PhD | Tumor and Stromal Cell Biology | Bioinformatics;Biomarkers;Cytokine;Monocyte/Macrophage;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 926 | Poster Presentation | Immune profiling of KEAP1-deficient NSCLC: development of therapeutic strategies to overcome resistance to immunotherapy | Ana Galan-Cobo, PhD; Yu Qian, PhD; Fuduan Peng, PhD; Daniel J. McGrail, PhD; Fahao Zhang; Xiang Zhang; Edwin R. Parra, MD, PhD; Minghao Dang; Saxon Rodriguez; Alexandre Reuben, PhD; Ignacio Wistuba, MD; Ferdinandos Skoulidis; Linghua Wang, PhD; John V. Heymach, MD, PhD | Tumor and Stromal Cell Biology | Biomarkers;Checkpoint blockade;Tumor microenvironment | |
| 933 | Poster Presentation | Immune infiltrates differences between central and periphery regions of colorectal and pancreas adenocarcinomas | Andreia Maia, PhD candidate; Joana R. Lérias, DVM, PhD; Luis Miguel Borrego, MD, PhD; Markus J. Maeurer, MD, PhD, FRCP(London); Mireia Castillo-Martin, MD, PhD | Tumor and Stromal Cell Biology | Adoptive immunotherapy;B cell;NK/NKT cell;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 943 | Poster Presentation | 3D in vitro tumor model platform rapidly assays immunotherapy efficacy with high content imaging and downstream phenotypic changes with flow cytometry and cytokine analysis | Bin Xue, PhD; Julia Schuler, DVM PhD; Christopher M. Harrod; Kolin C. Hribar, PhD | Tumor and Stromal Cell Biology | Immune suppression;T cell;Tumor microenvironment;Tumor stroma | |
Late-Breaking | ||||||
| 946 | Poster Presentation | Standardized transcriptional profiling for optimizing cellular therapies: A Multi-Center PICI-NanoString collaboration | Sarah E. Church, PhD; Christina M. Bailey, MS; Sarah E. Warren, PhD; Lisa H. Butterfield, PhD; | Cellular Therapies | RNA;Adoptive immunotherapy;Bioinformatics;Biomarkers;CAR T cells;Gene expression;Immune monitoring;Immune toxicity;Leukemia/Lymphoma;Solid tumors | |
| 947 | Poster Presentation | Recombinant Myxoma Virus MC509-N1 Demonstrates Antitumor Efficacy as Monotherapy and in Combination with Immune Checkpoint Inhibitors | Enkhtaivan Gansukh, PhD; Tommy Alain, PhD; Tae-Geuk Kim; Ye-Na Namgung; Ka-Yeon Son; Yeo-Jin Jeong; Yeon-Sook Lee; | Checkpoint Blockade Therapy | Checkpoint blockade;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 948 | Poster Presentation | Final results from AIPAC: A phase IIb comparing eftilagimod alpha (a soluble LAG-3 protein) vs. placebo in combination with weekly paclitaxel in HR+ HER2- MBC | Hans Wildiers, MD; Luc Dirix; Anne Armstrong; Eveline De Cuypere; Florence Dalenc; Steven Chan; Frederik Marme; Carolina Pia Schröder; Jens Huober; Peter Vuylsteke; Jean-Philippe Jacquin; Etienne Brain; Sherko Kümmel; Zsuzsanna Pápai; Christian Mueller, MSc; Chrystelle Brignone; Frederic Triebel, MD, PhD; | Clinical Trials Complete | Antigen presenting cells;Chemotherapy;Clinical study;Clinical trial;Dendritic cell;T cell | |
| 949 | Poster Presentation | First-in-human study of the first acid pH-sensitive and recycling CTLA-4 antibody that preserves the immune tolerance checkpoint to avoid immunotherapy-related adverse events in cancer patients | Tianhong Li, MD, PhD; Mei Tang, MD, PhD; Karen Kelly, MD; Hui Amy Chen, MD; Stacy S. Joo; Imaan Khan; Nicole Do; Raymond Touomou; Dan Chen, MD, PhD; Yang Liu, PhD; Pan Zheng, MD, PhD; | Clinical Trials Complete | Antibody;Checkpoint blockade;Clinical trial;Solid tumors | |
| 951 | Oral Presentation | A Phase 1 first in human study of adenovirally transduced anti-HER2 CAR Macrophages in subjects with HER2 overexpressing solid tumors: preliminary safety, pharmacokinetics, and TME reprogramming data | Kim A. Reiss, MD; Yuan Yuan, MD, PhD; Debora Barton, MD; Amy Ronczka, BS; Daniel Cushing, PhD; Michael Klichinsky, PharmD, PhD; Sascha Abramson, PhD; Rehman Qureshi; Thomas Condamine, PhD; Elizabeth C. Dees, MD, MSC; | Clinical Trials In Progress | Adoptive immunotherapy;Antigen presenting cells;Clinical study;Clinical trial;Immune monitoring;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy;Tumor microenvironment | |
| 953 | Poster Presentation | Transcriptional Analysis of Leukocytes from COVID Convalescent Donors Reveals Persistent Activation of the Innate and Adaptive Immune System | Mallikarjuna R. Gedda, PhD; Patrick Danaher, PhD; Lipei Saho, PhD; Martin Ongkeko, PhD; Leonard Chen, MD; Mame Thioye Sall, MS; Opal L. Reddy, MD; Christina M. Bailey, MS; Amy Wahba, PhD; Inna Dzekunova, MS; Valeria De Giorgi, PhD; Robert Somerville, PhD; Jin Ping, PhD; Kamille West, MD; Sandhya Panch, MD, MPH; David F. Stroncek, MD; | Clinical Trials In Progress | RNA;COVID and Immunotherapy;Antibody;Clinical study;Gene expression;Granulocyte;Immune monitoring;Inflammation;Regulatory T cell (Treg cell);T cell | |
| 958 | Oral Presentation | BNT211: A phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumors | Andreas Mackensen, MD; Christian Koenecke, MD; John B. Haanen, MD; Winfried Alsdorf; Alexander Desuki, MD; Eva Wagner-Drouet, MD; Daniel Heudobler, MD; Peter Borchmann, MD; Erol Wiegert; Catrine Schulz; Benjamin Rengstl, MD, PhD; Liane Preussner, MD; Oezlem Tuereci, MD; Ugur Sahin, MD; | Clinical Trials In Progress | RNA;Adoptive immunotherapy;CAR T cells;Clinical trial;Costimulation;Solid tumors;T cell;Tumor antigens;Vaccine | |
| 959 | Oral Presentation | Safety and anti-tumor activity of TCR-engineered autologous, PRAME-directed T cells across multiple advanced solid cancers at low doses – clinical update on the ACTengine® IMA203 trial | Martin Wermke; Apostolia-Maria Tsimberidou; Ali Mohamed; Andrea Mayer-Mokler; Arun Satelli; Carsten Reinhardt; Dejka Araujo; Dominik Maurer; George Jr Blumenschein; Harpreet Singh; Jason J. Luke; Kerstin Guenther; Mamta Kalra; Manik Chatterjee; Norbert Hilf; Regina Mendrzyk; Steffen Walter; Stephen Eck; Tobias A.W. Holderried; Toni Weinschenk; Van Morris; Winfried Alsdorf; Cedrik M. Britten; | Clinical Trials In Progress | Adoptive immunotherapy;Clinical study;Clinical trial;Solid tumors;T cell;Targeted therapy | |
| 960 | Poster Presentation | Randomized multicenter study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer | Osama E. Rahma, MD; Mathew HG. Katz, MD; Todd W. Bauer, MD; Brian Wolpin, MD; Chee-Chee H. Stucky, MD; Tanios S. Bekaii-Saab, MD; Rawad Elias, MD; Andressa Dias-Costa, MD; Jonathan Nowak, MD; Lenehan Patrick, MD; Gina R. Petroni; Stephanie Dougan, PhD; Craig L. Slingluff, Jr., MD; | Clinical Trials In Progress | Checkpoint blockade;Chemotherapy;Clinical study;Clinical trial;Radiotherapy;Surgery;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 962 | Poster Presentation | Integrative immunomics highlight the immunomodulatory impact of neoadjuvant chemotherapy and immune-based treatments in resected non-small-cell lung cancer | Stephanie T. Schmidt, PhD; Younghee Lee, PhD; Cheuk H. Leung, MS; Lorenzo Federico, PhD; Heather Lin, PhD; Annikka Weissferdt, MD; Apar Pataer, MD, PhD; Hitoshi Dejima, PhD; Alejandro Francisco-Cruz, PhD; Frank Rojas, MD; Luisa M. Solis, MD; Edwin R. Parra, MD, PhD; Monika Pradhan, PhD; Haiping Guo; William N. William, MD; Alexandre Reuben, PhD; Humam Kadara, PhD; Ignacio Wistuba, MD; Jianjun Zhang, MD, PhD; Stephen G. Swisher, MD; Ara A. Vaporciyan, MD; Marcelo V. Negrao, MD; Christopher A. Bristow, PhD; Timothy P. Heffernan, PhD; Chantale Bernatchez, PhD; Jack J. Lee, PhD/DDS; John V. Heymach, MD, PhD; Boris Sepesi, MD; Don L. Gibbons, MD, PhD; Cara Haymaker, PhD; Tina Cascone, MD, PhD; | Combination Immunotherapies | Bioinformatics;Checkpoint blockade;Chemotherapy;Tumor microenvironment | |
Presented By:
